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Effects of a Decision Aid with and without additional 
decisional counseling for patients being examined for 
coronary artery disease on cardiac risk reduction 
behavior and health outcomes- 
A randomized controlled trial 
 
Abstract 
Introduction 
This three group randomized controlled trial evaluated the effect of a Decision Aid 
(DA) with and without an additional Decisional Counseling Program (DCP) for patients 
being examined for coronary artery disease (CAD) on patient-reported health outcomes and  
health related quality of life (HRQoL), mediated by adherence to cardiac risk reduction 
behavior. We also explored how adherence to cardiac risk reduction behavior was 
influenced by patients’ intentions to follow recommendations for a healthy lifestyle, their 
knowledge about risk factors for CAD, perceived health beliefs, perceived benefits and 
barriers to cardiac risk reduction behavior, and decisional conflict. Furthermore, we 
explored relationships between adherence to cardiac risk reduction behavior, health 
outcomes and HRQoL. 
Methods
368 patients > 18 of age were randomly assigned to: (1) the Intervention group I 
where patients received, for take home, the DA prior to their scheduled angiogram; (2) the 
Intervention group II where patients, in addition to the DA received the DCP from a trained 
nurse counselor in their homes prior to their angiogram; and (3) the Control group who 
received “usual care”. Data were collected at four time points: at baseline prior to patients’ 
angiogram, and at 2, 4, and 6 months. ANCOVA was used to compare differences in group 
means at 6 months following the angiogram after statistically controlling for baseline 
scores. Linear regression and mixed effects models were used to explore relationships 
between primary outcomes and mediating variables.  
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Results
While there were no significant differences between the Da group and the Control 
group on any variables, The DA+DCP group had a significant decrease in Body Mass 
Index compared to the Control group 6 months after the intervention. Furthermore, patients 
in the DA+DCP group significantly improved HRQoL on several dimensions over the 
study period compared to the Control group. There was also a significant decrease in 
perceived barriers to cardiac risk reduction behavior in the DA+DCP group compared to 
the Control group. We found no significant group differences in adherence to cardiac risk 
reduction behavior.  
Greater adherence to healthy life style recommendations, better HRQoL and better 
health outcomes were significantly related. Intentions to follow lifestyle recommendations 
were significant predictors of adherence to cardiac risk reduction behavior. Increased 
perceived susceptibility of illness was significantly related to lower adherence to non- 
smoking behavior, while increased perceived barriers to cardiac risk reduction behavior 
was related to lower adherence to diet recommendations. Higher decisional conflict 
significantly predicted lower adherence to diet recommendations, activity 
recommendations, and taking medications. The patients appraised both the DA and the 
additional decisional counseling program as helpful.  
Conclusion
In this study the DA alone was not sufficient to improve health behaviors and 
outcomes. However, the addition of the DCP had significant effects on reduced BMI, better 
HRQoL on several dimensions, and reduced perceived barriers to cardiac risk reduction 
behavior in patients being examined for CAD.  The DCP supported patients to individually 
tailor their lifestyle changes to their health beliefs and preferences, resulting in better health 
outcomes and HRQoL. We do not know however, if these effects would have occurred by 
the DCP alone, without combining it with the DA. Finally, this study contributed to a better 
understanding of variables related to adherence to lifestyle recommendations and health 
outcomes.  
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Chapter 1 
Background 
 
 
Introduction 
 
In spite of considerable reductions in mortality rate caused by cardiovascular disease 
(CVD) from 49% of all deaths in Norway in 1979 to 32.6 % in 2009, CVD still remains the 
main cause of mortality in all adults in Norway (Statistics Norway 09.12.10). 13 489 people 
in Norway died of CVD in 2009; 54% were women, and 5 378 (40%) of the deaths were 
caused by coronary artery disease (CAD); 47 % were women. The demographic of people 
with CAD have changed, and older and sicker adults are surviving cardiac events. While 
better treatment methods and medication may explain the lower mortality over the past 
decades, in the recent years there has been only a minor reduction in the mortality rate 
caused by CAD. 
 
Because CAD is a disease that is highly associated with lifestyle related factors and 
health behavior, there is much to gain from health behavior change to reduce the risk for 
CAD and cardiac events, such as quitting smoking, a healthy diet including increased 
intake of fish fatty acids, exercise, stress reduction, and adherence to blood pressure-, and 
cholesterol lowering medications (Edwards et al., 2006; Pedersen, Tverdal & Kirkhus, 
2004; Yusuf et al., 2004). Although the relationships between these factors and CAD are 
well known, studies have shown that life-style changes and adherence to cardiac risk 
reduction behavior has considerable room for improvement (Burke et al., 1997; Rogers & 
Bullman, 1995; Sackett & Haynes, 1976; WHO, 2003). Data indicate that knowledge of the 
effects of cardiac risk reduction behavior and/or fear of a cardiac event is not enough to 
motivate CAD patients to maintain long-term lifestyle changes. Therefore better 
interventions to increase adherence to a healthy lifestyle are needed.  
 
Cardiac risk reduction behavior is important for the general public, but it is even more 
important for people with CAD, because they have more at stake. They are at increased risk 
2 
 
for having a heart attack, a percutaneous coronary intervention (PCI), a bypass procedure, 
or needing more medication, but can lower their chances of experiencing an actual cardiac 
event and improve their physical functioning and quality of life by changing their lifestyle 
to a more healthy behavior. A number of studies have tested interventions to improve 
cardiac risk modification behavior, primarily based on cognitive-behavioral approach. 
However, so far interventions to produce lasting health behavior change have only shown 
limited effects (Ebrahim et al., 2006). Therefore there is a need to explore additional 
promising approaches to health behavior change that can increase adherence to a healthy 
lifestyle in cardiac patients. 
 
One such promising and widely advocated approach is interventions to help patients 
to make decisions about health care options and to involve them in their care (Elstein et al., 
2004). This has led to the development and use of decision aids (DAs) for different 
treatment or screening decisions with the purpose of helping patients understand treatment 
or screening options, potential outcomes, clarify their preferences for treatment options in 
light of the provided information, and prepare patients for shared decision-making with 
their care provider (O’Connor et al., 1998a; O’Connor et al., 1998b). 
 
Because DAs are developed to prepare patients for shared decision-making they 
differ from other health education materials because of their specific, detailed, and 
individualized focus on possible options and outcomes. A DA developed for CAD patients 
may therefore help patients’ with risk of CAD or CAD progression to see that a behavioral 
change needs to be made, to know the different options and outcomes, to assess how 
personal values and preferences affect the decision, to know what matters most, and to be 
able to discuss these matters with their health care provider, and thereby become involved 
in their care in preferred ways.  
 
DAs exist today for a number of different treatment decisions, and two systematic 
reviews of randomized controlled trials of DAs conclude that DAs do increase a patient’s 
participation in decision-making, increase knowledge, reduce decisional conflict, and help 
uncertain people to make decisions (Molenaar et al., 2000; O’Connor et al., 2009), 
however, the effects on outcomes of decision remains uncertain (Charles et al., 2005; 
Kennedy, 2003; O’Cathain & Thomas, 2004; O’Connor, Rostom et al., 1999; Sepucha & 
Mulley, 2003). Other consistent findings are that decisional conflict scores decreased 
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(Briggs et al., 2004; Davison et al., 1999; Dolan et al., 2002; Goel et al., 2001; Man-Son-
Hing et al., 1999; Montgomery et al., 2003; Murray et al., 2001a, 2001b; O’Connor et 
al.,1998a; O’Connor et al.,1998b; Stalmeier et al., 1999; Whelan et al., 2004) and increase 
congruence between patients’ preferences/values and actual choice are found (Barry et al., 
1995; Holmes-Rovner et al., 1999; O’Connor et al., 1998a). Studies also show that patients 
who were well informed and considered the personal value they place on outcomes were 
less likely to accept ineffective or risky procedures. (Dodin, Legare, Daudelin, Tetroe & 
O’Connor, 2001)  This was supported in three studies: the rates of coronary artery bypass 
surgery declined in favor of options that are more conservative without affecting patients’ 
outcomes (O’Connor, Legare & Stacey, 2003); Morgan et al. (2000) found that patients 
who had seen the video of treatment options for CAD underwent less invasive procedures 
than the usual care group, yet there were no differences in angina scores or general health 
scores in the two groups at six months; and Phelan et al. (2001) found that patients had a 
slightly lower preference for surgery after viewing the DA video-presentation of informing 
patients about back surgery. 
      
 The evidence of the effects of DAs on adherence of chosen option is unclear 
(Charles et al., 2005). Five studies measured adherence to chosen options, warfarin versus 
aspirin ( Man-Son-Hing et al., 1999), oral bisphosphonate medications (Oakley & Walley, 
2006), blood pressure medications (Montgomery et al., 2003), and Hormone replacement 
therapy (Deschamps et al., 2004; Rothert et al 1997). There were no significant differences 
between groups in adherence to chosen options.   
 
To which degree DAs are effective in helping people in decisions about their personal 
health behavior has been less explored. Only few DAs exist to help CAD patients to modify 
risk factors to increase a more healthy lifestyle (Koelewijn-van Loon et al., 2009, 2010; 
Krones et al., 2008, 2010; Lalonde, et al., 2004, 2006; Lenz et al., 2009; Pignone et al., 
2004; Sheridan et al., 2006, 2010b; van Steenkiste et al., 2007, 2008). However, so far 
effects of DAs in this area are sparse and inconclusive. Therefore, to better understand if 
DAs have positive effects on risk reduction behavior and outcomes in cardiac patients, 
more studies are needed. 
  
Traditionally DAs have not targeted the implementation of the decision, which is 
particularly important for health behavior change. For a decision to have any consequence 
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heavily depends on the decision maker’s ability and motivation to carry it out. How well a 
person at risk for CAD or progression of CAD implement his or her decision about lifestyle 
change subsequently affect a range of other variables, including choice of options and 
outcomes. However, behavior change can be difficult if a person judges the inconvenience 
associated with the recommended lifestyle change greater than the desirability of future 
health benefits gained from risk reduction behavior. Patients’ preferences for health 
behavior influence their decision to start and continue the behavior (Eraker & Sox, 1981; 
Eraker & Politser, 1982).  Therefore it is important to assess and assist individual in 
identifying their beliefs, expectations, and personal preferences for health behavior change. 
Patients also need the motivation, confidence, or resources to implement their risk 
modification behavior. Patients may achieve better results from a DA if is supplemented by 
individual counseling to elicit their beliefs, expectations, and motivations, and to assist 
them in goal setting and devising action plans for how to succeed in implementing long-
term lifestyle changes that are consistent with their personal preferences. 
 
Another limitation of DAs is that they use risk estimates aggregated from many 
studies and patients, and the patients’ individual risk profile may be far off from this 
average data. There is evidence that risk information is more effective if it includes 
individually calculated estimates (Edwards & Elwyn, 1999a; Edwards, Elwyn & Mulley, 
2002). Furthermore, it has been repeatedly demonstrated that many people lack the skills 
necessary to critically read quantitative information (Mazur & Hickam, 1990; 1993, 
Woloshin, Schwartz, Moncur, Gabriel & Tosteson, 2001). Patients may still be uncertain 
about how relevant the numbers presented in the DA are to them and how to apply them. 
Patients may therefore benefit more from a DA if it is supplemented with individual 
counseling to help them adjust the information in the DA to their personal illness history 
and help them decide what cardiac risk reduction behavior they would prefer to engage in. 
 
So far the effects of a DA with and without the benefits of additional individual 
decisional counseling to adjust lifestyle changes to CAD patients’ individual risk profiles 
and personal preferences and beliefs are not known. Therefore, in addition to testing the 
DA for CAD patients and including health behavior and health measures as outcomes in 
this study, we developed a decision counseling program (DCP) to help patients clarify their 
beliefs and perceptions about the susceptibility and severity of potential progression of their 
CAD, their perceived benefits and barriers to risk modification behavior, and to guide 
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patients in individually designing a preference-based risk reduction behavior program that 
could be easier for them to maintain over time. At the concept level, the psychological 
situation is represented by barriers and benefits. Barriers are the perceived negative costs of 
health action that arouse avoidance motives. Benefits are the perceived positive payoffs that 
lead to health and care activities (Rosenstock, 1974).  
 
 
Purpose 
 
The specific aims of this three group randomized clinical trial (RCT) was to evaluate 
the effects of a DA to assist cardiac patients in lifestyle changes with and without an 
additional individual decisional counseling program (DCP) on health outcomes and quality 
of life mediated by adherence to cardiac risk reduction behavior. The DA used in this study, 
“Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke” (DA) 
was developed by Ottawa Health Research Institute at Ottawa Hospital in collaboration 
with investigators from the Division of Clinical Epidemiology at Montreal General 
Hospital (Lalonde et al., 2002).  The DA provides information about options patients have 
for reducing their risk of heart disease and stroke by changing their lifestyle and taking 
medication. The additional individual decisional counseling program (DCP) was developed 
by the research team in this study based on principles from the Health Belief Model as 
described in greater detail below. The DCP was designed to systematically guide patients 
through the process of making decisions among options of lifestyle changes, and to help the 
patients decide what cardiac risk reduction behaviors they would be able to, and prefer to, 
engage in. At the end of the DCP the patients could write their action plan for their planned 
behavioral change the next 6 months.  
        
Specifically, this RCT tested and compared the effects of the DA with and without 
the DCP on:  
(1) Primary health outcomes: body weight, cholesterol, blood pressure, amount of 
tobacco use, and Health-related quality of life (HRQoL)  
(2) Intermediate outcomes: Adherence to cardiac risk reduction behavior.  
(3)  Mediating variables: knowledge about risk factors and CAD, perceived health 
beliefs, and perceived benefits and barriers to cardiac risk reduction behavior 
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To explore the relationships that may explain the mechanisms by which the two 
interventions (DA and DA+DCP) may affect outcome behavior we examined the 
relationships between primary and intermediate outcomes and mediating variables 
associated with behavioral change in the literature; intentions to have a healthy lifestyle, 
knowledge about risk factors and CAD, perceived health beliefs, perceived benefits and 
barriers, and decisional conflict. 
The study was carried out in two phases:  
  Phase I: Adjustment of the previously developed Canadian DA to Norwegian 
language and data on risk factors in Norway; development of the DCP as described in 
Chapter 3; and pilot testing.  
  Phase II; a RCT where 368 patients > 18 of age scheduled for a coronary angiogram 
at Oslo University Hospital HF- Rikshospitalet were randomly assigned to: (1) The DA 
group  where patients received, for take home, the DA prior to their scheduled angiogram; 
(2) The DA+DCP group where patients in addition to the DA received an individual 
decisional counseling program (DCP) from a trained nurse counselor in their homes prior to 
their angiogram; and (3) The Control group who received “ usual care”. Data were 
collected at four time points: at baseline prior to the patients’ angiogram (T1); and two 
(T2), four (T3), and six (T4) months following the angiogram.  
Rationale
CAD is a pathological progression, and PCI and CABG procedures are palliative 
treatments that do not correct or alter the progression of the disease. Therefore, patients 
may benefit from interventions that are designed to help them modify factors to reduce their 
risk. The rationale for the DA is that it may encourage the patients to engage in lifestyle 
changes by helping them to evaluate accurate information about options of life style 
changes and their consequences consistent with personal values (O’Connor, Stacey, et al., 
2003). There is evidence that CAD patients often have unrealistic expectations about the 
long-term benefits they can achieve from PCI and CABG surgery, and may be not be aware 
of the fact that management of the pathological progression requires changes in the 
individuals’ lifestyle to stabilize or reverse the atherosclerotic process (Krannich et al., 
2008). Therefore it is important to offer patients information about the options they have to 
manage the pathologic progression of CAD by cardiac risk reduction behavior, so as to 
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reduce the risk of having a heart attack, a PCI, a by-pass procedure, or needing more 
medications.  
 
The information in the DA used in this study is presented in a booklet and is tailored 
to CAD severity and major risk factors. It presents structured information about options 
patients have to reduce the risk of heart disease and stroke. The content is based on an 
extensive review of the literature with evidence from randomized trials published up to 
2002 (Lalonde et al., 2002). The information in the booklet is however, aggregated from 
systematic reviews of the scientific literature and not tailored to the individual patients’ 
personal risk profile that may be different from this average based data. CAD patients with 
a similar degree of disease differ significantly in symptom severity and tolerance (Nease et 
al., 1995; Nichol et al., 1996), and patients may still be uncertain about how relevant the 
presented numbers are to them, and how to apply them. Therefore we developed an 
individual decisional counseling program to help patients comprehend the information, 
adjust this information to their personal illness history, elicit their preferences for cardiac 
risk reduction behavior in light of this personalized information, and help them write a 
personal action plan. The underlying assumption is that people are more likely to choose an 
alternative which they, according to their preferences, perceive will be effective in 
achieving individually valued outcomes, avoiding individually undesirable outcomes, and 
see the ability to carry them out.  
 
The importance of cardiac risk reduction behavior 
Coronary heart disease is the most common reason for hospitalization in Norway, 
counting for approximately 116 000 admissions in 2010.  11 387 persons were admitted for 
their first MI in 2010 ( http://www.ssb.no/pasient/ 07.06.11). The  incidence of CAD  
increases with age (Anand et al., 2008). In general, CAD hits non-smoking women about 
ten years later than men, mainly from 60 years of age. However, women with risk factors 
lose their gender advantage (Shaw et al., 2009; Folkehelseinstituttet. Hjerteinfarkt - fakta 
om infarkt og annen iskemisk hjertesykdom 07.06.11.) Even if the incidence and mortality 
of CAD is low in younger people, it is important to notice that 170 men and 38 women 
aged 25- 54 suffered a premature death caused by CAD in Norway in  2009 
(http://www.ssb.no/emner/03/01/10/dodsarsak/tab-2010-12-03-02.html 07.06.11).  
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CAD is usually a result of multiple interacting risk factors. The occurrence of CAD 
strongly relates to life styles and to modifiable risk factors. Cardiac risk reduction behavior 
means management of the individual behavior that has a positive impact on reducing total 
risk of cardiac disease. Healthy lifestyle in the general population has the following 
characteristics: No smoking; healthy food choices; physical activity at least 30 min of 
moderate activity a day; Body Mass Index < 25 (kg/m2); and avoidance of central obesity; 
blood pressure < 140/90 mmHg; total cholesterol < 5 mmol/L; LDL cholesterol < 3 
mmol/L. It is recommended that patients with established CAD and possible high risk 
should try to achieve Blood pressure under 130/80; Total cholesterol < 4,5mmol/L with an 
option of 4 mmol/L if feasible; LDL cholesterol < 2,5 mmol/l with an option of < 2 mmol/L 
if feasible (Graham et al., 2007).  
 
The standard modes of treatment for CAD are coronary artery bypass graft (CABG) 
surgery, medication, and PCI. In 2007 mean age for PCI in Norway was 60 years and for 
CABG surgery five years more; approximately 40 % of patients were over the age of 60 
years, and 27, 8% were women (Melberg & Svennevig, 2009). All three treatments for 
CAD work better when combined with cardiac risk reduction behavior (Yusuf et al., 2004). 
After a diagnosis and/or treatment of CAD, some people think that it is too late or not 
necessary to make lifestyle changes. By stopping smoking, lowering cholesterol, reducing 
fat in diet, watching calories, exercising regularly, and reducing stress, they may, however,  
still have much more to gain. (McAlister et al., 2001; Ornish et al., 1998; Selmer & 
Tverdal, 2003).  
      
Patients at low risk of CAD mortality should be assisted to maintain the low risk 
state, while patients with multiple risk factors resulting in a  5% 10 years risk of CAD 
mortality should receive interventions that focus on helping them achieve a healthy lifestyle 
(Graham et al., 2007).  Interventions that focus on cardiac risk reduction behavior have 
shown to improve care; reduce readmission to hospital; reduce mortality especially in high 
risk groups and when exercise is included in the intervention (Clark, Hartling, Vandermeer, 
& McAlister, 2005; McAlister et al., 2001).  
      
However, some patients may have concepts about their illness that may interfere with 
their ability or willingness to accept the importance of recommended treatment. They may 
also have varying beliefs of their own susceptibility and possible severity of illness. 
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Therefore it is important to design interventions that involve the patients in decisions about 
cardiac risk reduction behavior, to explicitly help them to consider their own perceived 
benefits and barriers, and support them in setting individual and achievable goals that are 
consistent with their individual plans as we did in this study. 
Previous interventions to promote health behavior change 
Current health behavior interventions are most often built on theories stating the 
unhealthy behavior as a deficit or a problem to be solved (Becker, 1974; Ewart, 1989; 
Prochaska & DiClemente, 1983). Interventions using a cognitive-behavioral approach such 
as self-efficacy enhancement (Cauley et al., 1987; Oman & King, 1998) and relapse 
prevention strategies (Marlatt & Donovan, 2005) have been shown to promote health 
behavior change in healthy adults. Interventions based on the stage of change 
(Transtheoretical model) theory (Prochaska & DiClemente, 1983) and environmental 
models (Humpel et al., 2002) have shown some effects in enhancing lifestyle changes. 
However, interventions based on these models are prescriptive and have had limited 
effectiveness in producing lasting behavior change (US Department of Health and Human 
Services, 2000). There are some theoretical models that involve less prescriptive 
components like motivational interviewing (Miller, 2002), learned resourcefulness 
(Zauszniewski, 1997), imagery (Kolcaba & Fox, 1999) and asset assessment (Delgado, 
1995). However, the content and dosage of these interventions are fixed; every component 
of the intervention that may be necessary for any particular participant is included in the 
intervention, and each participant is given the same intervention. Although it is recognized 
that individuals may have different intervention needs, it is expected that the intervention is 
in no way diluted or made counterproductive if components that are particularly relevant 
for an individual are combined with components that may have less, or even no, relevance 
for that individual. Thereby they lack the ability for patients to integrate the interventions in 
their own lives based on individual risk profiles, personal values and preferences.  
Patients’ preferences
There has been an increasing focus on the influence of patients’ underlying value 
system on their health-related decisions. Eliciting patients’ preferences has been a 
successful strategy to assist patients making health-related decisions that are consistent with 
their values. For example, interventions to increase patient involvement in health-related 
decisions have resulted in higher satisfaction with, and more active participation in, 
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decision-making (O’Connor et al., 2009), better scores on general health perceptions and 
physical functioning (Goldstein et al., 1994; Ruland, 1999), higher compliance (Greenfield 
et al., 1988; Joos et al., 1996), improved knowledge (O’Connor et al., 1998b) and reduced 
decisional conflict (O’Connor et al., 2009). If patients can change their behavior in 
accordance with their preference and individual lifestyle, it may become easier to maintain 
the behavior over time. This study is based on an approach to promote healthy behavior that 
combines the elicitation of patients’ preferences with individual tailoring, instead of one-
size-fits all approach. Each patient is asked to devise their individual action plan based on 
their individual risk profile, perceived health beliefs, and personal preferences. Rating of 
the importance of the perceived benefits/advantages minus the importance of perceived 
barriers/disadvantages will provide a possibility for patients to identify critical trade-offs 
between perceived benefits/advantages and perceived barriers/disadvantages in a 
quantifiable manner.  
 
The mechanisms by which DAs work 
       DAs are more effective than routine information in enabling patients to make different 
treatment choices (O’Connor et al., 2009). The effectiveness of DAs can be explained in 
terms of either the facilitation of cognitive strategies or changes to emotional processes. 
The mechanisms through which DAs impact on cognitive strategies are addressed briefly 
here. The visual representation of possible decisions/solutions provides a direct memory 
support that summarizes all the relevant information during decision-making (O’Connor, 
1995), reduces the cognitive load during decision-making (Bekker et al., 1999; Ubel & 
Loewenstein, 1997), and ensures that patients’ judgment is made based on complete 
information rather than based on memory-accessed and/or biased details (Shafir et al., 
1993; Wilson et al., 1993). The eliciting of normally unarticulated cognitive mechanisms 
assists patients in generating more reasons for and against the options and encourages them 
to integrate verbally the decision information with their beliefs (O’Connor, 1995; Ubel & 
Loewenstein, 1997). It is likely that these techniques together (1) enable patients to justify 
the different choices to their individual life (Shafir et al., 1993) and (2) ensure that patients 
more fully explore the reasons associated with the options (Frisch & Jones, 1993). This 
process of systematic evaluation of decisional information against personal beliefs leads 
patients to develop more robust cognitions, associated with less decisional conflict and 
greater decisional satisfaction (Holmes-Rovner et al., 1996).   
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The impact of DAs on emotions is less clearly understood. One explanation may be that 
DAs encourage patients to evaluate relevant information rather than focusing on emotion 
and feelings (O’Connor, 1995). Another explanation may be that eliciting patient values 
about options and consequences increases patients’ expression of emotions during decision-
making (Pauker & Pauker, 1977). There is evidence that expression of affect about stressful 
events is associated with better long-term health outcomes (Pennebaker & Francis, 1996; 
Pennebaker, 1997). Therefore it is possible that DAs may facilitate patient decision by 
increasing the expression of emotions during decision-making, but this is not known. 
 
 Adherence to cardiac risk reduction behavior  
 Adherence to health recommendations continues to be a significant and 
multidimensional problem. Non-adherence is widespread, and research has established that 
the prevalence of non-adhering to proposed behavior is averaging 24.8 % (DiMatteo, 2004 
a). It has been assumed that non-adherence to medical regimens occurs primarily because 
people are ignorant about the benefits or have not understood or remembered how to 
perform the medical regimen. Research has subsequently shown that, far from being 
ignorant, the understanding, concerns, and priorities among patients differ from the 
perceptions of their health care providers, and many patients make informed and rational 
decisions not to perform the prescribed medical regimen (Donovan & Blake, 1992). Non-
adherence may therefore be seen as a rational choice as patients attempt to maintain their 
personal identity, achieve their goals, and preserve their quality of life (Conrad, 1985; 
Donovan & Blake, 1992; Lambert et al., 1997; Lynn & DeGrazia, 1991; Trostle et al., 
1983). Furthermore, patients have their own perceived cognitive models of illness that need 
to be challenged in a positive way. Data indicate that adherence is  influenced by health 
beliefs such as risk perception, perceived benefits and barriers to treatment, self-efficacy, as 
well as stage of change, and communication problems (Avis et al., 1989; Bellg, 2003; 
Lutfey & Wishner, 1999).  
 
Increased awareness of how people reason is an important clinical skill (Redelmeier 
et al., 1993). The use of open-ended questions may encourage patients to participate and 
engage in decision-making (Donovan & Blake, 1992; Redelmeier et al., 1993). The 
relationship between the health care provider and the patient has been shown to have a 
strong effect on adherence (DiMatteo, 1994). Such communication is based on trust and 
good communication. DiMatteo (2004b) describes necessities of adherence as the 
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availability of practical and emotional support, to keep treatment simple and able to fit into 
patients’ life, and the consideration of beliefs to make the communication effective. 
Interventions to promote adherence and offer a more open, cooperative relationship 
between the caregiver and patient as used in this study may be worthwhile. 
Therefore, this study included and tested an intervention (DCP) tailored to each 
patients needs and preferences, designed to help patients become more involved in actions 
to fulfill their goals and thereby increase adherence to cardiac risk reduction behavior. 
The value of DAs and additive counseling  
As mentioned earlier, the quality of a decision depends on the ability of patients to 
carry them out. There are two important steps that are often neglected in current DAs; 
people need help to prepare for making a choice, and implement this choice in daily life 
activities. Decisions are the intersection between thoughts and actions. The competence to 
carry out the decision is equally important as the skills to make the decision. DAs can 
therefore benefit from adding information that is targeted to help prepare and implement 
decisions (Kennedy, 2003; Sepucha & Mulley, 2003). People also may pay more attention, 
process more deeply, and make greater behavioral changes when messages are tailored 
rather than generic (Kreuter et al., 1999; Noar et al., 2007; Skinner et al., 1999). A study on 
a DA for women with breast cancer demonstrated that the addition of individual counseling 
created even more realistic expectations, helped the uncertain become more certain, 
reduced decisional conflict and psychological distress, and increased intentions to improve 
life-style practices more than the DA only (Stacey, O’Connor, DeGrasse & Verma, 2003). 
This supports that more studies are needed to identify and test strategies and support 
systems that can improve adherence and outcomes. 
  
Using goal setting and action plans is a useful strategy to encourage behavior change 
(Bandura, 1986; Handley et al., 2006; Stretcher, et al 1995). Other elements associated with 
improved health behavior outcomes include assessment of individual beliefs and 
preferences, and subsequent tailoring of intervention elements to address assessment 
(Ammerman et al., 2002; Babor & Higgins-Biddle, 2001; Bodenheimer et al., 2002; 
Glasgow et al., 2002; McAlister et al., 2001; McTigue et al., 2003; Pignone et al., 2003; 
Whitlock et al., 2004), interventions that include self-monitoring, identification of barriers, 
goal setting, and problem-solving (Babor et al., 2001;  Bodenheimer et al., 2002; Fiore et 
al., 2008; Glasgow et al., 2002; Kahn et al., 2002;  McTigue et al., 2003; Pignone et al., 
13 
 
2003; Whitlock et al., 2004). Since DAs are meant to be adjuncts to counseling, the DA 
supplemented with an individual decisional counseling program (DCP) was developed to 
help patients comprehend the information, adjust this information to their personal illness 
history, elicit their preferences for cardiac risk reduction behavior in light of this 
personalized information, and set mutually-agreed and realistic goals in an action plan. The 
structured communication between the healthcare provider and the patient in this study was 
therefore hypothesized to be a powerful relationship that may enhance patients’ coping with 
illness and adherence to recommended risk reduction strategies and medication.  
 
When presented with more than one option for lifestyle changes, each of which has 
multiple characteristics, patients might find themselves in a state of uncertainty or difficulty 
in identifying the best alternative due to the risk or uncertainty of outcomes, and the need to 
make value judgments about potential gains versus potential losses (Keeney, 1988), a state 
that is defined as decisional conflict. O’Connor (1995) describes that decisional conflict 
appears from two sources; first, people are uncertain because of the inherent difficulty of 
the choice they face, and second the uncertainty is higher if a person feels uninformed, is 
unclear about personal values, and feels unsupported or pressured to choose an action. 
Therefore, the DCP in this study was designed to help patients to reduce the perceived 
uncertainty, and personalize the decision among options of lifestyle change and adherence 
to cardiac risk reduction behavior.  
 
There has been a tendency that DAs have focused on a single factor (such as 
treatment A vs. treatment B). Based on the fact that a healthy lifestyle is a combination of 
several behaviors that influence each other, it is important for lifestyle change interventions 
to take more than one factor into consideration. The multiple behavior change approach has 
shown to be most effective (WHO, 2003).  The DCP used in this study is a multiple 
behavior change intervention designed to tailor patients’ perceptions regarding 
susceptibility and severity of potential progression of their CAD, eliciting perceived 
benefits and barriers likely to be derived, and guide patients to individually design a 
preference-based cardiac risk reduction behavior program that are easier for patients to 
maintain over time. 
 
After the preliminary examination for CAD at the Cardiac Outpatient Clinic, patients 
are faced with possible decisions among options of lifestyle change that may significantly 
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affect their life. This time point represents a crucial moment of opportunity, is it now time 
to quit smoking, lose weight, start exercising, and do something about their stressful life? It 
is well known that people who feel ill tend to speak about planned lifestyle changes as 
some kind of intention to change. When people at least reflect and think about changing 
their behavior, one can assume that patients are best motivated for a lifestyle change when 
they are ill and under treatment. Therefore, this study enrolled the patients to be engaged in 
decisions about their options for lifestyle change right after the first consultation (initial 
visit).   
 
 
Significance 
 
So far, no known previous studies have compared the effects of a DA with and 
without the supplement of individual decisional counseling program (DCP) as we did in 
this study. Also, the degree to which patients’ preferences can explain adherence with 
cardiac risk reduction behavior has not been a focus of empirical investigations. By 
systematically eliciting patients’ cardiac risk reduction behavior preferences, the patients 
are allowed to select and determine the relative importance of behavior changes they 
consider important to maintain long-term cardiac risk reduction behavior. When people can 
perform cardiac risk reduction behavior in accordance with their preferences, it may 
become easier to adhere to this reduction behavior over time which in turn may improve 
HRQoL and health outcomes.  
       
 
Theoretical framework 
 
This study was guided by The Health Decision Model derived from The Health Belief 
Model. 
 
The Health Belief Model was proposed in the 1950s by a group of US Public Health 
Service social psychologists (Hochbaum, 1958; Rosenstock, 1960; 1974), and connects 
theories of decision-making to individuals’ decisions about alternative health behaviors. 
The underlying theoretical relationships in the model are that behavior depends on two 
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variables; (1) the value placed on a particular outcome, and (2) the individuals estimate that 
a given action will result in that outcome. According to this, to be able to take action to 
reduce the risk of a disease, a person would need to believe (1) that he was susceptible to 
the disease, (2) the occurrence of the disease would have at least moderate severity on some 
parts of life, and (3) that taking a specific action would be beneficial by reducing the 
susceptibility, and /or reducing the severity, and that the action taken would not involve 
overwhelming barriers like costs, comfort, humiliation, and pain (Eraker, Kirscht & Becker, 
1984; Janz, Champion & Strecher, 2002).  
  
The Health Decision Model is a third generation model of patient behavior developed 
from the Health Belief Model and deals with health decisions by combining aspects of 
decision analysis, behavioral decision theory, patient preferences, and health beliefs to yield 
a unifying model of health decisions and behavior outcome (Eraker et al., 1984; Eraker, 
Becker, Strecher & Kirscht, 1985). The model hypothesizes that compliance with provider 
advice depends to some extent on the patient’s perceptions regarding susceptibility to a 
disease, severity of the disease if contracted, and the benefits and barriers likely to be 
derived and encountered relative to undertaking a recommended action. A number of 
general inferential rules that patients employ is identified to reduce difficult mental tasks to 
simpler ones.  In this study decision analysis provides a quantitative means for patients to 
express their preferences about critical trade-offs by weighting their possible benefits 
against their possible constraints or barriers on a balance weight (Hershey, 1979; von 
Winterfeldt & Edwards, 1986; Weinstein & Fineberg, 1980). The Health Decision Model 
also includes the importance of other factors affecting health decisions and behavior, such 
as knowledge, experience, and social and demographic variables. The bidirectional arrows 
and feedback loops reflect the notion that adherence behavior can change health beliefs 
(Eraker et al., 1985). In this study we have addressed directional arrows only as shown in 
Figure 2.  
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Figure 1 Health Decision Model (Eraker, et al., 1984) 
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occurs. Both perceived susceptibility and severity is connected to strong cognitive 
components, and are at least partly dependent on knowledge. However, the acceptance of 
susceptibility to a disease that is considered serious will provide a need to take action, but 
not necessarily define the direction of action that is likely to be taken (Eraker et al., 1985). 
 
The individual’s beliefs regarding the relative effectiveness of possible available 
alternatives to reduce the threat are supposed to guide the direction of the action taken. The 
behavior is thought to depend on what benefits he believes the possible actions would be in 
the actual case. An action is considered as beneficial when it is related to reduction in 
perceived susceptibility and/or severity. The actual course the individual will take is 
dependent on the beliefs rather than the objective facts about availability and effectiveness. 
An individual may believe an action will be effective, but at the same time believe the 
action has some inconveniences, is expensive, discomfort or even painful. Thus it is likely 
that negative aspects of possible actions will serve as barriers to action and create 
conflicting motives of avoidance (Eraker et al., 1984).  
      
Studies testing the Health Belief Model suggested that perceived barriers and benefits 
determine how much a person values health. For example, the relationship of certain health 
beliefs and values to influenza vaccination rates were studied among 232 high-risk patients. 
The patients vaccinated believed the vaccine to be more efficacious than patients not 
vaccinated (Larson et al., 1979). That study and others (Heinzelmann & Bagley, 1970; 
Parcel et al., 1980) indicated that individuals who perceive the benefits of a preventive 
behavior as outweighing the barriers, or disadvantages,- usually have a higher health value 
orientation and undertake the preventive behavior. Studies of the Health Belief Model also 
demonstrated that perceived benefits and barriers determine participation in health care 
activities. Findings related to pap smear testing revealed that women who held the belief 
that early detection of a disease was beneficial reported more regular tests than those who 
did not hold this belief (Kegeles et al., 1965). Thus, individuals undertake health care 
activities to the extent that perceived benefits outweigh perceived barriers (Maiman et al., 
1977; Oldridge, 1979; Sennott-Miller & Miller, 1987).   
 
A number of studies that have used the HBM variables to examine preventive health 
behavior in cardiac patients are described in Chapter 2. 
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Investigated Relationships 
 
In this study we investigated the difference in effects of the two interventions DA with 
and without additive individual decisional counseling (DCP) and “the usual care” on 
several outcomes. We hypothesized that the interventions will increase the primary health 
outcomes and HRQoL mediated by improvement of the intermediate outcome adherence to 
cardiac risk reduction behavior. Behavioral theories often contain common mediating 
variables These variables are usually used to explain the mechanisms through which 
behavioral interventions affect outcome behavior (Baranowski, Lin, Wetter, Resnicow & 
Davis Hearn, 1997). By designing interventions to produce change in mediating variables 
that in our study were knowledge about risk factors and CAD, perceived health beliefs, and 
perceived benefits and barriers allows us potentially to link mediating variables to 
outcomes of intermediate outcomes of adherence and primary health outcomes. 
 
Several effects were investigated:  
(1) The effects of the two additive interventions on primary health outcomes: (a) body 
weight, cholesterol, blood pressure, and amount of tobacco, and (b) Health-related 
quality of life (HRQoL).  
(2) The effects of the two additive interventions on intermediate adherence outcomes.  
(3) The effects of the two additive interventions on several of  the hypothesized 
mediating variables (knowledge about risk factors and CAD, perceived health beliefs, 
perceived benefits of, and barriers to cardiac risk reduction behavior).  
(4) The relationship between intermediate adherence outcomes and primary health 
outcomes: body weight, cholesterol, blood pressure, health service used, and amount 
of tobacco use.  
(5) The relationship between intermediate adherence outcomes and HRQoL. 
(6) The relationships between the primary health outcomes and HRQoL. 
(7) The relationships between the hypothesized mediating variables (intention to adhere 
to cardiac risk reduction behavior, knowledge about risk factors and CAD, perceived 
health beliefs, perceived benefits of and barriers to cardiac risk reduction behavior, 
and decisional conflict) and intermediate adherence outcomes.  
Figure 2 displays the study variables and their proposed directional relationships in our 
study.  
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Figure 2  Study variables and their relationships 
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Definitions of study variables 
Independent variables 
The interventions in this study and thus the independent variables were 
1. The DA 
2. The DA with the addition of the DCP 
Primary outcomes 
Body weight was defined as the mass of an organism's body. Body weight is 
measured in kilograms. We calculated the person’s body mass index (BMI) by the 
equation: BMI= Mass (kg)/ (Height (m))2            
 
Cholesterol. Cholesterol is a lipid bound to proteins in blood plasma to form 
lipoproteins. Dependent of type, size, and concentration in plasma the degree to causes of 
possible atherosclerosis differ. HDL does actually have antiatherogenic properties, and low 
levels measured as HDL-cholesterol (less than 1 mmol/l in men and less than 1.2 mmol/l in 
women) is considered a marker of increased risk and poor outcome (Graham et al., 2007). 
However, most of the cholesterol in blood plasma is normally carried in LDL, and there is a 
strong positive association between total-cholesterol as well as LDL-cholesterol and the 
risk of CAD (Clarke et al., 2002; Maniolo et al., 1992; Neaton et al., 1992). A reduction of 
LDL, measured as LDL-cholesterol is a primary outcome for CAD patients.   
 
Blood pressure. A number of studies have identified elevated blood pressure as a risk 
factor for CAD in both men and women in all groups ranging from 40-89 years of age 
(Graham et al., 2007). The Fourth Joint Force of the European Society of Cardiology and 
other Societies on Cardiovascular Disease Prevention in Clinical Practice recommend that 
patients qualified for treatment should try to lower blood pressure to at least below 140/90 
mmHg, and that lower values are preferred if tolerated by risk subjects (Graham et al., 
2007). 
 
Amount of tobacco. The evidence of an adverse effect of tobacco is great, and related 
to the amount and duration of daily tobacco use. Tobacco smoking increases the risk of 
atherosclerotic disease in several ways. Smoking tobacco is responsible for 50% of all 
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avoidable deaths, and one half of these are due to CAD in long-term smokers (Graham et 
al., 2007). In this study we defined smoking as the daily use of tobacco products, and 
measured it in grams of tobacco each week including different forms of smokeless tobacco.  
 
Health service use was in this study defined as the persons’ self-reported use of four 
predetermined examples of health services focusing on reduction of cardiac risk, during the 
last two months. The four services encompassed participation in cardiac rehabilitation, quit 
smoking course, weight reduction courses, and diet course.    
 
Health-related quality of life (HRQoL) in this study was defined as the self-reported 
and valued level of wellness and illness, taking into account the presence of biological or 
physiological dysfunction, symptoms, and functional impairment. The valued level of 
wellness and illness were in this study measured by following indicators in SF-36: the 
extent of patients physical functioning, the extent of their role-functioning, the intensity of 
their bodily pain, their perceived general health, their feeling of vitality, the extent of their 
social functioning, the extent of their role functioning emotionally, and their perceived 
mental health. The level of satisfaction with the treatment for chest pain, chest tightness, or 
angina, and the limits in quality of life because of chest pain, chest tightness, or angina 
were measured by Seattle Angina Questionnaire (SAQ) by patients regarding themselves as 
having angina pectoris. 
 
Intermediate outcome 
Adherence to cardiac risk reduction behavior was defined as the patients’ perception 
of the degree to which they actually perform the prescribed actions on cardiac risk 
reduction regimen after their angiogram, such as healthy eating, quitting smoking, 
exercising regularly, taking their prescribed medications, and modifying responses to stress 
(Miller et al., 1982a; 1982b). 
 
Mediating variables 
Knowledge about risk factors and CAD was in this study defined as the actual 
knowledge of what CAD is, and what its predisposing risk factors are, and how to provide 
them. 
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Health Beliefs was defined as the perceived susceptibility and perceived severity of 
receiving CAD for the patients not yet diagnosed, and perceived CAD progression for 
patients already diagnosed. 
 
Perceived susceptibility of CAD or CAD progression was defined as the patient’s 
perception of how susceptible he is of CAD/potential progression of his CAD (Eraker et al., 
1984).  
 
Perceived severity of CAD or CAD progression was defined as the patient’s 
perception of the severity of CAD/potential progression of his CAD (Eraker et al., 1984).  
 
Perceived benefits of cardiac risk reduction behavior were theoretically defined as 
the perceived benefits to undertake cardiac risk reduction behavior (Murdaugh & Verran, 
1987). 
 
Perceived barriers to cardiac risk reduction behavior were theoretically defined as 
the perceived barriers to undertake cardiac risk reduction behavior (Murdaugh & Verran, 
1987).  
 
Decisional conflict was defined as a patient’s state of uncertainty about which option 
to choose, the factors contributing to this uncertainty, and the effectiveness of the decision 
(O’Connor, 1999).  
 
Control variables 
The control variables in this study were: Gender, Age, Cardiac functional status, 
Previous cardiac events, Disease severity, Comorbidity, Medication intake, Received 
treatment and they are described in detail in Chapter 3, page 67-69. 
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There are several dimensions of risk: biological, environmental, social, and 
behavioral. Behavioral risk factors are risks identified specifically with practice, or failure 
to practice, an action or series of actions that are associated with health outcomes. The term 
cardiac risk reduction behavior is in this study used synonymously with cardiac risk factor 
modification, lifestyle modification, risk reduction behavior, and lifestyle behaviors. A 
composite of various healthy behaviors is often referred to as a healthy lifestyle. It 
encompasses quitting smoking, lowering cholesterol, reducing fat in diet, watching calories, 
exercising regularly, and reducing stress.  
 
 
Hypothesis and research questions 
 
Hypothesis
This study tested the hypothesis that patients in the DA+DCP group will achieve 
significantly better outcomes over the study period than patients in the DA group who in 
return will achieve better outcomes than the Control group (“usual care”). Particularly, for 
patients in the DA+DCP group we would observe: 
 
1. Better primary health outcomes in terms of better body mass index, cholesterol, 
blood pressure, and less amount of tobacco, and better HRQoL 
2. Better intermediate outcomes in terms of greater adherence outcomes (following the 
diet recommendations, activity recommendations, taking their prescribed 
medication, stress reduction, and no smoking)  
3. Better outcomes in terms of greater knowledge about risk factors and CAD, 
perceived susceptibility and severity of CAD or CAD progression, and more 
perceived benefits and less perceived barriers to cardiac risk reduction behavior   
 
 
Additional research questions 
To better understand the mechanism by which these effects may occur, additional 
research questions explored:  
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1. What are the relationships between Adherence outcomes and health outcomes at two, 
four, and six months following the angiogram?        
2. What are the relationships between Adherence outcomes and HRQoL at two, four, and 
six months following the angiogram?     
3. What are the relationships between health outcomes and HRQoL at two, four, and six 
months following the angiogram?     
4. What are the relationships between the intentions at baseline, knowledge about risk 
factors and CAD, perceived susceptibility and severity of CAD progression, 
perceived benefits and barriers of cardiac risk factor reduction, and decisional conflict 
two months following the angiogram, and adherence outcomes two, four, and six 
months following the angiogram?  
5. What is the acceptability to patients of the DA with and without additional counseling?  
6. What is the acceptability to patients of the DCP? 
 
 
Study Assumptions 
 
People are more likely to choose an alternative which they, according to their 
preferences, perceive will be effective in achieving individually valued outcomes and 
avoiding individually undesirable outcomes. Although this is not necessarily true, the 
assumption underlying DAs and HBM is that people make rational choices. 
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Chapter 2 
Review of the literature 
 
 
Introduction 
 
This chapter presents a review of the literature that supports hypothesized 
relationships and study questions and identifies knowledge gaps that are the rationale 
behind this study. Particularly this review synthesizes: effects of DAs, (2) effects of 
individual decisional counseling, (3) the Health Belief Model (HBM) and predictors of 
adherence to cardiac risk reduction behavior, and (4) the relationships between adherence to 
cardiac risk reduction behavior, health outcomes, and HRQoL as depicted in Figure 2 page 
19. Although this study was conceptualized in 2007, the review presented here includes 
literature until 2010.  
 
 
Effects of Decision Aids 
 
A systematic review showed that the most consistent benefits of DAs relative to usual 
care are better knowledge of options and possible outcomes, and more accurate perceptions 
of the probabilities of possible outcomes (O’Connor et al., 2009). However, decisions about 
lifestyle changes and interventions designed to promote adherence to a recommended 
behavior were excluded from the systematic review on DAs. Furthermore, decisional 
conflict scores decrease consistently (Briggs et al., 2004; Davison et al., 1999; Dolan & 
Frisina, 2002; Goel et al., 2001; Man-Son-Hing et al., 1999; Montgomery et al., 2003; 
Murray et al., 2001a; 2001b; O’Connor et al., 1998a; O’Connor et al., 1998b; Stahlmeier et 
al., 1999; Whelan et al., 2004). Greater congruence between patients’ preferences/values 
and their actual choice has been well established in three studies (Barry et al., 1995; 
Holmes-Rovner et al., 1999; O’Connor et al., 1998a). However, effect sizes vary across 
studies, and many studies were underpowered (O’Connor et al., 2009).  
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The effects of DAs are most often measured in terms of their ability to increase 
knowledge, reduce decisional conflicts, increase participation in decision-making, the rate 
of people remaining undecided, the preference or uptake of options, and accurate risk 
perception. However, it has been argued that when the purpose of a DA is to help patients 
to make a decision that is consistent with the values/preferences they place on potential 
consequences and possible options, the effects of DAs should be judged by the extent to 
which a patient actually implements the decision, but only few studies address this. 
Furthermore, several authors have argued that increased knowledge and reduced decisional 
conflict are not sufficient evidence of DAs effectiveness (McCaffery et al., 2007; Nelson et 
al., 2007). McCaffery and colleagues (2007) are suggesting that longer-term health and 
quality of life outcomes should be the focus of DA evaluation. Therefore, in this study 
outcome measures include decision implementation and HRQoL. 
      
To summarize the effects of DAs on lifestyle changes we performed a systematic 
search of the following electronic databases: MEDLINE, CINAHL, EMBASE, and 
PsychINFO. The search was conducted for the time period from January 2001 to December 
2010. Detailed search strategies were developed for each electronic database based on the 
search strategy developed for MEDLINE. In each database, we searched for every term 
listed in Table 1 below in the database thesaurus and used the free text/key word method. 
We also searched for synonyms and modified versions of these terms to best utilize each 
database/thesaurus. The inclusion criteria were adults 19 years or older; English and 
Scandinavian language articles; randomized controlled trials. Excluded were studies testing 
interventions for assisting hypertensive patients or patients with dyslipidemia in the 
decision whether to start drug therapy or not.  
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Table 1  
Overview of searches and terms as conducted in MEDLINE database 
 
Patient Intervention Comparis
on 
Outcome 
Search # 1 
 
Decision Aid  Cardiac risk factor 
modification behavior 
ƔCoronary Artery 
Disease 
ƔAngina pectoris/ 
or angina , 
unstable 
ƔAdults 19 or 
older 
ƔDecision Support Techniques/ 
ƔDecision-making/ 
ƔChoice behavior/ 
Ɣdecision aid$ or decision support$ or 
choice behavior$ 
 
 
 
 
Usual care ƔHealth behavior/ 
ƔPatient compliance/ 
ƔMedication Adherence/ 
ƔRisk reduction behavior/ 
ƔTobacco use cessation/ 
ƔSmoking cessation/ 
ƔLifestyle/ 
ƔLife change events/ 
ƔSedentary lifestyle/ 
ƔExercise/  
ƔDiet/ 
ƔStress, Psychological/ 
Patient Intervention Comparis
on 
Outcome 
Search #2 Decisional counseling  Cardiac risk factor 
modification behavior 
ƔCoronary Artery 
Disease 
ƔAngina pectoris/ 
or angina , 
unstable 
ƔAdults 19 or 
older 
ƔCounseling/ 
ƔPatient education as Topic/ 
ƔCognition/ 
ƔAwareness/ 
ƔComprehension/ 
ƔPerception/ 
ƔMotivation/ 
ƔPower (psychology)/ 
ƔPatient  preference/ 
Ɣcounsel$ or aware$ or motivat$ or Coach$ 
or empower$ or personal$ health plan$ or 
patient preferenc$ or value clarificat$ or 
goalsetting or action plan$ or patient 
experience$ or patient percept$ or 
comprehend$ 
Usual care ƔHealth behavior/ 
ƔPatient compliance/ 
ƔMedication Adherence/ 
ƔRisk reduction behavior/ 
ƔTobacco use cessation/ 
ƔSmoking cessation/ 
ƔLifestyle/ 
ƔLife change events/ 
ƔSedentary lifestyle/ 
ƔExercise/  
ƔDiet/ 
ƔStress, Psychological/ 
 
Patient Intervention Comparis
on 
Outcome 
Search #3 Cardiac risk factor 
modification behavior 
 Health outcomes 
ƔCoronary Artery 
Disease 
ƔAngina pectoris/ 
or angina , 
unstable 
ƔAdults 19 or 
older 
ƔHealth behavior/ 
ƔPatient compliance/ 
ƔMedication Adherence/ 
ƔRisk reduction behavior/ 
ƔTobacco use cessation/ 
ƔSmoking cessation/ 
ƔLifestyle/ 
ƔLife change events/ 
ƔSedentary lifestyle/ 
ƔExercise/  
ƔDiet/ 
ƔStress, Psychological/ 
Usual care ƔBody Mass Index/ 
ƔBody weight/ 
ƔBody weight changes/ 
ƔWeight gain/ 
ƔWeight loss/ 
ƔCholesterol/ 
ƔCholesterol HDL/ 
ƔCholesterol, LDL/ 
ƔBlood pressure/ 
ƔQuality of life/ 
 
The search on the online databases yielded 241 titles from the search. From the 
searches 235 were excluded after the abstract had been read, as they did not meet inclusion 
criteria. 6 articles were retained.  
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As shown in Table 2 we found only one study (van Steenkiste et al., 2007) that showed 
significant lifestyle improvements resulting from an intervention to promote shared decision-
making. Therefore we also assessed studies testing DA on other outcomes related to lifestyle 
change. 
     
To summarize; the evidence of the effects of DAs on adherence to a chosen option is 
unclear. Five studies measured adherence to the options chosen, warfarin versus aspirin  
( Man-Son-Hing et al., 1999), oral bisphosphonate medications (Oakley & Walley, 2006), 
blood pressure medications (Montgomery et al., 2003), and Hormone replacement therapy 
(Deschamps et al., 2004; Rothert et al., 1997). There were no significant differences between 
groups in adherence to options chosen. Holmes-Rovner and colleagues (1999) measured the 
correlation between patients’ subjective expected value of hormone treatment and their 
likelihood of taking hormones. The results showed that the DA with an explicit value 
clarification exercise had higher consistency between expected values and taking medication 
than decision support without explicit value clarification.  
      
Several studies have compared DAs to usual care in terms of general health outcomes 
using the SF-36 or the SF-12 as outcome measures. These studies found no significant 
statistical differences between the DA and the usual care group ( Bernstein et al., 1998; 
Morgan et al., 2000; Murray et al., 2001a: Stewart, 1995). One Canadian study (Liao, Jollis, 
DeLong, Peterson, Morris, & Mark, 1996) and one American study (Morgan et al., 2000) that 
tested the effects of a treatment DA for CAD patients compared to usual care, found that 
patients had increased confidence in their treatment choice (Liao, et al., 1996), higher 
knowledge scores, and demonstrated increased decision-making autonomy, without apparent 
impact on quality of life (Morgan et al., 2000). Barry and colleagues (1997) found that 
physical functioning and general health outcomes were significantly better in the DA group 
compared to the usual care group for men considering treatment for benign prostate disease. 
Kennedy and colleagues (2002) reported that women considering treatment for abnormal 
uterine bleeding showed a statistically significant improvement in the role physical function 
variable in the SF-36. Altogether, there has been very little research to measure the effect of 
DAs for health behavior change and health outcomes. 
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Effects of individual decisional counseling 
 
A large number of studies have supported positive effects of individual counseling. 
There is evidence of the positive effects of medium to high intensity dietary counseling 
delivered by trained clinicians to high risk patients (Pignone et al., 2003; U.S. Preventive 
Service Task Force, 2003a). A patient-centered counseling model has been found to enhance 
long-term dietary adherence (Rosal et al., 2001). There is also fair- to good evidence that high 
intensity counseling and behavioral intervention strategies that address physical activity, 
dietary improvement, or both, can produce moderate sustained weight loss in obese patients 
(McTigue et al., 2003; U.S. Preventive Service Task Force, 2003b). In addition, behavioral 
risk reduction interventions can reduce smoking (Fiore et al., 2008).These interventions 
include brief advice and counseling, interventions that are feasible in outpatient clinical 
settings. Steptoe and colleagues (1999) found that a brief behavioral counseling for men and 
women who were at increased risk of CAD resulted in reduced dietary fat intake, decreased 
number of cigarettes smoked per day, and increased physical activity in the experimental 
group at 4 and 12 months. Intensive counseling compared to brief counseling did not show 
any significant difference in smoking relapse in five studies (Landcaster & Stead, 2005).  
 
Several studies suggest that goal setting and action plans may be more effective in 
promoting behavioral change than traditional advice (Ammerman et al., 2002; Cullen et al., 
2001; Handley et al., 2006; Moore & Kramer, 1996; Shilts, et al., 2004). Counseling is used 
as a method to help patients develop an individualized tailored action plan (Ammerman et al., 
2002; Babor et al., 2001; Bodenheimer et al., 2002; Fiore et al., 2008; Glasgow et al., 2003; 
Lorig & Holman, 2003; McTigue et al., 2003; Pignone et al., 2003; Whitlock et al., 2004). 
Data indicate that people are more likely to translate their good intentions into action when 
they make an action plan: intentions foster an action plan, and the action plan fosters 
behavioral change (Gollwitzer & Sheeran, 2006). It is argued that the action plan must be 
clear and accurate because mixed messages and health misinformation affect involvement in 
the plan (Woodard et al., 2005).  In our study we therefore included development of an 
individual action plan based on patients’ preferences for cardiac risk reduction behavior in the 
DCP. 
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Significant progress has been made in developing effective health behavior change 
interventions that address single factors (Goldstein et al., 2004; Moore et al., 2006), but large 
gaps remain in the development of effective methods for addressing multiple behaviors 
(Glasgow et al., 2004; Goldstein et al., 2004; Orleans, 2004). The most promising evidence 
for addressing multiple behavior risk factors comes from interventions that address secondary 
prevention among patients with existing CAD. Once illness is present, there is a growing 
body of evidence to support the impact of multimodal risk factor interventions on a variety of 
outcomes, including adherence to cardiac risk reduction behavior (Appel et al., 2003; 
Ebrahim et al., 2006; Ketola et al., 2000; Knowler et al., 2002; McAlister et al., 2001; 
Murchie et al., 2003). Koertge and colleagues (2003) found that a multicomponent lifestyle 
change program for diet, activity, stress reduction, and social support can improve health 
outcomes and HRQoL, when maintained over a period of one year. 
      
Feedback and assessment enhance the success of health behavior counseling 
interventions and are often used in multiple risk behavior interventions (Bodenheimer et al., 
2002; Fiore et al., 2008; Glasgow et al., 2001; Glasgow, 2003; Glasgow et al., 2003; Pignone 
et al., 2003; van Steenkiste et al., 2007; Wasson et al., 2003; Whitlock et al., 2004). Patient 
involvement in medical decisions has been shown to impact adherence (Cooper et al., 2002). 
Patients need to be informed, motivated, and skilled in the use of strategies if they are to cope 
efficiently with recommendations regarding their illness.  While DAs can provide patients 
with helpful knowledge if supplemented with individual counseling this may be even more 
effective. No known previous studies have compared the effects of a CAD-DA with and 
without the supplement of individual decisional counseling as we did in this study.  
         
The short- and long-term success of CABG surgery depends on the occlusion rate of the 
bypass grafts and the ongoing occlusion of the native coronaries. Krannich and colleagues 
(2008) noticed that many CABG patients assume that they are completely cured after surgery 
when symptoms and pain are no longer present. Within the first year after CABG surgery 
about 12-20% of the vein grafts are occluded again, and after 10 years this ratio increases to 
41-50 % (Zellweger et al., 2001). Therefore, after surgery patients risk perception is 
weakened, pointing to the fact that people generally do not know that CAD is a chronic 
condition. Krannich and colleagues (2008) found that motivation for lifestyle changes 
decreases shortly after CABG surgery and argue that patients should be informed about their 
option for secondary cardiac prevention as early as possible. In our study we therefore 
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included patients before the angiogram to ensure early start of introducing options for a 
healthy lifestyle. 
      
Programs that allow individuals to choose any number of their own unhealthy behaviors 
to reform, can provide risk reduction for a broad spectrum of patients, with a wide range of 
traditional risk factors (Calfas et al., 2002; Grant, 2003). These strategies should work by 
effecting favorable changes in patient behavior, which would then lead to improved 
cardiovascular risk by modifying a number of risk factors and improving control of several 
risk conditions (Gæde et al., 2003; Koertge et al., 2003; Strandberg et al., 2006). The DCP 
intervention in our study was developed based on this strategy and to structure situations 
where patients were able to discover the importance of choosing any number of healthy 
choices in diet, activity, stress reduction, and smoking cessation, thereby preventing CAD or 
CAD progression.  It was designed to improve patients’ cognitive and affective understanding 
of the importance of a healthy lifestyle, and elicit their preferences for change. 
 
A review by Ashenden et al. (1997), found evidence that interventions in general 
practice have a modest and variable effect on lifestyle and concluded that the small changes in 
behavior that was found not seem to produce substantial changes. This is supported in a 
review by Ebrahim et al. (2006) that evaluated the effects of multiple risk factor interventions 
for reducing cardiovascular risk factor among adults with no clinical cardiovascular disease. 
A Cochrane review shows that there is limited evidence of long-term effectiveness of 
interventions for promoting physical activity (Foster et al., 2005). The Norwegian Knowledge 
Centre (Flottorp et al., 2008) summarized Cochrane reviews on the effects of non-
pharmacological interventions to support lifestyle changes and found that several 
interventions may have small or moderate positive effects on smoking, physical activity, 
overweight, and diet. Sebregts et al. (2000) suggest in their review of risk factor modification 
behavior through non pharmacological interventions in CAD patients that it is important to 
scrutinize the quality of information that patients receive. The DA in our study provided 
thorough information. DAs are developed to encourage patients to engage in decision-
making. They differ from other health education materials because of their specific, detailed, 
and personalized focus on options and outcomes. DAs deliver information in various ways, 
including: (a) written materials, (b) oral (audio) presentation of information combined with 
written and/or visual materials (c) video programs (d) computer programs, and, (e) individual 
counseling /explicit value clarification exercises, often combined with written and/or visual 
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information. The DA in this study contained text, graphics, and exercises to illustrate and 
personalize the provided information.  DAs are designed to help patients: (1) recognize that a 
decision needs to be made, (2) understand the options and outcomes, (3) see how values and 
preferences affect the decision, (4) understand what matters most, and can discuss these 
matters with their health care providers, and (5) become involved in preferred ways 
(Molenaar, et al., 2000; O’Connor, Rostom, et al., 1999; O’Connor et al., 2009).  
 
 
The Health Belief Model (HBM) and predictors of adherence 
 
Janz and colleagues (2002) identified the HBM as one of the most studied theories in 
health education, used successfully with varying populations, health conditions, and 
interventions. The HBM has been used to examine risk reduction behaviors such as breast-
self-examination, undergoing mammography, and quitting smoking. Support for the HBM 
variables to predict behaviors are not consistent across studies.  
 
Health beliefs and adherence.  
Ali (2002) tested several predictors of CAD preventive behaviors derived from the 
HBM in a sample of 178 healthy women. Susceptibility and severity of CAD, knowledge of 
risk factors, and general health motivation explained a substantial amount of variance in 
healthy behavior practice. For example women who perceived themselves as significantly 
more likely to get a heart disease, and believed that heart disease was a serious condition were 
more likely to use hormone replacement therapy (Ali, 2002). 
       
In a study comparing a smoking prevention intervention with an approach based on the 
HBM among women showed no significant difference (Schmitz, et al., 1999). At baseline 
women with established CAD perceived themselves as being more susceptible to cardiac 
health problems related to future smoking, but gave relatively lower ratings regarding the 
severity of such problems than at-risk women. Furthermore, women with established CAD 
reported fewer benefits of quitting. Data indicated that having already suffered from the 
negative effects of smoking these women felt highly threatened by their current behavioral 
patterns yet they did not believe that change would be beneficial in reducing the perceived 
threat. One of the most important findings in Schmitz and colleagues’ (1999) study was the 
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significance of sample characteristics as a predictor of outcome. The odds of being abstinent 
at 6 months were 2.2 times greater for at-risk women when compared with women with 
established CAD. This appears inconsistent with other literature suggesting that the presence 
of a disease condition itself is generally a robust predictor of smoking cessation (Burling et 
al., 1984; Gritz et al., 1993; Perkins, 1988). To enroll patients at the initial visit at the Cardiac 
Outpatient Clinic may therefore increase the likelihood of quitting smoking. 
      
It is commonly believed that CAD is not feared as much as cancer, and is often seen as a 
quick preferable death (Emslie, et al., 2001). The perceived severity of the disease threat has 
shown mixed results regarding adherence to cardiac rehabilitation. In a study by Oldridge & 
Streiner (1990) the perceived severity was associated with adherence to cardiac rehabilitation, 
while other studies found small associations between perceived severity and adherence to 
cardiac rehabilitation (Muench, 1987; Tirrell & Hart, 1980). Patients’ perceived severity of, 
and susceptibility to CAD have been shown to be positively related to adherence to 
antihypertensive medication, and smoking cessation (Janz, 1988; Janz & Becker, 1984). Thus 
data indicate that beliefs about risk and disease are an important component in adherence to 
recommended guidelines and influence adherence. We therefore included perceived 
susceptibility and severity as key components in our DCP. 
        
Perceived benefits and barriers, and adherence.   
The concept of perceived benefits and barriers to an action are known as decisional 
balance, or benefits/advantages minus barriers/disadvantages, pros minus cons, where patients 
intellectually think about the advantages and the disadvantages of engaging in a particular 
action. Perceived benefits have been associated with adherence to cardiac rehabilitation (Ades 
et al., 1992; Al-Ali & Haddad, 2004; Moore et al., 2003; Oldridge et al., 1990). Counseling on 
perceived benefits has been demonstrated to help motivate weight loss, patients to begin 
exercising, and eating low-fat diets (Clark, et al., 1996). Counseling on the perceived barriers 
have had mixed effects based on the type of intervention. Perceived barriers such as side 
effects and complexity have been found to be negatively related to adherence (Sackett, et al., 
1975), and associated with non-adherence to cardiac rehabilitation (Oldridge et al., 1985; 
Oldridge et al., 1990). After discussing the perceived barriers of the time it takes to do a 
breast examination, women more often reported performance of breast examination 
(Champion, 1993). During the discussion of the barriers the patient may reflect on how to 
overcome these barriers and find solutions for performing the new behavior.  
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Sustaining change is difficult even for the most motivated person, and when the effect of 
the intervention fades, the adherence decreases. Adherence also decreases when patients do 
not perceive any benefit in changing their behavior (Schaffer & Yoon, 2001). Thus data 
indicate that perceived benefits are important factors for behavioral change. In our study we 
therefore included assessment and weighting of individual perceived benefits and barriers of 
cardiac risk reduction behavior in our DCP. 
      
Relapse and relapse prevention.   
The prevalence rate of adherence to medical recommendations is on average, 75.2 % in 
a meta-analysis of the literature from 1948-1998 (DiMatteo, 2004a). Adherence to healthy 
behaviors, diet, and exercise yield lower adherence averages, each is significantly lower than 
its comparison with other regimens: Healthy behavior adherence is 69.7 %, exercise 
adherence is 72.0 %, and diet adherence is 59.3 %. The average adherence in studies of CAD 
patients showed a mean adherence of 76.6 % (DiMatteo, 2004a).               
      
Non-adherence was significantly higher among patients with age less than 45 years 
(Sherbourne et al., 1992). Older patients, despite greater difficulties due to higher medical 
complexity, may have developed a stronger allegiance to their provider by virtue of greater 
dependency and greater utilization of the health care system. Cardiac patients with higher 
education, who were older, and those who were dissatisfied with the technical quality of care 
were more likely to adhere to a specific recommendation. DiMatteo (2004a) states that the 
relationship between education and adherence is weaker in the acute care than in the care of 
chronic disease, and he reports that in chronically ill patients adherence is positively 
correlated with patient education. Adherence is also positively correlated with income and 
socioeconomic status. Data indicate that changeable factors like depression and support have 
greater effects on adherence than non-changeable factors like age and gender. Unrecognized 
clinical depression might bring about poor adherence and post treatment outcomes, 
particularly for heart disease (Ziegelstein et al., 2000, DiMatteo et al., 2000). Depression is 
also a significant predictor of HRQoL after CABG (Krannich et al., 2007). 
       
Reasons for poor medication adherence can be non-intentional such as carelessness or 
forgetfulness, or intentional when making an active choice to deviate from the treatment 
regimen (Lowry et al., 2005). Non-adherence to cardiovascular medications has been 
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associated with increased risk of morbidity and mortality (Rasmussen et al., 2007; Spertus, 
Kettelkamp et al., 2006b). Studies show that adherence continues to decline during the long-
term follow up phase for CAD.  Jackevicious and colleagues (2008) found that almost 25% of 
patients did not even fill their cardiac medication seven days after discharge for acute 
myocardial infarction. Another study (Ho et al., 2006) found that 34 % stopped at least one of 
the medications (statins, beta-blockers, and aspirin) and 12 % of all medication within one 
month after discharge for acute myocardial infarction. Economic limitations that prevent 
patients from following drug regimen are small in Norway because of the economic support 
of medication by government paid “blue” prescriptions and a ceiling level for high expenses. 
Because cardiac risk-reducing medical treatments and risk reduction behavior are poorly 
maintained over time (Haynes, 2001), it is important to design and test interventions that may 
increase the adherence to cardiac risk reduction behavior which was a purpose in this study. 
      
There are certainly patients who are simply unwilling to follow medical advice or to 
adhere to complex medical regimens (Ho et al., 2009). Adherence is not fostered by 
convincement but rather through a partnership based on communication that builds trust. 
Sherbourne and colleagues (1992) found that satisfaction with medical care was a predictor of 
patient adherence. A relationship between caregiver and patient that is positive and supportive 
is a key to effective communication (DiMatteo et al., 2002). Burke & Dunbar-Jacobs (1995) 
emphasize the mutual responsibility between patient and provider, and reinforce the 
commitment of the health care provider to help the patient implement and follow their 
treatment plan. Aspects of healthy provider-patient communication might increase the chance 
of patient adherence, and therefore improve the outcomes of medical treatment (DiMatteo, 
1994). Finally, it is important to consider the perspective of patients, many of whom may 
view non-adherence as a rational choice (Donovan et al., 1992). Therefore, it is necessary to 
work more collaboratively with patients to develop and expand the possible solutions that 
better fit the patient’s preferences and needs. Our study was designed to create such a 
collaborative environment in the individual counseling sessions.  
      
Generally, patients are more likely to choose an alternative that they perceive will be 
effective in achieving valued outcomes and avoiding undesirable outcomes. When presented 
with more than one option of choice, each of which has multiple characteristics, patients 
might find themselves in a state of uncertainty or difficulty in identifying the best alternative 
due to the uncertainty of outcomes, and they need to make value judgments about potential 
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gains versus potential losses (Keeney, 1988). This state is defined as decisional conflict. 
Multiple studies have investigated the relationship between DAs and decisional conflict. The 
most often used measurement was the Decisional Conflict Scale (DCS) (O’Connor, 1995) 
which measures the following dimensions: a person’s personal uncertainty in making a choice 
about health care options, the modifiable factors contributing to this uncertainty, and the 
quality of the decision made. Remarkably consistent results have emerged. These findings 
show that DAs help the patient to lower decisional conflict, feel less uninformed, and feel less 
unclear about personal values (O’Connor et al, 2009).  
 
Even with good adherence to a healthy behavior, relapse is common. There has been a 
wide acceptance in recent years that behavior change is a process, not an event. To undertake 
initial behavior change and maintain behavior change are different, and require different types 
of interventions. For example, to maintain non-smoking requires self-management and coping 
strategies, establishment of new patterns of behavior, increased perceived control, and 
confidence to avoid temptation. Our study, therefore addresses the individuals’ beliefs 
regarding the perceived risk associated with certain behaviors, patients’ preferences and 
experiences, the vulnerability to worsening disease, a decisional balance assessment, and 
taking action to change behavior in order to decrease the risk of CAD or CAD progression.  
 
 
Relationship between adherence to cardiac risk reduction behavior and 
health outcomes 
 
Adherence is generally associated with one’s ability to maintain the behaviors 
associated with a plan of care. Adherence in the healthcare literature is also referred to as 
compliance and maintenance. Compliance is viewed by some as a paternalistic term, and 
maintenance is used more often when describing persistent health behavior such as exercise 
and weight loss. Adherence, compliance and maintenance are measured from short-term 
behaviors like a single point, to long-term behavior over several years (Shay, 2008).  
     
Since the first empirical studies on adherence in the late 1960s, researchers have 
attempted to assess, understand, predict, and change patients’ responses to medical advice 
because, it is argued, adherence to treatment improves outcomes.  Patients’ adherence to 
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medical recommendations is believed to be an important mediator between physicians’ 
therapeutic expertise and patient outcomes. Self-care is a central element in the overall 
management of chronic diseases. Despite an assumed linkage between adherence and health 
outcomes in chronic disease, empirical studies have yielded mixed results (DiMatteo et al., 
2007; Roter et al., 1998). Therefore, the magnitude of the relationship between adherence and 
treatment outcomes remains to be determined. 
      
The adherence-outcomes complexity.   
The adherence-outcome relationship is complex. Factors like the strength and efficacy 
of recommendations and treatments, genetic variances in response rate, adverse drug 
reactions, misdiagnosis, and limitations in current understanding of the disease can affect 
outcomes. Studies with non-disease specific outcome measures like pain and health-related 
quality of life yielded higher effects than did those with disease-specific outcomes measures 
like blood pressure and cholesterol levels. There were no differences between studies on 
prevention and those of treatment or between studies in which patients were asked to adhere 
to one versus more than one regimen (DiMatteo et al., 2002). On average 26% more patients 
experienced a good outcome by adhering than by not adhering, consistent with a review on 
adherence and heart disease outcomes (McDermott, et al., 1997).  
      
Factors that modify the adherence-outcome relationship, particularly those involving the 
nature of the disease and of patient characteristics, appear to be complex. For example, the 
adherence-outcome relationship is higher in studies of chronic conditions than studies of acute 
conditions (DiMatteo et al., 2002). One possible explanation is that acute illness might be 
more self-limiting, making adherence less important in the acute care. Chronic conditions 
involve more non-medical regimens, are less serious, and studies of chronic illness are more 
likely to use continuous measures of adherence, all factors associated with higher adherence-
outcome correlations. The adherence-outcome relationship was lower in studies of more 
serious conditions, a finding that could be explained by a correlation with other moderating 
factors, or by the possibility that a patient’s adherence behavior makes a greater difference 
under less extreme medical circumstances (DiMatteo et al., 2002). Perceptions of poor health 
were related to a tendency toward non-adherence, and avoidance as a coping style was found 
to be an important predictor of non-adherence. Those reporting use of avoidance like hope for 
a miracle tended to be less likely to adhere to advice and recommendations (Sherbourne et al., 
1992).  
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Studies have found that adherence to pharmacological therapy, even if it is adherence to 
a placebo, is associated with better outcomes than for patients who are non-adherent to active 
treatment (Epstein, 1984; Horwitz et al., 1990; Irvine et al., 1999; The Coronary Drug Project 
Research Group, 1980). This effect is often named “healthy adherer” effect (Simpson et al., 
2006). The healthy adherer effect implies that a lower risk of adverse outcomes associated 
with adherence may be a surrogate marker for overall healthy behavior. Irvine and colleagues 
(1999) analyzed potential predictors of adherence and found few relationships that explained 
the positive, nonspecific effects of adherence to placebo. Further research on adherence and 
relationships to outcomes are necessary. 
      
Positive expectations might influence both outcomes and motivation to adhere 
(DiMatteo et al., 2002). Patients who are more likely to adhere might have personality 
characteristics (optimism, conscientiousness, personal adjustment) that are positively 
correlated with better health outcomes. Certain life circumstances like socioeconomic status 
might make it easier for patients to adhere and more likely to achieve positive health 
outcomes. Reverse causality may also play an important role (DiMatteo et al., 2002), so that a 
good outcome may promote subsequent adherence, particularly during long courses of 
treatment.  
 Adherence and measurement.  
The conception and operation of measurement appears to be critical to understanding 
the adherence-outcome relationship. Quality of measurement affects the adherence-outcome 
relationship, underscoring the importance of effective adherence assessment. Three aspects of 
adherence measurement (scale, number of measures and use of self-report) moderated the 
adherence-outcome effect, although the scale of adherence measurement was the only 
significant predictor (DiMatteo et al., 2002). These findings suggest that whenever possible, 
research should use measures that are continuous instead of dichotomous, use more than one 
measure of adherence, and include self-report. In adherence research self-reports can be 
direct, simple, and inexpensive, and although limited somewhat by memory (DiMatteo, 
2004a). It is important to note that adherence and treatment outcomes, while correlated, are 
distinctly different conceptually and empirically, and outcomes should never be used as 
proxies for adherence in adherence research (DiMatteo et al., 2002). 
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Risk factors and CAD.
In apparently healthy and asymptomatic people, the incidence of CAD is explained by 
the modifiable risk factors: serum total cholesterol and high LDL, blood pressure, poor diet, 
lack of exercise, and cigarette smoking (Edwards et al., 2006; Yusuf et al., 2004).  Secondary 
prevention of CAD involves risk factor reduction through control of health behaviors such as 
diet, physical activity, smoking, and medication adherence using a coordinated approach and 
referrals to health professionals. Modification of risk factors such as blood cholesterol, blood 
pressure, physical inactivity, smoking, and obesity can reduce cardiovascular events, the need 
for coronary revascularization and improved HRQoL (McAlister et al., 2001).  Studies of 
cardiac rehabilitation that include comprehensive lifestyle modifications before the era of 
statin therapy and improved coronary interventions also revealed a modest reduction of 
coronary artery stenosis (Haskell et al., 1994; Ornish et al., 1990; Ornish et al., 1998; Schuler 
et al., 1992). 
      
A systematic review by Buckley and colleagues (2010) showed weak evidence that 
secondary prevention services with regular planned recalls for appointments, monitoring of 
risk factors, and education can increase the proportion of patients whose total cholesterol 
levels and blood pressure are within target levels. The authors did not find significant effects 
of interventions on body mass index, cholesterol levels, mean blood pressure, or smoking 
status (Buckley et al., 2010). Studies of less intensive cardiac rehabilitation programs indicate 
that lifestyle and risk factors do not improve or even deteriorate (Lear et al., 2003; Willich et 
al., 2001).      
      
Diet and health outcomes.
There is evidence that lowering lipids both by dietary means, which includes reduced 
intake of saturated fat, and use of lipid-lowering drugs, have positive effects on lowering 
cardiovascular risk, and the effect is clearly related to the effect on the most important lipid 
fraction in blood (LDL). Effects on lipids are generally regarded as the most important of the 
dietary changes, but interventions to reduce obesity are also important. Each incremental 25% 
increase in the proportion of days covered with statin medications was associated with an 
approximately 3.8 mg/dl reduction in LDL cholesterol (Ho et al., 2006). 
Several studies have delivered specific interventions on changing risk factor status 
(Campbell et al., 1998; DeBusk et al., 1994; Heller et al., 1993; Jolly et al., 1999; Kirkman et 
al., 1994; Racelis et al., 1998; Vale et al., 2002). Two were effective (Campbell et al., 1998; 
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De Busk et al., 1994) in showing a significant difference in lipid concentrations between the 
intervention group and the control group. The effects in those studies may be explained by the 
increased uptake of lipid-lowering drug therapy, compared with the control group. In contrast, 
Vale and colleagues (2002) found that the effects of their coaching intervention best were 
explained by both adherence to drug therapy and adherence to lifestyle advice. The other four 
studies aimed to modify diet and other behavior according to therapeutic guidelines and were 
not effective in modifying lipid levels. The objective of those studies was to influence the 
process towards risk reduction. Achievement of goals related to this process did not result in 
improved risk factor levels. In the study of Heller et al., (1993) and Kirkman et al. (1994) 
there was found improvement in self-reported adherence to regimens that might reduce 
coronary risk, but this was not reflected in the objective measures of risk factors.  
     
Vale and colleagues (2003) and Jelinek and colleagues (2009) reported that an intensive 
coaching intervention program improved cardiac risk factors from entry to exit of the 
program. The coaching was aimed to train patients to take responsibility for the achievement 
and maintenance of the target lipid levels by visiting their doctors and following appropriate 
nutritional guidelines. The coaching was performed by a dietician trained in patient education. 
Six months later there was a small decline in the risk status and after 24 months the cardiac 
risk factors status and adherence to medications was slightly less than measured at the end of 
the intensive coaching intervention. Nearly all variables were significantly better after 24 
months. The authors concluded that the cardiac risk factor status was maintained and better 
than at the entry of the study. 
    
Medication intake and health outcomes.  
Several trials have documented preventive effects with blood pressure-lowering drugs. 
High adherence to antihypertensive medication was associated with higher odds of blood 
pressure control compared to those with medium or low levels of adherence (Bramley et al., 
2006). However, due to side effects of pharmacological interventions any intervention that 
could lower blood pressure or prevent its increase would be preferred. It has been shown that 
a change in diet to lower levels of salt intake can significantly lower blood pressure (Sacks et 
al., 2001; Sacks & Campos, 2010).   
  
 
 
 
 
43 
 
Physical activity and health outcomes.  
Yusuf and colleagues (2004) have shown that low physical activity is an independent 
risk factor for MI. Regular physical activity may decrease morbidity and mortality rates 
associated with CAD through multiple mechanisms (Franklin et al., 2004).  In a randomized 
trial of 101 men with stable CAD and an angiographically documented stenosis amenable to 
PCI, the authors compared a 12 month exercise training program and medical therapy with 
standard PCI and reported that participants in the exercise group had a longer event-free 
survival and increased exercise capacity at lower costs (Hambrecht et al., 2004). Physical 
activity can prevent and treat established risk factors, such as elevated blood pressure (Fagard 
& Cornelissen, 2007). The recommendation to adopt moderate-intensity physical activity does 
not suggest an all-or-nothing approach, but rather that it is important to consider physical 
activity on a continuum and that incremental change in behavior is important. It is more likely 
that a sedentary individual will adopt moderate-intensity activity first, and later adopt 
vigorous-intensity physical activity. Further, adopting moderate-intensity physical activity is 
likely to be easier and safer for sedentary patients. Recommending moderate-intensity 
physical activity can provide more options to patients, while recognizing that the greatest 
benefits are associated with vigorous-intensity activity (Fagard, 2001). It is generally agreed 
that physical activity is important to prevent weight increase. No interventions supported the 
value of increased physical activity on CAD incidence, but there are found positive effects 
from physical activity on blood lipids and general well-being. With the relatively small risk 
for adverse effects, increased activity is generally recommended.  
     
Smoking and health outcomes.  
There is overwhelming evidence for an adverse effect of smoking (US Department of 
Health and Human Services, 2004). There is a graded relationship between the amount of 
tobacco consumed and CAD morbidity, but it is also documented that there is no level of 
smoking that is safe. There is evidence for long-term positive effects on smoking cessation 
interventions, including brief behavioral counseling and pharmacotherapy delivered in the 
primary care setting (Pinto et al., 2005). 
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Relationships between adherence to cardiac risk reduction behavior 
and HRQoL. 
 
Health-related quality of life (HRQoL) is a measure of perceived well-being and ability 
to function-physically, mentally, emotionally and socially. Prior research has documented 
profound negative effects of cardiac disease on HRQoL as demonstrated in studies of post-
bypass, post myocardial infarction, and patients undergoing PCI (Bosworth et al., 2000; 
Mendes de Leon et al., 1998; Myles et al., 2001; Pocock et al., 2000).  Poor preoperative 
HRQoL and low scores in the physical functioning QoL domain among CAD patients have 
been associated with poorer post-hospitalization general health, higher admission rates, and 
increased mortality among CAD patients (Rumsfeld et al., 1999: Rumsfeld et al., 2001). 
      
Multiple studies have demonstrated that HRQoL improves, on average after CABG 
(Krannich et al., 2007; Lindsay et al., 2000; Rumsfeld et al., 2001) with women scoring lower 
than men (Lindquist et al., 2003). Christian and colleagues (2007) found that HRQoL is 
reduced among women hospitalized for CAD with average scores 13 points below normative 
data compared to healthy adults. The major predictors of HRQoL among these women six 
months later were baseline HRQoL, adherence to physical activity goal ( 3 days/week, at 
30 min/day), and being married.  
      
Aldana and colleagues (2006) found that the intensive Ornish program may affect 
significant greater improvements’ in HRQoL compared to traditional cardiac rehabilitation, 
while the poorest outcomes in HRQoL was seen in the control group who received standard 
care.  
      
Hays and colleagues (1994) could not conclude that assessing patients with hypertension 
and post myocardial infarction to adhere to their physicians’ recommendations will 
necessarily lead to better health over time. They examined the relationship between self-
reported adherence to medical recommendations and health outcomes over time for patients 
with one or more of these conditions; diabetes, hypertension, congestive heart failure, and 
recent myocardial infarction with or without symptoms of depression. There was a very small 
association between improvement in health outcomes and patient adherence. For patients with 
recent myocardial infarction the authors found a significant beneficial effect of adherence on 
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emotional well-being. Physical health improved for diabetic patients with recent MI or CAD 
when they adhered to a diabetic diet. Hays and colleagues (1994) concluded that the 
relationship between health outcomes and adherence is more complex than assumed.  
 
 
Summary 
 
     For patients to adhere to treatment or life style recommendations, they must know 
what to do, be committed to doing it, and have the resources to be able to do it.  The literature 
clearly documents that adhering to a healthy life-style and reducing risk factors is particularly 
important for CAD patients, and that there is a relationship between healthy behavior, 
secondary CAD prevention and health outcomes. Whilst many of the lifestyle interventions 
show promise in effecting small changes in behavior, none appears to produce substantial 
changes. It is clear that if lifestyle interventions are to be effective in a public health sense, a 
greater number of health care providers will need to be involved in promoting behavior 
change than the literature suggest is currently occurring.  
 
    DAs have been widely used to assist patients in treatment decision-making, but few 
studies have evaluated DAs designed to assist in behavioral change or have attempted to 
address multiple behavioral risk factors. Also, evidence of the effects of DAs on adherence to 
an option chosen by the patient is unclear. Furthermore, the literature reports that not all 
patients are able to use the information in a DA to arrive at a decision, and need additional 
help to combine evidence with their personal values that enables them to choose among 
several possible courses of action. 
      
Research findings have shown that brief individual counseling interventions can 
effectively address lifestyle changes and are feasible in routine practice. While perceived risk 
is an important aspect of decision-making, no previous known studies have included personal 
risk profiles together with eliciting patient preferences for behavioral change in a decisional 
counseling intervention. Combining DAs with decisional counseling to address patients’ 
individual risk files and help them comprehend information provided in a DA may therefore, 
be worthwhile. So far no previous studies have compared the effect of a DA with and without 
additional individual preference-based decisional counseling on behavioral change and health 
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outcomes. The literature review therefore, supports the need for our study to test the effects of 
DA with and without an individual preference-based decisional counseling on health 
outcomes and HRQoL mediated by adherence to cardiac risk reduction behavior.  
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Chapter 3 
Methods 
 
 
Introduction 
 
This study consisted of two phases. Phase I included the translation and adjustment of 
the Canadian version of the DA into Norwegian, development of an individual decisional 
counseling program (DCP), and pilot testing of the adjusted DA and the DCP. In Phase II we 
conducted a three group RCT to evaluate the effects of the DA, with and without the 
additional DCP, on patient outcomes in 368 patients scheduled for a coronary angiogram at 
Oslo University Hospital HF-Rikshospitalet.   
 
 
Phase I: Translation and adjustment of the DA, development of the 
DCP, and pilot testing 
 
The research team had an agreement with the developers of the DA from Canada to 
translate and use the DA: “Making Choices: Life Changes to Lower Your Risk of Heart 
Disease and Stroke” in this study. The DA was designed as a booklet and presented 
information about CAD, the possible risks, and how to lower risks by making healthy choices. 
The content of the DA is based on an extensive review of the literature with evidence from 
randomized trials published up to 2002, expert content, and focus groups with patients and 
clinicians.  The information in the DA is conveyed as a combination of pictures, text, graphs, 
and tables that present how to live a healthy life with CAD (Lalonde et al., 2002).  
      
Text, pictures, and tables in the DA were translated and back translated by translators 
into Norwegian using the forward – backward method as described later. The content 
presented in the Canadian DA was compared to Norwegian treatment recommendations in 
2007, and some adjustments were made in collaboration with the Canadian research team.  
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Design and development of the DCP intervention 
The purpose of developing an individual decisional counseling program (DCP) was to 
design a program that structures situations in which patients can adjust the information in the 
DA to their personal illness story. In light of this personalized information they can identify 
the types of cardiac risk reduction behavior that are important for them to accomplish. The 
design phase consisted of several steps including identification of theory, modeling process, 
and expected outcomes. The DCP encompassed the following components and features (se 
Appendix B):  
 
(1) CAD knowledge comprehension after reading the DA  
(2) Health beliefs about CAD and CAD progression after presentation of individual risk 
profile 
(3) Identification of perceived benefits and barriers to cardiac risk reduction behavior 
(4) Finally, patients, together with the counselor, developed a written action plan for                      
cardiac risk reduction behavior. 
      
Table 3 shows an overview of the structure and the content in the DCP. 
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Table 3.  
An overview of the structure and content of the intervention “Decisional Counseling 
Program” (DCP) 
 
 
TOPIC SECTION/ 
OUTCOME 
TOPIC AREA TEACHING 
METHODS 
INSTRUMENTS 
Introduction Process issues are 
identified 
Goal for 
counseling  
Desired 
participation 
No right or 
wrong answers 
Conversation 
 
Presentation guide 
 
 
TOPIC 1.     
Knowledge  
 
Experience 
 
Diagnosis 
Prognosis 
Health 
recommendations 
Short repetition 
if necessary 
Help to 
comprehend. 
Adjustment to 
personal illness 
history and 
future. 
Booklet prior to 
counseling 
 
Interview, 
questioning 
DA prior to counseling 
 
 
Interview guide 
 
TOPIC 2.     
General 
health beliefs 
 
Specific 
health beliefs 
The perceived 
susceptibility of CAD 
or CAD progression 
Individual risk 
profile 
 
Help to  
comprehend the 
possible risks 
Presentation of  
individual Risk 
profile 
(computation) 
 
Conversation 
“HeartScore®” 
 
 
 
Interview guide 
TOPIC 3.     
Perceived 
Benefits and 
Barriers 
Believe the action is 
beneficial (reduced 
perceived susceptibility 
and severity) 
Believe there are no 
overwhelming barriers 
Rating of 
importance of 
potential actions 
Assessment of 
all perceived 
benefits 
Assessment of 
all perceived 
barriers 
Questionnaire  
 
Worksheet 
 
Balance scale 
“Perception of Importance 
of Cardiac risk reduction 
behavior” 
“Work sheet Cardiac Risk 
Reduction Behavior” 
TOPIC 4.     
Decision Cardiac risk reduction 
behavior: selection 
Action items 
Barriers and resources  
Social support 
Action plan for Cardiac 
risk reduction behavior 
What is best? 
Written plan 
Who needs to do 
what and by 
when? 
What do you 
need to perform 
the behavior 
chosen? 
Complete the  
decision in a form 
 
 
 
Evaluation of the 
counseling 
Interview guide 
 
“ My plan for Cardiac Risk 
Modification Behavior” 
 
“1 Minute evaluation” 
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 The Health Belief Model with its concepts provided a map for addressing the topics 
covered in the DCP. The model makes assumptions about behaviors that may reduce the risk 
for health problems in cardiac patients that are logical, consistent with everyday practice, are 
used in previous successful programs, and are supported by research in the CAD area (Clark 
& Becker, 1998; Croog & Richards, 1977; Miller et al., 1988). 
     
The Health Belief Model emphasizes the individual’s perceptions of the threat posed by 
a health problem (perceived susceptibility and severity of CAD), the perceived benefits of 
avoiding the threats, and factors influencing the decision to act (barriers, cues to action, and 
self-efficacy). The researcher combined these theoretical assumptions, identified variables 
consistent with the Health Belief Model, specified the additional procedural elements of the 
DCP, and developed an observation system of fidelity (see Appendix C). The DCP also 
utilized principles from decision theory that provides quantitative means for patients to 
express their preferences about critical trade-offs between perceived benefits and barriers of 
cardiac risk reduction behavior.  
    
The major criterion to implement a choice is the extent to which a patient can feel 
significantly related to it (Brown, 1975). Cognitions, feelings, emotion, action, and motivation 
are easily separated by theoretical abstractions, but no single one of these can function 
independently of the others.  These components interact, and influence one another. The 
counseling methods used in the DCP were designed to stimulate the awareness and intention 
by convergent and cognitive processes integrated with, or parallel to patient experience. 
      
One example of such a process used in the DCP is a Sentence completion form which 
uses open non-directional sentences the patient had to complete. The sentence completion 
form makes it possible to make the implicit explicit, to discover what is most important, and 
what is not by integrating the subject matter and the personal awareness. Sentences are started 
and the patient is asked to finish them. The lesson helps create an involvement that starts an 
ongoing spontaneous activity of writing here and now, creative and inventive. The empty 
spaces in the sentence can contribute to an increased number of answers than without these 
open spaces (Brown, 1975; Grendstad, 1986). The purpose is to structure situations that help 
the patient to recognize his personal position and relationship towards perceived benefits and 
barriers to cardiac risk reduction and the problems that can occur related to CAD. The method 
allows patients to arrive at solutions to their problems by examining their own thoughts, 
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feelings, emotions, and motivation. This aids patients in finding their own solutions to their 
problems. Patients can then decide for themselves in what ways they need or want to change. 
The counselor’s role is that of a facilitator with the goal to provide a comfortable 
environment, rather than to drive and direct the patient toward the “right” solution.           
      
Strict standardization of the intervention was inappropriate in this study because the 
actual intervention may work better if a specified degree of adaptation to local circumstances 
(individual risk profile) is allowed for in the protocol. Therefore, the DCP was designed to let 
the content in the topic area (the means of intervening) vary according to individual patient 
risk profiles, while the function (theorized mechanism) of the DCP remained unchanged over 
place and time. The local circumstances that were allowed to be changed or adapted in this 
study were: individual risk profile, individual’s perceived benefits of potential action taken, 
individual’s barriers to potential action taken, and the individual’s decision that resulted in the 
individual plan for cardiac risk reduction behavior. 
       
During the design period the researcher specified procedural elements of the DCP and 
developed an observational system to check the fidelity of the intervention (Bellg et al., 2004; 
Borrelli et al., 2005; Resnick et al., 2005). Procedural elements encompass incorporated, 
informal, and training materials like teaching/counseling methods, instruments, written 
interview guides, worksheets, and training manuals for the counselor. Fidelity is not always 
straightforward in relation to an intervention that takes place in different settings (Craig et al., 
2008). Therefore, the observational system encompassed tools to control the way in which the 
intervention was implemented to assess fidelity and quality of implementation. The 
intervention fidelity strategies described how much change or adaptation is permissible and 
the counselor records variations in implementation so that fidelity can be assessed in relation 
to the degree of standardization required by the study protocol.   
      
Once the first preliminary DCP with procedures and instruments were developed, 
simulated patients were used to test the preliminary DCP outside the normal clinical setting.  
The simulation made an identification of the likely outcome for a range of simulations 
(Oakly, Strange et al., 2006). This way of modeling the DCP provided important information 
about improvement, and allowed the research team to redesign the DCP several times. As the 
intervention emerged in stages, it was repeatedly “tested” in simulations and counseling from 
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advisors. At last, a prototype did not provide more revisions and the developed DCP 
intervention was tested clinically in this study.  
     
After a preliminary Norwegian version of the DA and the DCP was ready, a focus 
group with expert clinicians (cardiologists, nurses) and CAD patients who had different 
treatment experiences were asked to critically review the content, design, and layout of the 
program, evaluate it for clarity, appropriateness, wording, and format, and add comments. 
Suggestions for revisions based on these evaluations were discussed in the expert clinician 
group and the DA and the DCP were adjusted accordingly. We collaborated with the 
Canadian team on the translations and adjustments on the DA prior to the main study.   
     
    Translation of instruments into Norwegian. All instruments that were not yet 
available in Norwegian ( Health Service Used; Health Behavior Scale; Knowledge 
Questionnaire; Health Belief Questionnaire; Benefits Scale; Barriers Scale; Decisional 
Conflict Scale; Acceptability Questionnaire) were translated and back translated. Two 
bilingual translators were used. One translator translated the text and instructions from 
English into Norwegian.  The second translator translated the Norwegian version back into 
English.  Secondly, a refinement group consisting of the two translators and the investigator 
reconciled and further refined the translations and grammar/syntax (Acquadro et al., 2004; 
Brislin, 1970; Brislin, Lonner, & Throndike, 1973). 
      
Prior to launching the RCT, the Norwegian version of the DA, the instruments, and the 
DCP were pilot tested in a sample of 15 CAD patients (5 per group) following the same 
procedures as in the RCT described below. Looking for feasibility of all study procedures, no 
corrections were seen as necessary.  
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Phase II: Randomized clinical trial 
Research design 
To answer the research questions, the proposed study used a three-group RCT design 
with four repeated measurement points over six months. Patients were randomly assigned to 
either (1) the DA group where patients received, to take home, the DA prior to their scheduled 
angiogram; (2) the DA+DCP group where patients, in addition to the DA, received an 
individual decisional counseling program (DCP) from a trained nurse counselor in their 
homes prior to their angiogram; and (3) the Control group who received “usual care”.  
      
Data was collected from all three groups at baseline at their initial visit to the Cardiac 
Outpatient Clinic (T1), and two (T2), four (T3), and six (T4) months after their angiogram. 
Analysis evaluated the effects of providing DA with and without the additional DCP on: (1) 
Primary health outcomes: (body weight, cholesterol, blood pressure, and amount of tobacco), 
and Health-related quality of life (HRQoL), (2) Intermediate outcomes of adherence to 
cardiac risk reduction behavior, (3) Mediating variables: Knowledge about risk factors and 
CAD, perceived susceptibility and severity of CAD or CAD progression, and perceived 
benefits and barriers to cardiac risk reduction behavior. Furthermore we (4) explored the 
relationships between intermediate adherence outcomes and primary health outcomes and 
HRQoL; between primary health outcomes and HRQoL, and between possible mediating 
variables (baseline intentions, knowledge about risk factors and CAD, perceived susceptibility 
and severity of CAD and CAD progression, perceived benefits and barriers of cardiac risk 
reduction behavior, and decisional conflict), and adherence to cardiac risk reduction behavior.      
 
The four measurement points were used to capture the variance in health status 
following the paths for CAD treatments like CABG, PCI, and medication therapy. The first 
measurement point (at initial visit before the angiogram) provided baseline measurements of 
the patients before randomizing them into different groups. The time of the angiogram was 
used as an anchor for measurement over time. The second measurement point (two months 
after the angiogram) permitted assessment of intermediate adherence outcomes and mediating 
variables. The third measurement point (four months after the angiogram) allowed capturing 
the variance in health status following different paths for CAD treatments. The last 
measurement point (six months after the angiogram) was selected because it is the assumed 
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usual time of completion of recovery and resuming functional status and normal roles after 
CABG surgery. 
Interventions– independent variables 
 Decision Aid (DA).  The DA “Making Choices: Life Changes to Lower Your Risk of 
Heart Disease and Stroke” (Lalonde et al., 2002) is a 49 page booklet for the patients to take 
home in both intervention groups (see appendix A). Patients were asked to read the DA at 
least once before their scheduled angiogram, or as often as they wished. 
     
Decisional Counseling Program (DCP). Patients in the DA+DCP group received both 
the DA and the DCP performed by a trained nurse counselor (the PhD student) in one home 
visit. This home visit was scheduled at the patients’ initial visit for a home appointment 
before their follow-up visit for an angiogram. The reason for using a home visit was the large 
possibility of diffusion of the intervention if the intervention took place at the hospital during 
the day of the angiogram. Patients were instructed to read the DA prior to the home visit. The 
components and features in the DCP were (see appendix B): 
 
(1) CAD knowledge comprehension 
The nurse counselor helped the patient to understand the information presented in the DA and 
how it might apply to his or her own illness history, answered questions, and discussed 
possible lifestyle options and the necessity of cardiac risk reduction behavior.  
 
(2) Health beliefs about CAD and CAD progression. 
The patient’s risk of CAD (HeartScore®) was presented and discussed together with the 
patient. HeartScore® (http://www.heartscore.org/se/Pages/Welcome.aspx) is an interactive 
tool for predicting and managing the risk of heart attack and stroke in Europe, and can be used 
to support clinicians to better identify patients at high total risk of developing cardiovascular 
disease, and through this information help individuals to engage in cardiac risk factor 
reduction behavior. The risk estimation is based on the following risk factors: gender, age, 
smoking, systolic blood pressure, and total cholesterol. The threshold for high risk for fatal 
cardiovascular events is defined as "higher than 5%". 
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 (3) Identification of perceived benefits and barriers to cardiac risk reduction behavior. 
The patients’ perception of the importance of different cardiac risk reduction behavior was 
assessed by using a visual analog scale that allowed patients to assign importance weights 
ranging from 0 (“not at all important to me”) to 10 (“extremely important to me”) for (a) 
quitting smoking, (b) healthy diet (c) reach or maintain a healthy body weight, (d) exercise 
regularly, and (e) reduce stress. Patients were then instructed to use a work sheet to identify 
what perceived benefits and barriers for cardiac risk reduction behavior that were important to 
them. The perceived benefits and barriers to the perceived important cardiac risk reduction 
behavior were graded and recorded on a balance scale. The balance scale provided 
visualization of the strength/weight of perceived benefits and barriers to important cardiac 
risk reduction behavior for the patient. 
 
(4) Finally, patients, together with the counselor, developed a written action plan for cardiac 
risk reduction behavior for the next six months. 
       
Usual care. In the Control group patients received usual care which means that they did 
not receive the DA and/or the DCP. There were pamphlets available at the clinic to take home 
if the patients asked for it. The pamphlets were developed by the Norwegian Health 
Association, the Norwegian Directorate of Health, and The Norwegian Heart and Lung 
Patient Organization, LHL.    
 
 Fidelity of the interventions. The intervention DCP took place in patients’ homes and 
was monitored strictly. The delivery of the intervention and monitoring of potential change 
over time were guided by training procedures, detailed manuals, and flow-charts that were 
monitored by personnel logs, personnel debriefing, and personnel monitoring of intervention 
delivery (see Appendix C).  
       
The risk for the potential influence from other ongoing research studies/interventions in 
the department was monitored by communication with the administration staff and other 
potential investigators. During the study period there were no systematic interventions 
regarding cardiac risk reduction behavior at the Cardiac Outpatient clinic. To control for 
possible diffusion of the intervention among DA group, DA+DCP group and the Control 
group the patients were told not to share information from DA and/or DCP to other patients. 
They were asked twice (T2 and T4) for any other information they may have looked up, or 
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received during the study period; particularly any information learned in discussion with 
study patients in other study groups. 
Research setting.  
Patients were recruited at their initial visit at the Cardiac Outpatient Clinic at Oslo 
University Hospital HF -Rikshospitalet, which is a large cardiac outpatient clinic in Norway. 
Approximately 1700 patients per year with risk of CAD or CAD progression are referred 
electively to the clinic for work-up; 92-96% (n= 1600) are referred to a coronary angiogram 
approximately 1-5 days after this initial visit. Approximately 35% (n= 600) of the patients 
who have an angiogram undergo PCI during the procedure. Treatment options for the 
remaining 65% (n= 1100) are medication or CABG surgery.  
 
Participants 
Sample eligibility criteria. All patients with risk of CAD or CAD progression referred 
to an elective coronary angiogram at the Cardiac Outpatient Clinic were candidates for this 
study if they were (1) age 18 and older, (2) able to read, write, and speak Norwegian, (3) lived 
within approximately 200 km of Oslo because of the distance to drive for the counselor, and 
(4) had a telephone.  They were not eligible for the study if they had cognitive impairments. 
 
Sample size. The sample size was determined using the power analysis procedures 
described by Cohen (1988). To estimate the effect size for the proposed study, previous 
studies on the same population of similar variables were reviewed (Chew et al., 1998; Morgan 
et al., 2000; Thanavaro et al., 2006). Given the effect sizes from the above studies, the 
proposed study used a medium effect size ES=.25. A sample size for Analysis of Covariance 
(ANCOVA) was computed for two sets of dependent variables, where a probability level of 
.05 and a power of .80 was selected based on the minimum basis for rejecting the null 
hypothesis using two tailed tests of significance (Lipsey, 1990). The Bonferroni correction 
was used to prevent inflation of the alpha level when testing three hypotheses on differences 
between the two intervention groups and the control group. According to the sample size table 
(Cohen, 1988) and G*Power analysis program (G*Power analysis program 
(http://www.psycho.uni-duesseldorf.de /aap/projects/gpower/) the estimated sample size was 
106 per group. Accounting for an estimated 10% attrition rate over the 6 month study period, 
the sample size of 120 patients per group, or a total of 360 patients were required (Cohen, 
1988).  
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The flow of patients during the study. Figure 3 shows the flow of patients through the 
study. Five patients told us they wanted to withdraw from the study at T2, and their data from 
baseline were deleted from the dataset, leaving 121 patients in each group at baseline. As seen 
in Figure 3 we received less questionnaires at T3, however, the patients remained enrolled in 
the study, and we received their measurement at T4, leaving more measurements in the study 
at T4 than at T3.  
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Figure 3. Flowchart of patient enrollment, randomization, and follow up through the study 
 
 
   Admitted to Initial visit 
N=765 
 
 
    144 did not 
meet inclusion 
criteria (18.8 
%) 
 
 Eligible for inclusion in the study 
N=621 
 
    253 did not 
want to 
participate in 
the study (40.7 
%) 
 
 Included in the study and randomized 
N=368 
59.3 % 
included 
  
 
  Five persons did 
withdraw at T2, 
and their data were 
deleted from the 
dataset (1,4 %) 
leaving a sample of 
363, 121 in each 
group 
 Allocated to 
Control group 
Allocated to 
DA group 
Allocated to 
DA+DCP group 
 
T1: Baseline: 
prior to 
randomization 
and  the 
angiogram 
n= 121 
 
All allocated to 
control conditions; 
usual care 
n=121 
 
All received 
allocated 
intervention and 
usual care 
n=121 
 
All received 
allocated 
intervention and 
usual care 
Sample at  
T1= 363 
  
 
   
T2: Two months 
after the 
angiogram 
Analyzed n=105 
 
15 lost to follow up 
1 dead 
 
Analyzed n=114 
 
7 lost to follow up 
 
 
Analyzed n=118 
 
3 lost to follow up  
 
 
Sample at  
T2= 337 
  
 
   
T3: Four months 
after the 
angiogram 
Analyzed n=87 
 
32 lost to follow up 
2 dead 
 
Analyzed n=102 
 
19 lost to follow up 
 
 
Analyzed n=99 
 
22 lost to follow up 
 
 
Sample at  
T3= 288 
  
 
   
T4: Six months 
after the 
angiogram 
Analyzed n= 100 
 
18 lost to follow up 
3dead 
Analyzed n= 113 
 
8 lost to follow up 
Analyzed n= 114 
 
7 lost to follow up 
Sample at 
T4=327 
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The patients who did not meet the inclusion criteria were monitored by their age and 
gender and reason for not meeting inclusion criteria. The patients who did not want to be 
enrolled in the study were monitored by their age and gender. An overview of patients’ age 
and gender are summarized in Table 4.  
 
Table 4 
Age and gender of participants and non-participants  
 
 Male Female All 
 
 
 
n   
 
% 
 
Age 
 
SD 
 
n   
 
% 
 
Age 
 
SD 
 
n 
   
Age 
 
SD 
 
Admitted to 
Initial visit 
 
464 
 
60.7 
 
62.94 
 
(10.94) 
 
301 
 
39.3 
 
61.94 
 
(11.52) 
 
765 
 
62.55 
 
(11.17) 
Did not meet 
inclusion 
criteria 
 
83 
 
57.6 
 
63.65 
 
(11.31) 
 
61 
 
42.4 
 
56.97 
 
(14.71) 
 
144 
 
60.82 
 
(13.23) 
Eligible for 
inclusion in 
the study 
 
381 
 
61.4 
 
62.79 
 
(10.86) 
 
240 
 
38.6 
 
63.20 
 
(10.22) 
 
621 
 
62.95 
 
(10.61) 
Did not want 
to be 
enrolled in 
the study 
 
152 
 
60.1 
 
63.53 
 
(11.72) 
 
101 
 
39.9 
 
64.92 
 
 
(10.74) 
 
253 
 
64.09 
 
(11.33) 
Included in 
the study and 
randomized 
 
229 
 
62.2 
 
62.29 
 
(10.26) 
 
139 
 
37.8 
 
61.96 
 
(9.67) 
 
368 
 
62.17 
 
(10.03) 
 
Sample 
analyzed  at 
T1  
 
224 
 
 
61.7 
 
62.41 
 
(10.27) 
 
139 
 
38.3 
 
 
61.96 
 
(9.67) 
 
363 
 
 
 
62.24 
 
 
 
(10.03) 
 
Control 75 62.0 63.25 (12.02) 46 38.0 61.41 (10.20) 121 62.55 (11.35) 
DA 76 62.8 62.66 (9.32) 45 37.2 63.20 (9.61) 121 62.86 (9.39) 
DA+DCP 
 
73 60.3 61.29 (9.24) 48 39.7 61.31 (9.30) 121 62.24 (10.03) 
Note: Values are presented as Mean (Standard Deviation), count and percent. Age is measured in years 
 
Patients who did not meet inclusion criteria were younger and a larger proportion was 
women. The causes for not meeting the inclusion criteria were: not referred to coronary 
angiogram (58, 3 %); not speaking Norwegian (19.4 %); referred to examination before valve 
surgery (13.9%); and problems due to aphasia, deafness, dyslexia, or dementia (8.3%). 
Patients who did not want to participate in the study were older than those enrolled.  
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Measurement 
     
Measurement of variables and instruments in the RCT 
Study concepts, variables, and instruments are summarized in Table 5 and described in 
the paragraphs that follow. 
 
Table 5. 
Study variables and their measurements    
 
Variables Instruments Authors 
 
Data Source T1 
Base-
line 
T2 
Two 
months 
after 
angio- 
gram 
T3 
Four 
months 
after 
angio-
gram 
T4 
 Six 
months 
after 
angio-
gram 
 
Primary outcome 
       
Body weight  Self-report 
Recorded in medical 
record 
Self-constructed 
questionnaire 
Self administrated 
questionnaire 
Medical record 
X X X X 
Blood Cholesterol level Blood test recorded in 
medical record 
Self-report 
Self-constructed 
questionnaire 
Self administrated 
questionnaire  
Medical record 
X X X X 
Blood pressure Self-report 
Recorded in medical 
record 
Self-constructed 
questionnaire 
Self- administrated 
questionnaire 
Medical record 
X X X X 
Health service use 
 
Patient diary U.S. Congress, 
Office of 
Technology 
Assessment, 
1990 
Diary X X X X 
Smoking and Amount of 
tobacco 
Self report Self-constructed 
questionnaire 
Self- administrated 
questionnaire/ 
 
X 
 
X 
 
X 
 
X 
Health-related quality of 
life 
SF-36 
 
 
 
Seattle Angina 
Questionnaire (SAQ) 
Medical 
Outcomes Study; 
Stewart et al., 
1992 
Spertus et al., 
1995 
Self administrated 
questionnaire  
X X X X 
 
Intermediate Outcome 
       
Adherence to cardiac risk 
modification behavior 
Health Behavior Scale 
(HBS) 
Miller et al. 
1982a;1982b, 
1990 
Self- administrated 
questionnaire 
 X X X 
 
Mediating variables 
       
Intentions to adhere to 
cardiac risk modification 
behavior 
Health Behavior Scale 
(HBS) – modified 
Miller et al. 
1982a; 1982b, 
1990 
Self- administrated 
questionnaire 
X    
Knowledge about  risk 
factors and CAD 
Knowledge 
Questionnaire 
(http://www.healt
hline.com/sw/qz-
heart-disease-
prevention-quiz) 
Self- administrated 
questionnaire 
X X   
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Variables Instruments Authors 
 
Data Source T1 
Base-
line 
T2 
Two 
months 
after 
angio- 
gram 
T3 T4 
Four  Six 
months months 
after after 
angio- angio-
gram gram 
Health Beliefs: Perceived 
susceptibility and severity 
of CAD progression 
Health Belief 
Questionnaire 
Mirotznik et al., 
1995 
Self- administrated 
questionnaire 
X X   
Perceived benefits and 
barriers of cardiac risk 
reduction behavior 
Benefits Scale 
Barriers Scale 
Murdaugh & 
Verran, 1987 
Self- administrated 
questionnaire 
X X   
Decisional conflict Decisional Conflict 
Scale 
O’Connor, 1995; 
1999 
Self- administrated 
questionnaire 
 X   
 
Control variables 
       
Demographics Gender & Age Self-constructed 
questionnaire 
Self- administrated 
questionnaire/Medi
cal record 
X    
Cardiac functional status Canadian 
Cardiovascular 
Society’s Grading of 
Angina Pectoris- CCS 
Ejection Fraction 
Campeau, 1972; 
2002 
Self- administrated 
questionnaire 
 
 
Medical record 
X 
 
 
X 
X 
 
 
X X 
Previous cardiac events Previous MI, PCI, 
CABG 
Self-constructed 
questionnaire 
 
Medical record 
 
X 
   
Disease severity Result from the 
angiogram, number of 
arteries with 
significant stenosis 
Self-constructed 
questionnaire 
 
 
 
Medical record 
X    
Comorbidity Charlson Comorbidity 
Index 
www.medalreg.com). 
Charlson, et al., 
1987 
Patient/Medical 
record 
X    
Medication intake: 
- anti-cholesterol       
medicine 
- antihypertensive 
medicine 
 
Taking medication 
 
Taking medication 
Self-constructed 
questionnaire 
Self- administrated 
questionnaire/ 
Medical record 
X X X X 
Received treatment CABG surgery, PCI, 
Medication only, 
None  
Self-constructed 
questionnaire 
Medical record X    
 
Descriptive variables 
       
Demographic Marital status, 
Education level, Total 
household income, 
Risk factors 
associated with CAD, 
and Smoking history. 
Self-constructed 
questionnaire 
Self-administrated 
questionnaire 
X    
Acceptability of DA and 
DCP 
Acceptability 
Questionnaire 
Ottawa Hospital 
Research 
Institute-Ottawa 
Hospital, 
Canada(http://de
cisionaid.ohri.ca/
docs/develop/To
ols/Acceptability
_osteoporosis.pdf
DA group and 
DA+DCP group 
only. 
Self-administrated 
questionnaire 
 X   
Diffusion of intervention Measure of possible 
intervention diffusion 
between groups 
Self-constructed 
questionnaire 
Self- administrated 
questionnaire 
  
X 
  
X 
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Primary outcomes
Body weight, serum cholesterol, and blood pressure were collected from medical 
records and patient questionnaires as these measures were not always available in the medical 
record. Body mass index (BMI) was calculated based on patients’ self-reported body weight 
and height. A baseline measurement of blood pressure (BP) was collected from the medical 
record at patients’ initial visit at the Cardiac Outpatient Clinic.  Baseline measurement of 
cholesterol levels were analyzed at Oslo University Hospital HF- Rikshospitalet as a part of 
patients’ examination at the hospital and were collected from medical records. Total 
cholesterol, Low-density lipoprotein (LDL), and High-density lipoprotein (HDL) were 
measured in mmol/L. All follow-ups of Cholesterol levels and BP were measured by patients’ 
primary physician and sent as self-report.  
      
Health service use was measured using an adapted version of the 21-item U.S. 
Congress, Office of Technology Assessment (1990) tool for health service use. The patients 
were able to select their use of four predetermined examples of health services focusing on 
reduction of cardiac risk during the last two months. The four services encompassed 
participation in cardiac rehabilitation, smoking cessation programs, diet meetings, and weight 
reduction meetings. 
      
 Smoking and amount of tobacco used were measured as self-reported yes/no, if yes: 
how many cigarettes and/or Packs of tobacco, and/or packs of snuff the patient smoked/used 
per week. These numbers were re-calculated into grams tobacco consumed every week. 
            
 Health-related quality of life was measured with the SF-36, originated from the 
Medical Outcomes Study (Stewart, Hays & Ware, 1992) and 2 subscales from the Seattle 
Angina Questionnaire (SAQ). The SF-36 is a generic 36 item health status questionnaire that 
reports HRQoL on the following scales: Physical functioning, Role functioning-physical, 
Bodily pain, General health, Vitality, Social functioning, Role functioning-emotional and 
Mental health (Ware Jr & Sherbourne, 1992). The raw scores on the scales are transformed to 
a score from 0-100, with higher value indicating a better level of functioning. The SF 36 was 
used in this study as it is widely used as the “standard” reference measure of HRQoL across 
patient populations and has been validated and used in patients with CAD (Brown et al., 
1999; Dempster & Donnelly, 2000; Dougherty et al., 1998; Failde & Ramos, 2000; 
McHorney et al., 1994; Smith et al., 2000; Ware et al., 2000). It allows comparisons between 
 
 
63 
 
this study and other patient populations from the literature. The reliability of the SF 36 has 
been well established in many studies. We used SF-36 Norwegian version 2.0. In this study 
the reliability measured as Crohnbach’s alpha ranged from .75 to .94 at baseline, and all 
subscales showed increased Crohnbach’s alpha throughout the study period on the SF-36 
subscales. Crohnbach’s alpha as a measure of reliability at T4 in this study ranged from .83 to 
.96.  
      
The patient’s level of satisfaction with the treatment for chest pain, chest tightness, or 
angina, and the limits in quality of life because of chest pain, and chest tightness were 
measured with 2 subscales from the Seattle Angina Questionnaire (SAQ) which is a disease 
specific, self-administrated instrument designed to measure CAD patients’ symptoms, 
function and quality of life. It has well-established validity, reproducibility, sensitivity to 
clinical change, reliability, and prognostic value (Dempster & Donelly, 2000; Pettersen et al., 
2005; Spertus et al., 1995; Spertus et al., 2002a; Spertus et al., 2006a). It has been used to 
assess outcomes in clinical trials, measure quality of care and support patient management 
(MacDonald et al., 1998; Spertus et al., 2002a, 2002b). In this study we only used the 
Treatment Satisfaction Scale (TSS) (4 items) quantifying satisfaction with current treatment 
of angina; and the Disease Perception Scale (DPS) (3 items), characterizing how patients 
perceive the disease to affect their quality of life (Rumsfeld, 2002). Items are scored on 5- or 
6-points scales. Each score on the two scales is calculated as the sum of item scores in the 
domain, and scores are standardized to a 0-100 scale with higher value reflecting better health 
and functioning (Bernstein et al., 1998; Spertus et al., 1995). In this study, Crohnbach’s alpha 
as a measure of internal consistency was .91 and .66 respectively. 
Intermediate adherence outcomes 
Adherence to cardiac risk reduction behavior was defined as the actual performance of 
prescribed actions on cardiac risk reduction regimen, (Miller et al., 1982b) and was 
hypothesized as an intermediate outcome. Adherence to cardiac risk modification behavior 
was measured using the Adherence to Cardiac Risk Factor Modification Health Behavior 
Scale (HBS) (Miller et al., 1982b; Miller et al., 1990).  The HBS assesses the behavior of an 
individual performance or non-performance of prescribed cardiac risk reduction behavior. 
HBS for adherence is a 20-item scale to which patients respond on a 5-point Likert scale 
ranging from 1 (“rarely”) to 5 (“almost always”). The wording is ‘I follow’ two, four, and six 
months after the angiogram and elicits patients’ self-assessment of actual following diet, stop 
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smoking, performing activity, taking medications, and modifying responses to stress. The 
average total score range is 5-25 with higher score indicating greater adherence. Cronbach’s 
alpha for the HBS have ranged from 0.81 to 0.99 (Miller et al., 1990). Content validity was 
established by experts in nursing, medicine, and psychology (Miller et al., 1982a; Miller et al., 
1982b). In this study, Crohnbach’s alpha as a measure of internal consistency ranged from .89 
to .93. 
Mediating variables 
A set of mediating variables was hypothesized to be a mechanism by which the 
interventions were affecting the intermediated outcomes and the primary outcomes.  
    
 Intention to adhere to cardiac risk reduction behavior was defined as the intention of 
performing the prescribed actions on a cardiac risk factor reduction regimen. (Miller et al., 
1982b). Intentions to adhere to cardiac risk modification behavior were measured using the 
Adherence to Cardiac Risk Factor Modification Health Behavior Scale (HBS) (Miller et al., 
1982b; Miller et al., 1990) as described above. The HBS for intention have response 
categories from 1 (“unlikely”) to 5 (“likely”). The wording is ‘I will follow in the future’. The 
average total score range is 5-25 with higher score indicating greater intention to adhere to 
cardiac risk reduction behavior. Content validity was established by experts in nursing, 
medicine and psychology (Miller, et al., 1982a; 1982b). Cronbach’s alpha for the HBS have 
ranged from 0.81 to 0.99 (Miller et al., 1990). In this study, Crohnbach’s alpha as a measure 
of internal consistency ranged from .79 to .92. 
     
 Knowledge about risk factors and CAD. Patients’ knowledge about steps to reduce 
their risk for heart disease was assessed using a Heart Disease Prevention Quiz 
(http://www.healthline.com/sw/qz-heart-disease-prevention-quiz). The quiz contains 10 
questions that assess knowledge about causes of heart disease, effects of restricted or blocked 
arteries, non-modifiable risk factors, borderline level for total cholesterol, considerations of 
“high blood pressure”, effects of smoking on heart disease, necessary minutes of daily 
exercise to prevent heart disease, the rise of risk when body mass index is more than 24.9, 
effects of too much alcohol, and symptoms of heart attack. Each question may have several 
correct answers. Scores range from 0-21 with higher scores indicating more correct answers 
regarding risk factors and CAD.  
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     Health Beliefs is defined as perceived susceptibility and perceived severity of 
receiving CAD or CAD progression for the patients already diagnosed.  
      
Perceived susceptibility of CAD or CAD progression was measured using the subscale for 
perceived susceptibility to illness from the Health Beliefs Questionnaire. The questionnaire 
was developed through operationalizing the dimensions in the Health Belief Model in the 
context of CAD patients to predict adherence to a rehabilitation exercise program. (Mirotznik 
et al., 1995; Mirotznik, Ginzler, Zagon & Baptiste, 1998). The perceived susceptibility 
subscale is an 8 item 5-point Likert scale ranging from 1(“Strongly agree”; “Not easily at all”; 
Much less susceptible”; “Very unlikely”; “Not at all at risk”; “No chance at all”) to 5 
(Strongly disagree”; “Extremely easily”; “Much more susceptible”; “Very likely”; “At very 
large risk”; “A very good chance”). To obtain a total score each item is summed up and 
averaged. The average total score range is 1-5. Higher scores mean higher perceived 
susceptibility to illness. In this study, Crohnbach’s alpha as a measure of internal consistency 
was .66.  
  
Perceived severity of CAD or CAD progression was measured using the subscale for 
perceived severity of illness from the Health Beliefs Questionnaire (Mirotznik et al., 1995; 
Mirotznik et al., 1998). The questionnaire was developed through operationalizing the 
dimensions in the Health Belief Model (Eraker et al., 1984) and the context of CAD patients. 
The questionnaire was used to predict adherence to a rehabilitation exercise program. The 
perceived severity subscale is 11 item 5-point Likert scale ranging from 1 “Very unlikely”; 5 
“Very likely”. To obtain a total score each item is summed and averaged. The average total 
score range is 1-5. Higher scores indicate higher perceived severity of illness. In this study, 
Crohnbach’s alpha as a measure of internal consistency was .88. 
 
Psychometric assessment indicated that perceived susceptibility and severity had 
various internal consistency reliability (mean alpha .80, range from .69 - .89) as well as test-
retest stability (mean Pearson r correlation .75, range from .71 to .80). The construct validity 
of the Health Belief Model measures was established in a confirmatory factor analysis 
(Personal note from J. Mirotznik, 2006). 
      
 
 
 
66 
 
Perceived benefits of cardiac risk reduction behavior were measured using the Benefits 
Scale (Murdaugh & Verran, 1987). The Benefits Scale measure the perceived benefits to 
undertake cardiac risk reduction behavior and is self-report questionnaire consisting of 12 
statements describing benefits to undertaking preventive behaviors. Participants indicate the 
extent of their agreement or disagreement with each statement using a 4-point Likert scale 
ranging from 1(“Strongly disagree”) to 4 (“Strongly agree”). To obtain a total score each item 
is summed and averaged. The average total score range is 1-4. Higher scores indicate greater 
perceived benefits of cardiac risk modification behavior. The statements for the Benefits scale 
were generated from a review of studies testing the Health Belief Model, and construct 
validity was estimated with factor analysis; one rotated factor accounted for 85% of the 
variance obtained for the benefit scale (Murdaugh & Verran, 1987).  The coefficient alpha 
reliability was .72 to .79 indicating it was a reliable tool for assessing barriers of undertaking 
cardiac risk factor modification behavior in healthy adults (Murdaugh & Verran, 1987). In 
this study, Crohnbach’s alpha as a measure of internal consistency was.85.  
 
Perceived barriers to cardiac risk reduction behavior were measured using the Barriers 
Scale (Murdaugh & Verran, 1987). The Barriers Scale measures the perceived barriers to 
undertake cardiac risk reduction behavior, and is self-report questionnaire consisting of 12 
statements describing barriers to undertaking preventive behaviors. Participants indicate the 
extent of their agreement or disagreement with each statement using a 4-point Likert scale. 
Responses range from 1(“Strongly disagree”) to 4 (“Strongly agree”). To obtain a total score 
each item is summed and averaged. The average total score range is 1-4. Higher scores 
indicate greater perceived barriers to cardiac risk modification behavior. The statements for 
the Barriers scale were generated from a review of studies testing the Health Belief Model, 
and construct validity was estimated with factor analysis; two rotated factors accounted for 
85% of the variance obtained for the Barriers scale. One factor loaded personal barriers and 
the other loaded general barriers (Murdaugh & Verran, 1987). The coefficient alpha reliability 
was .72 to .76 indicating it was a reliable tool for assessing barriers of undertaking cardiac 
risk factor modification behavior in healthy adults (Murdaugh & Verran, 1987). In this study, 
Crohnbach’s alpha as a measure of internal consistency was.85. 
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Decisional conflict was defined as a patient’s state of uncertainty about which option to 
choose, the factors contributing to this uncertainty, and the effectiveness of the decision. 
(O’Connor, 1999). Decisional conflict was measured using the 16 item Decisional Conflict 
Scale (O’Connor, 1995, 1999) that measures a person’s perception of the difficulty making a 
decision, ranging on a 5-point Likert scale from 0 (“strongly agree”) to 4 (“strongly 
disagree”). This study used the Statement format. Total score for Decisional Conflict range 
from 0 (no decisional conflict) to 100 (extremely high decisional conflict). There are five 
subscores: their perceived (1) Uncertainty in choosing between options: 3 items with scores 
range from 0 (feels extremely certain about best choice) to 100 (feels extremely uncertain 
about best choice). Three modifiable factors contributing to uncertainty such as (2) Feeling 
uninformed subscore; 3 items with scores range from 0 (feels extremely informed) to 100 
(feels extremely uninformed); (3) Feeling unclear about personal values subscore; 3 items 
with scores range from 0 (feels extremely unclear about personal values for benefits and risks) 
to 100 (feels extremely unclear about personal values), and (4) Feeling unsupported in 
decision making subscore; 3 items with scores range from 0 (feels extremely supported in 
decision making) to 100 (feels extremely unsupported in decision making). The last subscore 
is (5) Quality of choice selected subscore, which is defined as informed, consistent with 
personal values, with which a person expresses satisfaction and expects to maintain 4 items .  
In previous studies the test, re-test, and alpha coefficients for this instrument exceeded 0.78, 
were sensitive to change (O’Connor et al., 1998a; Drake, Engler-Todd, O’Connor, Suhr, & 
Hunter, 1999; Fiset, O’Connor, Evans, Graham, DeGrasse, & Logan, 2000), and 
discriminated between different decision support interventions (Man-Son-Hing, et al. 1999; 
O’Connor et al., 1998b). Scores lower than 25 are associated with implementing decisions; 
scores exceeding 37, 5 are associated with decision delay or feeling unsure about 
implementation (O’Connor, 2005). In this study, Crohnbach’s alpha as a measure of internal 
consistency was .93. 
 
Control variables 
Gender is a dichotomous, categorical variable and was measured by self report.
Age was measured on a ratio level scale defined as present age in years, collected at 
baseline by the patient’s response to a self reported question of age in years. 
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Cardiac functional status was measured in two ways: (1) the Canadian Cardiovascular 
Society’s Grading of Angina: Grade 0: Asymptomatic; Grade I: Angina only during strenuous 
or prolonged physical activity, Grade II: Slight limitation, with angina only during vigorous 
physical activity Grade III: with mild exertion: a. Walking 1-2 level blocks at normal pace, b. 
Climbing one flight of stairs at normal pace, Grade IV: Inability to perform any activity without 
angina or angina at rest, i.e., severe limitation (Campeau, 1976; 2002). (2) The ejection fraction 
(EF). The EF is the fraction of blood ejected by the left ventricle relative to its end-diastolic 
volume and is reported as a percentage (interval scale measurement). The EF was extracted 
from the patient’s medical record after the angiogram as a clinical index to evaluate the 
inotropic status of the heart. However, EF was missing in medical record unless the patient 
had CABG surgery.  
      
Previous cardiac events were collected from medical record and categorized in previous 
myocardial infarction (MI), previous PCI, and previous CABG surgery. 
 
Disease severity was defined as the objective seriousness of the patient’s cardiac disease 
based on the findings in the angiogram measured as the numbers of vessels with significant (> 
50%) stenosis. 
      
Comorbidity was assessed using the Charlson’s Comorbidity Index (CCI) developed to 
ascertain the presence of comorbid conditions that contribute significantly to the overall 
burden of disease as well as being significant predictors of morbidity and mortality.  The CCI 
is a weighted index, composed of 16 conditions, with higher numbers representing a poorer 
prognosis.  The index predicts mortality immediately after hospitalization and after 10 years, 
which supports its predictive validity. Also, validity has been supported through significant 
correlations with six-week hospital mortality, and length of stay (Charlson, Pompei, Ales, & 
MacKenzie, 1987). Data to ascertain the CCI was collected from the patient’s medical record 
and entered without personal identification into a computerized version of CCI 
(http://www.medal.org/OnlineCalculators/ch1/ch1.13/ch1.13.01.php).  
 
Medication intake was collected by self-report about; taking anti cholesterol medication 
or not, and taking antihypertensive medication or not (yes/no).  
 
 
 
69 
 
Received treatment was obtained from the medical record based on the treatment 
following the angiogram into; (1) CABG with or without valve surgery, (2) PCI, (3) 
medication treatment only, and (4) no medication or medical treatment. 
 
Descriptive variables 
Demographics included: marital status, education level, total household income, risk 
factors associated with CAD (patients’ response to their subjective presence or not to 
increased body weight, increased blood pressure, emotional stress, diabetes, increased 
cholesterol levels, lack of regular physical activity, and heredity for CAD), and smoking 
history. Smoking was measured as the number of cigarettes and/or packs of tobacco, and/or 
packs of snuff the patient smoked/used per week. Two data collection forms were used to 
describe demographic variables. One form to collect data from the patient’s medical record, 
and one form for the patients to complete.  
           
Acceptability of the DA and DCP was assessed by self-report using open- and closed-
ended questions based on an acceptability questionnaire developed by the Ottawa Hospital 
Research Institute, Ottawa Hospital, Canada:  
(http://decisionaid.ohri.ca/docs/develop/Tools/Acceptability_osteoporosis.pdf). Closed-ended 
questions elicited feedback on the ways the information was presented, length, amount, and 
usefulness of the information, and whether the information was presented in a balanced 
manner.  
       
Diffusion of the intervention was measured to control for eventual leak of information 
from patients in DA group and DA+DCP group to the others by asking patients of sources of 
information during study period twice, two months (T2), and six months (T4) following the 
angiogram. 
 
 
Procedures 
 
Information to staff.  Administrators at Oslo University Hospital HF- Rikshospitalet 
were approached for permission to recruit patients, and the head of the department gave his 
support. Prior to the patient recruitment period, a meeting between the research staff and 
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clinical staff was conducted, and clinicians who were expected to see patients were informed 
about the study and asked for their support.  
 
Patient enrollment.  During the recruitment period three persons, either one of the two 
study’s Interview Assistants (IAs) or the PhD student went to the Cardiac Outpatient Clinic 
every morning. Patients coming for their initial work-up visit had received a letter at home 
before this first visit with information about the study and an invitation to participate. Those 
who were referred to an angiogram and met the other inclusion criteria were identified by the 
nurse or primary physician during the consultation and referred to the present IA waiting in 
the next room. The IA ensured that the inclusion criteria were met by explicitly asking the 
nurse and /or primary physician for the patients’ orientation for time, person, and place before 
further approach. The patient then had the purpose of the study explained and asked for their 
written informed consent. Intervention assignments were not computed until after participants 
had completed baseline questionnaires. Because of the anesthetic drugs used during the 
angiogram we enrolled the patients on their initial work-up visit and not at the visit when they 
had their angiogram done. The recruitment period took place from April 2008 to January 
2009. 
 
Randomization and data collection from patients.  Patients who gave their consent to 
participate were asked by the IA to complete baseline measurements as described in Table 5. 
After completion of these baseline measures patients were randomly assigned to study groups 
by the IA. A computer program was used in the allocation sequence, and the program used the 
minimization method for random assignment (Zeller, Good, Anderson, & Zeller, 1997). The 
computerized minimization algorithm simultaneously capitalized on the benefits of random 
assignment and, at the same time, equalized the proportion of cases on covariates, so that 
differences between groups on covariates did not emerge based on the "randomness" of 
random assignment. To ensure that the sample was as equalized as possible for the population 
the study groups were equalized on gender. The assignment of participants to groups was 
done with the patient present. The IA selected the correct gender on the computer screen and 
entered the “Auto assign group”. The patients’ assigned ID number and group assignment 
showed immediately at the computer screen, and the IA showed the patients their group 
assignment and told them what it involved. Patients in the DA group and DA+DCP group 
received the DA to take home at this visit. In addition, for DA+DCP group an appointment 
was set up for a home visit by the nurse counselor. Patients were instructed to read the DA 
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prior to this home visit. Patients in the Control group were told that they would receive the 
DA by mail when they had completed the data collection six months later, which they did. 
Due to the nature of the intervention, blinding was not possible in this study. 
      
Approximately two months (T2), four months (T3), and six months (T4) after the 
angiogram, all patients were asked to complete the T2, T3, and T4 questionnaires that were 
mailed to them along with a stamped, addressed envelope for the return of questionnaires. To 
minimize attrition and maximize response rate, a phone call was made to patients who have 
not returned the questionnaires one week after two, four and six months after the date of the 
angiogram and they were offered to answer the questionnaires by interview over the phone. 
The data collection was completed in August 2009. 
      
Chart abstraction. Data collection from patients’ medical record was done by the 
researcher. Chart abstraction included blood pressure and lipids at the initial visit, previous 
cardiac events, and the results from the angiogram including following treatment.  
 
 
Human subjects and ethical considerations 
 
Prior to the Phase II, approval was obtained from the Regional Review Board (REK) the 
18th of February 2008 and The Data Inspectorate the 19th of February 2008. The proposed 
study involved the recruitment of 368 patients who were scheduled for an angiogram. Patients 
received a written description stating the purpose, nature, risks, and benefits of the study, and 
were asked to sign a written informed consent. They kept a copy of the consent form that 
included the phone number of the PhD student who was available for any questions and con-
cerns. Patients were assured that their participation was voluntary and that they could 
withdraw from the study at any time.  There were no costs to patients, and they were not 
being paid for participation. There were no anticipated physical risks from any data collection 
procedures. Any psychological risks were likely to be restricted to the degree that the study 
may have focused patients’ attention on their serious health condition. To safeguard 
confidentiality, patients were assigned a sequential record number (computer generated) at the 
time of enrollment. No names appeared on any data collection forms. All personal 
identification was separated from the data set except for the coding list with identification 
numbers; that list was kept in a locked file cabinet in the PhD student’s office, and destroyed 
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at the end of the study. All results were reported in aggregated form. No breach of 
confidentiality occurred.  
 
Data analysis 
 
Collected data were entered into SPSS statistical software version 16 (SPSS Inc., 
Chicago, IL) and R version 2.9.1 (Venables, Smith and the R Development Core Team) for 
subsequent analysis of research questions. Exploratory data analytic techniques were used to 
ensure the appropriateness of data for the proposed analyses. Between group baseline 
comparisons of variables were evaluated with Chi-square tests and a simple analysis of 
variance (ANOVA). 
     
To test the hypothesis 1-3 the effects of the interventions were assessed using analysis 
of covariance (ANCOVA) to investigate changes in the variables at six months controlled for 
baseline values.   
      
To answer research questions 1-4 analyzing relationships between intermediate 
adherence outcomes and primary health outcomes and HRQoL; between primary health 
outcomes and HRQoL, and between possible mediating variables (knowledge about risk 
factors and CAD, perceived susceptibility and severity of CAD and CAD progression, 
perceived benefits and barriers of cardiac risk reduction behavior, and decisional conflict), 
and adherence to cardiac risk reduction behavior, the data was analyzed using linear mixed 
effect models which is interested in the pattern of change over time (Pinheiro & Bates, 2000). 
The slope of a line represents the rate of change over time by analyzing the slope of the line 
that most accurately fits the four data points; baseline, two, four, and six months following the 
angiogram. The results of these models indicate whether changes in the values of a trait from 
baseline to follow-up. A slope of 0 indicates no change. To investigate the overall 
relationships in the proposed model, the mixed effect model included all available follow-up 
data. The model included random effects in intercept and slope. If the model was unstable, we 
included random effects in intercept only. 
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Research questions 5 and 6 asking about the acceptability to patients of the DA group 
and DA+DCP group were answered using descriptive statistics and Chi-square tests. 
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Chapter 4 
Results 
 
 
Preliminary data analysis 
 
Data was entered into SPSS statistical software version 16 (SPSS Inc., Chicago, IL) and 
R version 2.9.1 (Venables, Smith and the R Development Core Team) and 10% were 
randomly assessed a second time to ensure accuracy. Descriptive analyses were conducted to 
examine the data for frequency distributions, out of range values, outliers, and missing data. 
Frequencies of all variables revealed no out of range values. 
 
 
Missing data 
 
There was a small amount of randomly missing data that was replaced according to 
manuals and literature when at least 50% of the questions were answered (Ware, Kosinski, & 
Dewey, 2000; Ware, Kosinski, & Gandek, 2000). The adherence scales and SAQ scales 
showed most missing data. The amount of missing data is addressed in superscript or by 
numbers (n) in the following tables. 
 
 
Testing the assumptions for data analysis techniques 
 
To evaluate the assumptions for regression analysis and the presence of potential 
influential data points and multicollinearity, a regression diagnostic was run (Tabachnick & 
Fidell, 2001). The residuals were normally distributed assessed by QQ-plots. The variance of 
the residuals at one point was equal to the variance at another point (homoscedasticity), 
assessed by the scatter plot to look for an even random scatter or a scatter spread around the 
zero line. To detect potential highly correlated IVs, the Tolerance was examined, and there 
were no high correlations between independent variables.      
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Preliminary checks were conducted to ensure that there were no violation of the assumptions 
of normality, linearity, homogeneity of variances, homogeneity of regression slopes, and 
reliable measurement of the covariate. 
 
 
Baseline data 
Testing for equivalence among groups 
Even if the patients were randomly assigned to groups, we tested groups for equivalence 
on variables that could have influenced the results. Groups were compared on demographic 
variables, covariates, and risk factors. 
 
Demographic characteristics of the study sample are summarized in Table 6, 7, 8 and 9. As 
seen in these tables there were no significant differences in baseline measures between study 
groups.  
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Table 6 
Age and gender of participants during the study period    
 
 Male Female All 
 
 
 
n   
 
% 
 
Age 
 
SD 
 
n   
 
% 
 
Age 
 
SD 
 
n 
   
Age 
 
SD 
 
Sample 
analyzed  at 
T1  
 
224 
 
 
61.7 
 
62.41 
 
(10.27) 
 
139 
 
38.3 
 
 
61.96 
 
(9.67) 
 
363 
 
 
 
62.24 
 
 
 
(10.03) 
 
Control 75 62.0 63.25 (12.02) 46 38.0 61.41 (10.20) 121 62.55 (11.35) 
DA 76 62.8 62.66 (9.32) 45 37.2 63.20 (9.61) 121 62.86 (9.39) 
DA+DCP 73 60.3 61.29 (9.24) 48 39.7 61.31 (9.30) 121 62.24 (10.03) 
Sample 
analyzed at 
T2 
 
210 
 
 
62.3 
 
62.46 
 
(10.28) 
 
127 
 
37.7 
 
62.69 
 
(9.14) 
 
337 
 
 
62.55 
 
(9.85) 
Control 69 65.7 63.26 (12.29) 36 34.3 62.83 (9.24) 105 63.11 (11.29) 
DA 70 61.4 62.81 (8.96) 44 38.6 63.61 (9.31) 114 63.12 (9.06) 
DA+DCP 71 60.2 61.34 (9.36) 47 39.8 61.70 (8.99) 118 61.48 (9.18) 
Sample 
analyzed at 
T3 
 
184 
 
 
63.9 
 
62.97 
 
(9.57) 
 
104 
 
 
36.1 
 
63.04 
 
(8.57) 
 
288 
 
 
62.99 
 
(9.21) 
Control 57 65.5 64.70 (10.83) 30 34.5 62.93 (8.94) 87 64.09 (10.20) 
DA 66 64.7 62.50 (9.27) 36 35.3 63.31 (8.54) 102 62.78 (8.99) 
DA+DCP 61 61.6 61.85 (8.51) 38 38.4 62.87 (8.54) 99 62.24 (8.49) 
Sample 
analyzed at 
T4 
 
203 
 
 
62.1 
 
62.66 
 
(10.29) 
 
124 
 
37.9 
 
62.87 
 
(8.77) 
 
327 
 
 
62.74 
 
(9.73) 
Control 65 65.0 63.52 (12.38) 35 35.0 62.37 (8.94) 100 63.12 (11.26) 
DA 70 61.9 62.81 (8.96) 43 38.1 64.02 (9.01) 113 63.27 (8.96) 
DA+DCP 68 59.7 61.66 (9.41) 46 40.3 62.17 (8.48) 114 61.87 (9.02) 
            
Note: Values are presented as Mean (Standard Deviation), count and percent. Age is measured in years 
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Table 7 
Group mean and SD at baseline for age, amount of tobacco, body weight, BMI, cholesterol 
levels, blood pressure, CCS, HeartScore®, and comorbidity 
 
  
Control group 
 
DA group 
 
DA+DCP group 
 
Total sample 
N=363 
   
 
 
n M SD M SD M SD M SD F p-value 
 
Age   
 
363 
 
62.55 
 
(11.35) 
 
62.86 
 
(9.39) 
 
61.3 
 
(9.23) 
 
62.24 
 
(10.03) 
 
0.823 
 
.440 
Amount of 
tobacco  
 
87 
 
62.21 
 
(48.58) 
 
62.97 
 
(66.06) 
 
69.17 
 
(54.17) 
 
64.78 
 
(56.16) 
 
.132 
 
.877 
 
Body Weight  
 
363 
 
81.67 
 
(16.59) 
 
84.70 
 
(16.70) 
 
82.29 
 
(16.13) 
 
82.89 
 
(16.53) 
 
1.14 
 
.322 
 
BMI  
 
363 
 
27.16 
 
(4.10) 
 
27.88 
 
(4.95) 
 
27.34 
 
(4.25) 
 
27.46 
 
(4.44) 
 
0.869 
 
.420 
Cholesterol 
levels  
 
 
          
Total 
cholesterol 
 
362 
 
4.52 
 
(1.02) 
 
4.49-1 
 
(0.97) 
 
4.56 
 
(0.98) 
 
4.53 
 
(0.99) 
 
0.174 
 
.841 
 
LDL 
 
362 
 
2.63 
 
(0.87) 
 
2.61-1 
 
(0.88) 
 
2.74 
 
(0.85) 
 
2.66 
 
(0.87) 
 
0.768 
 
.465 
 
HDL 
 
362 
 
1.36 
 
(0.56) 
 
1.35-1 
 
(0.42) 
 
1.31 
 
(0.36) 
 
1.34 
 
(0.46) 
 
0.468 
 
.627 
Blood 
Pressure  
 
 
          
 
SBP 
 
363 
 
145.31 
 
(22.27) 
 
148.65 
 
(20.35) 
 
147.63 
 
(22.45) 
 
147.2 
 
(21.70) 
 
0.751 
 
.473 
 
DBP 
 
363 
 
78.98 
 
(10.54) 
 
80.01 
 
(11.70) 
 
79.50 
 
(11.35) 
 
79.49 
 
(11.18) 
 
0.257 
 
.773 
 
HeartScore®  
 
 
          
 
Baseline 
HeartScore® 
 
 
362 
 
 
4.54 
 
 
(3.85) 
 
 
5.10-1 
 
 
(3.94) 
 
 
4.52 
 
 
(3.80) 
 
 
4.72 
 
 
(3.86) 
 
 
0.887 
 
 
.417 
 
Treatment 
goal 
HeartScore® 
 
 
 
362 
 
 
 
2.42 
 
 
 
(1.74) 
 
 
 
2.48-1 
 
 
 
(1.58) 
 
 
 
2.31 
 
 
 
(1.63) 
 
 
 
2.40 
 
 
 
(1.65) 
 
 
 
0.358 
 
 
 
.699 
 
Comorbidity  
 
 
          
 
Weighted 
index of 
comorbidity 
 
363 
 
0.95 
 
(1.10) 
 
1.12 
 
(1.3) 
 
1.02 
 
(1.20) 
 
1.03 
 
(1.20) 
 
0.633 
 
.532 
Combined 
condition and 
age related 
scores 
 
363 
 
2.78 
 
(1.72) 
 
2.93 
 
(1.65) 
 
2.73 
 
(1.60) 
 
2.81 
 
(1.66) 
 
0.513 
 
.599 
Estimated 10 
years 
survival 
 
 
363 
 
70.69 
 
(27.72) 
 
69.92 
 
(28.32) 
 
73.42 
 
(26.01) 
 
71.34 
 
(27.33) 
 
0.547 
 
.579 
Note: Values are presented as Mean (Standard Deviation). Numbers in superscript are the amount of missing data  
Age= years of age; Amount of tobacco= gram tobacco consumed each week; Body weigh measured in kilogram; BMI =Body Mass Index calculated 
by weight in  kg/height in m2;Total Cholesterol/Low-density lipoprotein(LDL)/ High-density lipoprotein (HDL) measured in mmol/L; Blood 
pressure=Systolic Blood pressure(SBP)and Diastolic Blood Pressure (DBP) measured in mmHg; HeartScore® is total CVD risk and refers to the 10-
year risk mortality in percent; Comorbidity= Weighted index of comorbidity, Combined condition and age-related score and Estimated 10 year 
survival in percent 
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Table 8 
Group distribution of demographic variables at baseline: gender, marital status, education, 
total household income, subjective risk factors, medication intake, grading of angina, and 
previous cardiac events 
 
  
Control 
group 
 
DA group  
 
DA+DCP 
group  
 
Total sample 
   
 
 
Demographic variables  
n 
 
% 
 
 
% 
 
% 
 
% 
 
Ȥ2 
 
p 
 
Gender  
 
363 
     
0.163 
 
.922 
Male 224 62.0 62.8 60.3 61.7 
Female 139 38.0 37.2 39.7 38.3 
  
 
Marital status  
 
363 
     
5.840 
 
.829 
 Married  214 63.6 69.4 68.6 67.2 
 Live-in partner 38 11.6 9.9 9.9 10.5 
 Unmarried 13 5.0 2.5 3.3 3.6 
 Separated 3 0.8 1.7 0.0 0.8 
 Divorced 35 8.3 10.7 9.9 9.6 
 Widowed 30 10.7 5.8 8.3 8.3 
  
 
Education level  
 
363 
     
2.467 
 
.872 
Primary/Elementary 
School  
 
94 
 
29.8 
 
22.3 
 
25.6 
 
25.9 
Secondary  
School                             
 
166 
 
42.1 
 
47.1 
 
47.9 
 
45.7 
College/University up 
to 4 years 
 
66 
 
19.0 
 
19.0 
 
16.5 
 
18.2 
College/University 
more than 4 years 
 
37 
 
9.1 
 
11.6 
 
9.9 
 
10.2 
  
 
Total household income 
 
354 
 
 
    
4.890 
 
.769 
Less than 
200 000NOK 
38 8.3 12.9 11 10.7 
200 000-399 999 NOK 109 34.2 28.4 29.7 30.8 
400 000-599 999 NOK 104 28.3 32.8 27.1 29.4 
600 000-799 999 NOK 58 17.5 12.1 19.5 16.4 
More than 
800 000NOK 
45 11.7 13.8 12.7 12.7 
  
 
Subjective perceived  
risk factors associated 
with heart disease 
 
 
 
      
Increased body 
weight/obesity 
 
347 
 
37.6 
 
50.4 
 
47.8 
 
45.2 
 
4.315 
 
.116 
High Blood Pressure 343 43.6 50.0 51.8 48.4 1.715 .424 
Emotional stress 334 41.6 50.5 49.1 47.0 2.050 .359 
Diabetes 339 12.1 14.8 14.8 13.9 0.476 .788 
High Cholesterol 321 40.6 39.6 46.2 42.1 1.079 .583 
Lack of regular 
physical activity  
 
343 
 
53.0 
 
59.1 
 
55.8 
 
56.0 
 
0.868 
 
.648 
Smoking  363 24.0 24.0 24.0 24.0 0.000 1.00 
Heredity for CAD  350 51.3 54.7 50.8 52.3 0.416 .812 
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Control 
group 
 
DA group  
 
DA+DCP 
group  
 
Total sample 
   
 
 
Demographic variables  
n 
 
% 
 
 
% 
 
% 
 
% 
 
Ȥ2 
 
p 
 
 
 
Medication intake 
       
Anti cholesterol 
medication 
 
360 
 
80.0 
 
75.6 
 
74.4 
 
76.7 
 
1.170 
. 
557 
Antihypertensive 
medication 
 
358 
 
68.9 
 
68.6 
 
69.4 
 
69.0 
 
0.018 
 
.991 
 
Self-reported Canadian 
Cardiology Society 
Grading of Angina     
 
 
350 
     
 
9.125 
 
 
.322 
Grade 0 No angina 
symptom 
 
94 
 
26.3 
 
29.1 
 
25.2 
 
26.9 
 
Grade I 
 
57 
 
21,1 
 
16,2 
 
11,8 
 
16,3 
 
Grade II 
 
95 
 
22.8 
 
27.4 
 
31.1 
 
27.1 
 
Grade III 
 
57 
 
20.2 
 
12.0 
 
16.8 
 
16.3 
 
Grade IV 
 
47 
 
9.6 
 
15.4 
 
15.1 
 
13.4 
  
 
Previous cardiac events  
 
363 
      
Previous myocardial 
infarction (MI) 
 
90 
 
25.6 
 
22.3 
 
26.4 
 
24.8 
 
0.621 
 
.733 
 
Previous PCI 
 
75 
 
16.5 
 
24.0 
 
21.5 
 
20.7 
 
2.117 
 
.347 
 
Previous CABG 
 
47 
 
13.2 
 
10.7 
 
14.9 
 
12.9 
 
0.929 
 
.629 
        
Note: Values are presented as Count and Percent  
 
     The study population had an average age of 62.2 (10.1). 38.3 % were women,  
about two third (67.2 %) were married, and 71.6 % had no further education after secondary 
school. The most often perceived risk factors were lack of physical activity (56.0 %), and 
heredity of early CAD (50.8%). The 87 smokers (24.0%) used an average amount of tobacco 
64.78 gram (56.16) per week. The mean HeartScore® data at baseline was 4.72 (3.86), and 
the treatment goal based on the HeartScore® was 2.40 (1.65). Weighted index of comorbidity 
was 1.03 (1.20) with the estimate of 10 years survival at 71.34 (27.33).  
      
76.7 % of the patients used anti- cholesterol medication, and 69.0 % used 
antihypertensive medication. 24.8 % had a previous MI, 20.7 % previous PCI, and 12.9 % 
previous CABG surgery. 
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We also compared groups for equivalence of results from the angiogram and further 
treatment after the angiogram.  The angiogram results and further treatment are summarized 
in Table 9.  
 
Table 9 
Group distribution of results from the angiogram and further treatment 
 
  
Control 
group 
 
DA group  
 
DA+DCP 
group  
 
Total sample 
   
 
 
Demographic variables  
n 
 
% 
 
 
% 
 
% 
 
% 
 
Ȥ2 
 
p 
 
Number of arteries 
with significant 
stenosis 
 
 
 
     
 
10.396 
 
 
.109 
No significant 
vessels disease 
 
165 
 
37.2 
 
52.1 
 
47.1 
 
45.5 
 
One vessel disease 
 
76 
 
29.8 
 
15.7 
 
17.4 
 
20.9 
 
Two vessels disease 
 
60 
 
17.4 
 
14.9 
 
17.4 
 
16.5 
 
Three vessels 
disease 
 
62 
 
15.7 
 
17.4 
 
18.2 
 
17.1 
  
 
Received treatment  
 
 
     
8.139 
 
.228 
None 48 15.7 12.4 11.6 13.3 
 
Medication only 
 
179 
 
41.3 
 
53.7 
 
52.9 
 
49.3 
 
PCI 
 
84 
 
29.8 
 
21.5 
 
18.2 
 
23.1 
 
CABG surgery 
 
 
52 
 
13.2 
 
12.4 
 
17.4 
 
14.3 
  
Note: Values are presented as Count and Percent  
Significant stenosis refers to > 50% stenosis in one or more of the coronary arteries 
      
The angiogram revealed that 45.5 % had no significant vessel disease. The most 
frequent treatment after the angiogram was medication only (49.3 %), followed by PCI (23.1 
%), CABG 14.3 %, 13.3 % of the patients received no treatment or medication for CAD. 
 
There were no statistically significant differences in baseline characteristics, including 
potentially confounding variables such as angina symptoms, gender, age, previous cardiac 
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events, results from the angiogram, and treatment following the angiogram, and we therefore 
did not include these variables as covariates in the analysis.   
 
Analysis of hypotheses and research questions 
    
Effects on primary outcomes 
    Before we analyzed the effects of the interventions on primary outcomes, we computed 
means and SD for the three groups at each measurement point, regarding the primary health 
outcomes and HRQoL summarized in Table 10 and 11. 
 
Table 10 
Group mean and SD for health outcomes at baseline, two, four, and six months following the 
angiogram  
 
    
Baseline 
  
Two months 
  
Four months 
  
Six months 
 
Dependent 
variables 
 
Group 
 
n 
 
M 
 
 
SD 
 
n 
 
M 
 
SD 
 
n 
 
M 
 
SD 
 
n 
 
M 
 
SD 
 
Control 
 
121 
 
27.16 
 
(4.10) 
 
105 
 
27.07 
 
(4.04) 
 
87 
 
27.29 
 
(3.94) 
 
100 
 
27.23 
 
(4.23) 
DA 121 27.88 (4.95) 114 27.59 (4.84) 102 27.75 (5.05) 113 27.54 (4.81 ) 
 
Body Mass 
Index 
DA+DCP 121 27.34 (4.25) 118 27.01 (4.12) 98 26.80 (3.88) 114 26.77 (3.97) 
 
Control 
 
121 
 
4.52 
 
(1.02) 
 
21 
 
4.68 
 
(1.24) 
 
24 
 
4.48 
 
(1.00) 
 
26 
 
4.70 
 
(0.94) 
DA 120 4.49 (0.97) 20 4.06 (1.01) 23 3.98 (0.60) 29 4.62 (1.01) 
 
Total 
Cholesterol 
DA+DCP 121 4.57 (0.98) 30 4.12 (0.85) 41 4.27 (1.27) 24 4.80 (1.57) 
 
Control 
 
121 
 
1.36 
 
(0.56) 
 
14 
 
1.31 
 
(0.36) 
20  
1.31 
 
(0.44) 
15  
1.42 
 
(0.73) 
DA 120 1.35 (0.42) 15 1.31 (0.49) 18 1.28 (0.42) 20 1.39 (0.27) 
 
HDL 
DA+DCP 121 1.31 (0.36) 23 1.22 (0.30) 37 1.28 (0.33) 19 1.40 (0.37) 
 
Control 
 
121 
 
2.63 
 
(0.87) 
 
14 
 
2.32 
 
(0.71) 
 
20 
 
2.57 
 
(0.86) 
 
15 
 
2.32 
 
(0.57) 
DA 120 2.61 (0.88) 16 2.22 (0.75) 18 2.17 (0.59) 22 2.64 (0.85) 
LDL 
DA+DCP 121 2.74 (0.85) 26 2.26 (0.60) 34 2.28 (0.74) 19 3.03 (1.75) 
 
Control 
 
121 
 
145.31 
 
(22.27) 
 
48 
 
131.42 
 
(16.11) 
 
39 
 
133.05 
 
(16.10) 
 
42 
 
134.83 
 
(13.47) 
DA 121 148.65 (20.35) 41 131.37 (14.47) 51 132.00 (12.95) 56 136.55 (17.64) 
SBP 
DA+DCP 121 147.63 (22.45) 53 133.57 (23.31) 52 134.44 (17.38) 64 135.23 (20.38) 
 
Control 
 
121 
 
78.98 
 
(10.54) 
 
48 
 
76.85 
 
(9.12) 
 
39 
 
77.54 
 
(7.96) 
 
42 
 
78.52 
 
(7.74) 
DA 121 80.01 (11.70) 40 79.93 (9.32) 51 77.24 (9.99) 56 78.84 (10.20) 
DBP 
DA+DCP 121 79.50 (11.35) 52 77.06 (9.10) 52 78.19 (9.47) 64 81.75 (11.52) 
 
Control 
 
29 
 
62.21 
 
(48.58) 
 
17 
 
61.94 
 
(34.15) 
 
13 
 
65.69 
 
(54.42) 
 
16 
 
50.69 
 
(26.59) 
DA 29 62.97 (66.06) 19 56.89 (35.96) 17 59.77 (48.07) 19 53.21 (43.80) 
 
Amount of 
TOBACCO 
per week DA+DCP 29 69.17 (54.17) 20 52.85 (46.70) 13 59.85 (46.79) 17 49.82 (47.48) 
 
Note: Values are presented as Mean (standard deviation). 
Domain abbreviations and unit of measure as for Table 7. 
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Table 11 
Group mean and SD for HRQoL at baseline, two, four, and six months following the 
angiogram 
 
   
Baseline 
 
Control:     n=121 
DA:            n=121 
DA+DCP:  n=121 
 
Two months after 
the angiogram 
Control:     n=105 
DA:            n=114 
DA+DCP:  n=118 
 
Four months after 
the  angiogram 
Control:      n=  87 
DA:             n=102 
DA+DCP:  n=  99 
 
Six months after the 
angiogram 
Control:     n=100 
DA:            n=113 
DA+DCP:  n=114 
Dependent 
variables 
 
Group 
 
M 
 
 
SD 
 
M 
 
SD 
 
M 
 
SD 
 
M 
 
SD 
 
Control 
 
67.30 
 
(21.76) 
 
71.65 
 
(23.44) 
 
72.83 
 
(24.07) 
 
72.91 
 
(24.45) 
DA 67.76-3 (24.41) 70.87-1 (24.72) 72.96-3 (23.41) 73.04 (25.17) 
 
Physical 
Functioning 
DA+DCP 68.29 (20.78) 72.89-1 (22.86) 75.07 (22.86) 76.79-1 (21.36) 
 
Control 
  
(29.84) 
 
58.60-2 
 
(33.82) 
 
62.72 
 
(32.10) 
 
56.63-1 62.62 
 
(31.37) 
DA 58.88-2 (29.86) 62.05-2 (31.15) 67.06-2 (30.51) 69.40-1 (29.05) 
 
Role 
Functioning
- Physical DA+DCP 56.00-2 (31.32) 62.97-2 (30.69) 72.11-1 (26.68) 71.60-2 (27.38) 
 
Control 
 
54.44 
 
(23.74) 
 
60.28 
 
(29.13) 
 
63.11 
 
(24.58) 
 
61.61-1 
 
(27.67) 
DA 54.28 (25.35) 60.30-1 (27.15) 65.29-1 (27.80) 63.76-1 (27.09) 
 
Bodily Pain 
DA+DCP 53.41-1 (24.55) 61.48-2 (26.85) 66.41-1 (26.18) 63.26-1 (26.90) 
 
Control 
 
56.87-7 
 
(20.67) 
 
57.24-3 
 
(22.89) 
 
59.79 
 
(23.55) 
 
58.53-2 
 
(25.05) 
DA 54.32-1 (20.95) 59.54-4 (23.29) 58.97-4 (22.85) 59.07-2 (22.60) 
 
General 
Health 
 
DA+DCP 
 
55.91-3 
 
(19.17) 
 
60.22-1 
 
(20.40) 
 
61.50-4 
 
(22.10) 
 
63.35-2 
 
(22.25) 
 
Control 
 
42.85-5 
 
(23.23) 
 
46.14-3 
 
(23.58) 
 
49.28 
 
(23.41) 
 
49.14-1 
 
(25.05) 
DA 44.25 (22.75) 49.89-3 (22.07) 50.49-5 (22.31) 52.29-3 (22.14) 
 
Vitality 
DA+DCP 43.50-2 (21.58) 48.81-1 (21.24) 54.43-3 (23.07) 54.20-1 (22.64) 
 
Control 
 
67.98 
 
(27.14) 
 
68.69 
 
(28.80) 
     
74.86 (23.15) 74.25 (26.10) Social 
Function DA 74.38 (25.86) 75.88 (28.01) 78.09-1 (25.46) 77.23-1 (27.33) 
DA+DCP 72.40-1 (26.87) 75.21-1 (25.69) 80.43 (24.82) 78.87-1 (24.50) 
 
Control 
 
71.36-3 
 
(27.53) 
 
68.77-2 
 
(34.02) 
 
72.22 
 
(28.29) 
 
72.25 
 
(30.13) 
DA 74.86-3 
 
Role 
Functioning
- Emotional 
(28.01) 79.32-2 (26.83) 81.85-1 (24.87) 80.21-1 (25.73) 
DA+DCP 74.79-1 (27.91) 80.10-2 (25.32) 82.14-1 (26.62) 82.67-1 (22.88) 
 
Control 
 
73.22-5 
 
(17.37) 
 
70.33-3 
 
(19.54) 
 
73.36 
 
(19.36) 
 
71.40-1 
 
(19.83) 
DA 74.50 (17.20) 74.16-4 (17.32) 75.99-5 (17.19) 76.11-3 (18.24) 
 
Mental 
Health 
DA+DCP 74.75-2 (17.38) 74.27-1 (17.46) 77.10-3 (19.19) 76.88-1 (17.68) 
          
Control 77,00-16 (19.13) 79.45-16 (22.49) 81.97-12 (20.20) 76.73-12 (23.18) 
DA 78.58-8 (20.17) 80.15-12 (23.15) 79.28-7 (24.76) 79.47-10 (25.17) 
Treatment 
satisfaction 
DA+DCP 82.10-11 (17.62) 79.57-24 (20.89) 83.82-18 (19.71) 80.83-20 (22.83) 
          
Control 51.56-14 (21.51) 65.50-19 (24.33) 66.00-12 (23.33) 67.94-18 (24.24) 
DA 52.32-8 (22.00) 68.96-14 (22.62) 69.78-7 (23.29) 71.20-10 (23.35) 
Disease 
Perception 
DA+DCP 51.21-11 (22.68) 67.06-22 (25.04) 73.66-18 (22.33) 74.82-19 (21.29) 
 
          
Note: Each observation is presented as Mean (standard deviation). Numbers in superscript are the amount of missing data. 
For all scales, higher scores indicate better health, satisfaction or quality of life. Scale range 0-100. 
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As seen in table 10 and 11 there was a trend that DA+DCP group reported higher scores 
than the other two groups in most HRQoL variables.  
 
Hypothesis 1.  We had hypothesized that the patients in DA+DCP group  would report 
significantly better primary health outcomes (body mass index, cholesterol, blood pressure, 
and amount of tobacco), and HRQoL  at six months following the angiogram than patients in 
DA group who in return would achieve better outcomes than the Control group. We used 
ANCOVA to compare the difference in group means at six months following the angiogram 
after statistical adjustment for the effect of the baseline scores. Six months was selected 
because it is the usual time of completion of recovery and resuming to functional status and 
normal roles. 
 
Table 12 and 13 shows the group differences for each of the health outcomes variables 
and HRQoL variables at six months, controlling for baseline scores 
 
Table 12  
Group differences in health outcomes at six months following the angiogram controlling for 
baseline scores 
 
 
 
 
Control  
group 
 
DA group  
 
DA+DCP group  
 
Dependent 
variables 
 
n 
 
M 
 
 
SD 
 
n
 
M
 
SD 
 
n
 
M
 
SD 
 
F 
 
p-value
        
Body Mass Index 
 
100 
 
27.41 (0.12) 113 27.20 (0.11) 114 26.95 (0.11) 4.17 .016 
Total Cholesterol 
 
26 4.75 (0.19) 29 4.71 (0.18) 24 4.71 (0.20) 0.01 .987 
HDL 
 
15 1.50 (0.11) 20 1.37 (0.09) 19 1.35 (0.10) 0.59 .556 
LDL 
 
15 2.36 (0.28) 22 2.83 (0.25) 19 2.80 (0.26) 0.93 .400 
SBP 
 
42 135 (2.64) 56 137 (2.29) 64 135 (2.14) 0.28 .758 
DBP 
 
42 78.38 (1.56) 56 79.02 (1.35) 64 81.69 (1.26) 1.70 .187 
Amount of tobacco 
 
16 51.72 (10.07) 19 53.83 (9.23) 17 48.16 (9.81) 0.09 .915 
Note: The differences are adjusted for covariate = the baseline scores 
Alpha =.05.  
Domain abbreviations and unit of measure as for Table 7. 
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After adjusting for baseline scores, there was a significant difference between the three 
groups on post-intervention (T4) scores of Body Mass Index. The Scheffé post hoc test was 
conducted to determine which IV groups were significantly different. Results show that 
DA+DCP group is significantly better than the Control group. 
 
Table 13  
Group differences in HRQoL outcomes at six months following the angiogram controlling for 
baseline scores 
 
 
 
 
Control group  
 
n=100 
 
DA group  
 
n=113 
 
DA+DCP group  
 
n=114  
 
   
Dependent 
variables 
 
M 
 
 
SD 
 
M 
 
SD 
 
M 
 
SD 
 
F 
 
p-value 
 
eta2 
          
Physical 
Functioning 
 
72.84 (1.83) 73.16 (1.75) 76.87-1 (1.73) 1.63 .197 .010 
Role Functioning 
Physical 
 
63.21 (2.42) 68.92-1 (2.29) 72.52-2 (2.30) 3.93 .021 .024 
Bodily Pain 
 
61.82-1 (2.28) 63.41-1 (2.14) 64.18-1 (2.14) 0.29 .745 .002 
General Health 
 
57.44-2 (1.85) 59.67-2 (1.09) 63.50-2 (1.70) 3.04 .049 .019 
Vitality 
 
48.56-1 (1.98) 51.70-3 (1.84) 55.89-1 (1.84) 3.74 .025 .023 
Social Functioning 
 
76.65 (2.08) 75.16-1 (1.96) 78.95-1 (1.96) 0.95 .388 .006 
Role Functioning 
Limitation 
 
74.01 (2.40) 80.27-1 (2.27) 82.43 (2.24) 3.49 .032 .022 
Mental health 
 
72.39-1 (1.53) 75.44 (1.42) 76.88-1 (1.41) 2.38 .094 .015 
Treatment 
Satisfaction 
 
78.61-21 (2.41) 80.37-15 (2.15) 79.83-24 (2.27) 0.15 .858 .001 
Disease Perception 
 
65.85-25 (2.31) 70.27-15 (2.02) 75.91-22 (2.09) 5.30 .006 .039 
Note: The differences are adjusted for covariate = the baseline scores.  
Alpha =.05 
Each observation is presented as Mean (standard deviation). Numbers in superscript are the amount of missing data. 
For all scales, higher scores indicate better health or quality of life.  
Scale range 0-100.  
 
We found a significant difference in 50 % of the HRQoL variables. The calculated 
effect sizes for each factor indicate that small proportions of HRQoL are accounted for by 
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each factor. The Scheffé post hoc test was conducted to determine which groups were 
significantly different. Results show that the DA+DCP group is significantly better than the 
Control group. Thus, hypothesis 1 was partly supported. 
Effects on intermediate adherence outcomes 
Before we analyzed the effects of the interventions on intermediate adherence 
outcomes, we computed means and SD for the three groups at each time point, for the 
adherence outcomes summarized in Table 14. 
 
Table 14 
Group mean and SD for adherence outcomes at baseline, two, four, and six months following 
the angiogram 
   
Baseline 
 Intentions 
 
Control:     n=121 
DA:            n=121 
DA+DCP:  n=121 
 
Two months 
after the 
angiogram 
 
Control:     n=105 
DA:            n=114 
DA+DCP:  n=118 
 
Four months 
after the 
angiogram 
 
Control:      n=  87 
DA:             n=102 
DA+DCP:  n=  99 
 
Six months after 
the angiogram 
 
Control:     n=100 
DA:            n=113 
DA+DCP:  n=114 
 
Dependent 
variables 
 
Group 
 
M 
 
SD 
 
M 
 
 
SD 
 
M 
 
SD 
 
M 
 
SD 
 
Control 
 
15.08-3 
 
(3.29) 
 
12.92-20 
 
(3.48) 
 
14.13-19 
 
(3.70) 
 
13.34-10 
 
(3.67) 
DA 15.43-7 (3.34) 12.61-16 (3.66) 13.40-13 (3.43) 13.53-14 (3.74) 
 
Adherence 
to  
Diet 
 recommen-
dations 
DA+DCP 15.38-9 (3.76) 13.67-1 (3.52) 14.04-10 (3.08) 14.12-14 (3.07) 
 
Control 
 
14.29-7 
 
(4.19) 
 
11.07-29 
 
(4.48) 
 
12.33-23 
 
(4.63) 
 
11.31-22 
 
(4.64) 
DA 14.91-8 (3.80) 11.28-22 (4.80) 12.21-17 (4.75) 11.91-22 (4.92) 
 
Adherence 
to activity 
recommen-
dations 
DA+DCP 15.29-12 (3.87) 11.63-21 (4.40) 12.71-17 (3.88) 12.84-19  (3.96) 
 
Control 
 
13.69-6 
 
(4.28) 
 
14.09-21 
 
(3.91) 
 
14.03-16 
 
(3.70) 
 
14.32-11 
 
(3.68) 
DA 14.56-7 (3.91) 14.03-16 (3.53) 14.15-9 (3.50) 13.97-12 (3.55) 
 
Adherence 
to stress  
reduction DA+DCP 14.59
-10 (3.68) 14.35-8 (3.72) 14.48-9 (3.40) 14.17-13 (3.76) 
 
Control 
 
19.63-3 
 
(1.41) 
 
19.45-24 
 
(1.95) 
 
19.63-17 
 
(1.78) 
 
19.11-17 
 
(3.25) 
DA 19.78-8 (0.96) 19.70-13 (1.00) 19.18-13 (2.80) 19.19-16 (3.02) 
 
Adherence 
to taking 
their 
medication 
 
DA+DCP 19.52-4 (1.57) 19.52-14 (1.80) 19.55-10 (2.19) 19.69-16 (1.28) 
Control 18.74-4 (3.16) 18.84-2 (3.20) 18.75-2 (3.55) 19.14-2 (2.30) 
DA 19.07-4 (2.59) 18.54-1 (3.68) 19.15-4 (2.65) 19.11-4 (2.72) 
Adherence 
to  
no smoking 
 
DA+DCP 18.94-5 (2.78) 18.88-3 (3.09) 19.14-3 (2.80) 18.96-3 (3.11) 
Note: Each observation is presented as Mean (standard deviation). Numbers in superscript are the amount of missing data. 
 For all scales, higher scores indicate higher adherence 
Scale range is 5-25 
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     Table 14 depicts that the intention to adhere to the actual recommendations were higher at 
baseline than the actual adherence reported two months later, except an increase in adherence 
to stress recommendations and taking their medication for DA group. The greatest decrease 
between intentions and actual adherence two months later was found for activity and diet. 
There was only a small change in adherence scores from two months to six months following 
the angiogram. The greatest increase was found in adherence to activity. Adherence to stress 
reduction showed a small decrease in both intervention groups, while the adherence to taking 
medication showed a decrease in the Control group and DA group. 
 
     Hypothesis 2. We tested the hypothesis that patients in DA+DCP group would report 
significantly greater adherence outcomes (following the diet recommendations, activity 
recommendations, no smoking, taking their prescribed medication and stress reduction) after 
six months than patients in DA group who in turn would achieve better outcomes than the 
Control group. We compared groups mean differences for the five adherence to cardiac risk 
reduction categories at six months controlling for scores at baseline. ANCOVA analysis was 
used to examine group differences at six months following the angiogram controlling for 
scores at baseline. Table 15 shows the group differences for each of the adherence outcomes 
variables at six months, controlling for baseline scores. 
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Table 15 
Group differences in adherence outcomes at six months following the angiogram controlling 
for baseline scores    
 
 
Control group 
 
DA group 
 
DA+DCP group 
  
 
Dependent 
variables 
 
n 
 
M 
 
SD 
 
n 
 
M 
 
SD 
 
n 
 
M 
 
SD 
   
F 
 
p-value 
 
Adherence to 
diet 
recommendation 
 
 
87 
 
 
13.24 
 
 
(3.66) 
 
 
94 
 
 
13.46
 
 
(3.81) 
 
 
93 
 
 
14.01
 
 
(3.11) 
 
 
1.06 
 
 
.348 
 
Adherence to 
activity 
recommendation 
 
 
76 
 
 
11.54 
 
 
(4.62) 
 
 
88 
 
 
12.01
 
 
(4.91) 
 
 
88 
 
 
12.71
 
 
(3.82) 
 
 
1.42 
 
 
.243 
 
Adherence to 
stress reduction 
 
85 
 
14.20 
 
(3.64) 
 
95 
 
14.99
 
(3.77) 
 
93 
 
14.20
 
(3.77) 
 
0.10 
 
.906 
 
Adherence to 
taking 
medication 
 
 
80 
 
 
19.08 
 
 
(3.31) 
 
 
93 
 
 
19.18
 
 
(3.06) 
 
 
96 
 
 
19.69
 
 
(1.29) 
 
 
1.39 
 
 
.251 
 
Adherence to no 
smoking 
 
 
94 
 
19.10 
 
(2.35) 
 
105
 
19.08
 
(2.76) 
 
106
 
19.06
 
(2.82) 
 
0.01 
 
.994 
Note: The differences are adjusted for covariate = the baseline scores 
Alpha =.05 
Each observation is presented as Mean (standard deviation). 
For all scales, higher scores indicate higher adherence 
Average scale range is 5-25 
 
Table 15 shows no significant group differences in any of the adherence outcomes. 
Hypothesis 2 was not supported. However, during the study period the proportion of 
individuals who succeeded to quit smoking in the DA+DCP group was higher (31.0%) than in 
DA group (20.7 %), which was higher than in the Control group (17.2 %). Table 16 shows the 
group differences for number of adherent quitters at the three measurement points. 
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Table 16 
Quitters of smoking at three measurement points by groups  
 
  
Control group 
 
DA group 
 
DA+DCP group 
 
Total 
Dependent 
variables 
n        % n      % n     % n    % 
 
Quitters at T2 
 
5      17.2 
 
7      24.1 
 
7     24.1 
 
19   21.8 
 
Quitters at T3 
 
4      13.8 
 
6     20.7 
 
7     24.1 
 
17   19.5 
 
Quitters at T4 
 
5     17.2 
 
6     20.7 
 
9    31.0 
 
20   23.0 
     
Note: Number of smokers at T1 was 87. 
Each observation is presented as count of people who reports quitting smoking at this measurement and percent. 
 
 
In the Control group seven (24.1 %) patients reported that they had tried to quit  
smoking during the study period, and five reported adherence in quitting smoking six months 
after the angiogram.  In DA group seven (24.1%) patients reported that they had tried to quit 
smoking during study period, and six (20.7 %) reported adherence in quitting smoking six 
months after the angiogram. In DA+DCP group eleven (37.9 %) patients reported that they 
had tried to quit smoking during the study period, and nine reported adherence (31.0%) in 
quitting smoking at six months. These differences are based on very small numbers.  
 
Effects on other outcomes 
Before we analyzed the effects of the interventions on the mediating variables, we 
computed means and SD for the three groups at baseline and two month for the mediating 
variables summarized in Table 17. 
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Table 17 
Group mean and SD for knowledge scores, perceived health beliefs, perceived benefits and 
barriers at baseline and at two months following the angiogram 
 
   
Baseline 
 
 
Control:     n=121 
DA:            n=121 
DA+DCP:  n=121 
 
 
Two months following the 
angiogram 
 
Control:     n=105 
DA:            n=114 
DA+DCP:  n=118 
Dependent variables  
Group 
 
M 
 
 
SD 
 
M 
 
SD 
 
Control 
 
14.51 
 
(4.42) 
 
15.75-1 
 
(4.01) 
DA 14.40 (4.41) 16.18 (3.47) 
Knowledge about risk 
factors and CAD 
 
DA+DCP 14.90 (4.01) 16.70-1 (3.46) 
 
Control 
 
3.05-2 
 
(0.58) 
 
2.95 
 
(0.63) 
DA 3.07-6 (0.57) 3.00 (0.69) 
Perceived Susceptibility 
of CAD or CAD 
progression 
 DA+DCP 3.06-1 (0.58) 2.90 (0.61) 
 
Control 
 
3.45-2 
 
(0.67) 
 
3.57-1 
 
(0.56) 
DA 3.38-8 (0.65) 3.42-3 (0.71) 
Perceived Severity of 
CAD or CAD 
progression 
 DA+DCP 3.41-3 (0.54) 3.41-2 (0.56) 
 
Control 
 
3.28-1 
 
(0.42) 
 
3.34 
 
(0.37) 
DA 3.26-3 (0.40) 3.38 (0.36) 
Perceived Benefits of 
cardiac risk reduction 
 
DA+DCP 3.37-2 (0.40) 3.40-2 (0.37) 
 
Control 
 
1.84-2 
 
(0.41) 
 
1.87-3 
 
(0.50) 
DA 1.85-5 (0.45) 1.81-2 (0.41) 
Perceived Barriers to 
cardiac risk reduction 
DA+DCP 1.77-3 (0.38) 1.68-1 (0.40) 
  
 
    
Note: Each observation is presented as Mean (standard deviation). Numbers in superscript are the amount of missing data. 
Knowledge: scores range is 0-21 with higher scores indicating more correct answers regarding risk factors and CAD. 
Susceptibility: average scores range is 1-5 with higher scores indicating higher perceived susceptibility of CAD or CAD progression 
Severity: average scores range is 1-5 with higher scores indicating higher perceived severity of CAD or CAD progression 
Benefits: average scores range is 1-4 with higher scores indicating higher perceived benefits of cardiac risk modification behavior. 
Barriers: average score s range is 1-4 with higher scores indicating greater perceived barriers to cardiac risk modification behavior. 
 
 
 
Improvements in knowledge scores were evident in all three groups, the most in 
DA+DCP group. The Control and DA group increased their perceived severity of CAD or 
CAD progression, while DA+DCP group kept their perceived severity stable. Regarding the 
perceived barriers of cardiac risk reduction behavior, the DA and DA+DCP groups decreased 
their perceived barriers, while the Control group increased their perceived barriers.  
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        Hypothesis 3. We hypothesized that patients in DA+DCP group would report 
significantly greater knowledge about risk factors and CAD, perceived susceptibility and 
severity of CAD progression, and perceived benefits and barriers of cardiac risk reduction 
behavior two months following the angiogram (T2) than patients in the DA group who in turn 
would achieve better outcomes than the Control group. We compared group differences for 
the dependent variables at two months controlling for baseline scores.  ANCOVA analysis 
was used to examine group differences at two months following the angiogram, controlling 
for scores at baseline. Table 18 shows the group differences for each of the adherence 
outcomes variables at six months, controlling for baseline scores. 
 
Table 18 
Group differences in knowledge scores, perceived health beliefs, perceived benefits and 
barriers at two months following the angiogram controlling for baseline scores 
 
 
 
  
Control 
group 
  
DA group  
  
DA+DCP 
group  
  
 
Dependent 
variables 
 
n 
 
M 
 
 
SD 
 
n 
 
M 
 
SD 
 
n 
 
M 
 
SD 
 
F 
 
p-value
            
Knowledge about 
risk factors and 
CAD 
 
104 16.13 (0.29) 114 16.19 (0.28) 117 16.88 (0.27) 2.28 .104 
Perceived 
Susceptibility of 
CAD and CAD 
progression 
 
103 2.99 (0.05) 109 3.02 (0.05) 117 2.88 (0.05) 1.91 .150 
Perceived Severity 
of CAD or CAD 
progression 
 
102 3.53 (0.05) 106 3.47 (0.05) 114 3.40 (0.05) 1.89 .152 
Perceived Benefits 
of cardiac risk 
reduction 
 
104 3.36 (0.03) 112 3.39 (0.03) 115 3.36 (0.03) 0.33 .720 
Perceived Barriers 
to cardiac risk 
reduction 
 
100 1.86 (0.04) 108 1.78 (0.04) 115 1.71 (0.04) 3.94 .020 
Note: The differences are adjusted for covariate = the baseline scores 
Alpha =.05 
Each observation is presented as Mean (standard deviation). 
Unit of measure and scores range as for Table 17. 
 
 
 
 
91 
 
Controlling for baseline scores, there was a significant difference between the three 
groups on post-intervention (T2) scores of perceived barriers to cardiac risk reduction 
behavior. The Scheffé post hoc test was conducted to determine which groups were 
significantly different. Results show that DA+DCP group is significant better than the Control 
group. Therefore, hypothesis 3 was partly supported. 
 
Relationships between adherence outcomes and health outcomes at two, four, and six 
months following the angiogram
Slopes were compared between the Adherence variables and the health outcomes 
variables using mixed-effects models. The model included random effects in the intercept and 
the slope. If the model was unstable we included random effects in the intercept only. Table 
19 shows the relationship per months (slope) for the variables.  
 
Table 19  
Relationships between adherence outcomes and health outcomes at two, four, and six months 
following the angiogram 
 
  
Adherence to  
diet 
recommendation 
 
Adherence to 
activity 
recommendation
 
Adherence 
to taking 
their 
medication 
 
Adherence 
to stress 
reduction 
 
Adherence 
to  no 
smoking 
  
Slope 
 
 
p -value 
 
Slope 
 
p -value 
 
Slope
 
p -value
 
Slope
 
p -value
 
Slope 
 
 
p -value
           
Body Mass 
Index 
-0.036 .043 -0.003 .840 0.021 .338 0.011 .418 0.025 .407 
           
 Total 
Cholesterol 
0.033 .178 -0.014 .398 -0.058 .164 0.031 .043 0.030 .570 
           
LDL 0.007 .751 -0.005 .752 -0.006 .864 0.027 .062 0.024 .637 
           
HDL 0.017 .072 -0.010 .140 -0.058 .002 0.001 .880 -0.021 .417 
           
SBP -0.105 .214 -0.029 .907 -0.124 .778 -0.387 .133 0.477 .211 
           
DBP -0.143 .469 -0.048 .751 0.001 .998 -0.080 .619 -0.058 .798 
           
Amount of 
TOBACCO 
per week in 
gram 
 
 
1.667 
 
 
.239 
 
-1.350 
 
.250 
 
0.367 
 
.719 
 
-0.491 
 
.623 
 
-2.071 
 
.052 
Note: Alpha =.05 
Domain abbreviations as for Table 7. 
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Findings show that greater adherence to diet recommendation was significantly related 
to lower Body Mass Index.   
 
Relationships between adherence outcomes and HRQoL at two, four, and six months 
following the angiogram
Slopes were compared between the Adherence variables and the HRQoL variable using 
mixed-effects model. The model included random effects in the intercept and the slope. If the 
model was unstable we included random effects in the intercept only. Table 20 shows the 
relationship per month (slope) for the variables.  
 
Table 20  
Relationships between adherence outcomes and HRQoL outcomes at two, four, and six 
months following the angiogram 
 
  
Adherence to  
diet 
recommendation 
 
Adherence to 
activity 
recommendation 
 
Adherence to 
taking their 
medication 
 
Adherence to 
stress 
reduction 
 
Adherence to  
no smoking 
  
Slope 
 
 
p -value 
 
Slope 
 
p -value 
 
Slope 
 
p -value
 
Slope 
 
p -value
 
Slope 
 
 
p -value 
 
Physical 
Functioning 
 
 
0.823 
 
 
.008 
 
 
0.204 
 
 
.402 
 
 
-1.101 
 
 
.005 
 
 
0.186 
 
 
.457 
 
 
0.413 
 
 
.161 
 
Role 
Functioning- 
Physical 
 
 
0.958 
 
 
.021 
 
 
0.210 
 
 
.520 
 
 
-0.806 
 
 
.126 
 
 
0.275 
 
 
.413 
 
 
0.521 
 
 
.187 
           
Bodily Pain 0.806 .025 0.198 .488 -0.822 .072 0.200 .489 0.300 .398 
           
General Health 0.616 .040 0.336 .160 -0.168 .658 0.097 .687 0.309 .306 
           
Vitality 0.349 .261 0.518 .036 -0.167 .672 0.214 .393 0.338 .264 
           
Social Function 0.539 .124 0.159 .565 -0.027 .952 0.225 .427 0.616 .071 
 
Role 
Functioning- 
Emotional 
 
 
1.289 
 
 
.0004 
 
 
-0.177 
 
 
.537 
 
 
-0.111 
 
 
.810 
 
 
0.083 
 
 
.776 
 
 
0.630 
 
 
.076 
           
Mental Health 0.514 .029 -0.012 .951 0.136 .646 0.148 .428 0.552 .025 
           
Treatment 
Satisfaction 
 
0.391 
 
.393 
 
0.247 
 
.462 
 
-0.076 
 
.933 
 
0.101 
 
.780 
 
-0.068 
 
.888 
 
Disease 
Perception 
 
 
0.352 
 
 
.445 
 
 
0.472 
 
 
.162 
 
 
1.346 
 
 
.138 
 
 
0.152 
 
 
.671 
 
 
0.871 
 
 
.076 
           
Note: Alpha =.05 
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Findings show that greater Adherence to recommendation was significantly related to 
better HRQoL on several variables.  
 
Relationships between health outcomes and HRQoL at baseline, two, four, and six months 
following the angiogram
Slopes were compared between the three groups for each outcome variable using 
mixed-effects model. The model included random effects in the intercept and the slope. If the 
model was unstable we included random effects in the intercept only.  Table 21 shows the 
relationship per month (slope) for the variables.  
  
Table 21  
Relationships between health outcomes and HRQoL outcomes at baseline, two, four, and six 
months following the angiogram 
 
  
Body Mass 
Index 
 
SBP 
 
DBP 
 
Health Service 
used 
  
Slope 
 
 
p -value 
 
Slope 
 
p -value 
 
Slope 
 
p -value 
 
Slope 
 
p -value 
Physical 
Functioning 
 
-0.78 
 
.0004 
 
-0.07 
 
.152 
 
0.11 
 
.227 
 
2.00 
 
.282 
 
Role 
Functioning- 
Physical 
 
 
-0.17 
 
 
.543 
 
 
-0.10 
 
 
.104 
 
 
-0.05 
 
 
.701 
 
 
0.95 
 
 
.710 
 
Bodily Pain 
 
 
-0.64 
 
.009 
 
0.03 
 
.530 
 
-0.12 
 
.262 
 
4.08 
 
.048 
General Health 
 
0.22 
 
.312 -0.01 .846 -0.02 .814 3.40 .046 
Vitality 
 
-0.26 .249 0.02 .688 -0.01 .973 5.32 .005 
Social Function 
 
-0.22 .402 0.06 .255 -0.04 .725 2.77 .184 
Role 
Functioning- 
Emotional 
 
0.01 
 
.962 
 
0.04 
 
.484 
 
-0.08 
 
.492 
 
2.09 
 
.361 
 
Mental Health 
 
0.12 
 
.505 
 
0.04 
 
.247 
 
0.01 
 
.877 
 
1.65 
 
.220 
 
Treatment 
Satisfaction 
 
 
-0.69 
 
 
.011 
 
 
0.07 
 
 
.221 
 
 
-0.13 
 
 
.291 
 
 
-0.18 
 
 
.941 
 
Disease 
Perception 
 
 
-0.68 
 
 
.024 
 
 
-0.11 
 
 
.071 
 
 
-0.04 
 
 
.766 
 
 
4.52 
 
 
.089 
         
Note: Alpha =.05 
Domain abbreviations as for Table 7. 
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Findings show that higher BMI was significantly related to HRQoL regarding lower 
physical functioning, greater bodily pain, less treatment satisfaction, and more limits in 
quality of life because of chest pain. Attendance in cardiac rehabilitation, courses in quitting 
smoking, weight reduction, and diet were significantly related to HRQoL in terms of less 
bodily pain, better general health, and increased vitality. 
 
Relationships between the intentions at baseline, and adherence outcomes two, four, and 
six months following the angiogram.
     Slopes were compared between the variables using the mixed-effects model. The model 
included random effects in the intercept and the slope. If the model was unstable we included 
random effects in the intercept only. Table 22 shows the relationship per month (slope) for the 
variables.  
 
Table 22 
Relationships between intentions and adherence outcomes at two, four, and six months 
following the angiogram 
 
  
Diet  
Intention 
 
Activity 
Intention 
 
Medication 
Intention 
 
Stress 
reduction 
Intention 
 
No Smoking 
Intention 
  
Slope 
 
 
p -value 
 
Slope 
 
p -value 
 
Slope 
 
p -value
 
Slope 
 
p -value
 
Slope 
 
 
p -value 
           
Adherence to 
diet 
recommendation 
 
 
0.27 
 
 
<.0001 
 
 
0.11 
 
 
.025 
 
 
0.11 
 
 
.398 
 
 
-0.00 
 
 
.962 
 
 
0.10 
 
 
.096 
 
Adherence to 
activity 
recommendation 
 
 
-0.07 
 
 
.373 
 
 
0.43 
 
 
<.0001 
 
 
-0.05 
 
 
.794 
 
 
-0.01 
 
 
.853 
 
 
-0.03 
 
 
.694 
 
Adherence to 
taking their 
medication 
 
 
0.02 
 
 
.678 
 
 
-0.00 
 
 
.943 
 
 
0.16 
 
 
.109 
 
 
0.00 
 
 
.935 
 
 
0.01 
 
 
.840 
 
Adherence to 
stress reduction 
 
 
0.02 
 
 
.780 
 
 
0.00 
 
 
.967 
 
 
-0.20 
 
 
.130 
 
 
0.16 
 
 
.0002 
 
 
0.08 
 
 
.236 
 
Adherence to  
no smoking 
 
 
-0.09 
 
 
.041 
 
 
0.03 
 
 
.498 
 
 
-0.25 
 
 
.008 
 
 
-0.03 
 
 
.330 
 
 
0.85 
 
 
<.0001 
           
Note: Alpha =.05 
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Findings revealed that intention to adhere at baseline was significantly related to actual 
adherence in several variables during the study period.  
 
Relationships between  the knowledge about risk factors and CAD, perceived susceptibility 
and severity of CAD or CAD progression, perceived benefits and barriers of cardiac risk 
reduction behavior, and decisional conflict two months following the angiogram, and 
adherence outcomes two, four, and six months following the angiogram.
Slopes were compared between the variables using mixed-effects model.  The model 
included random effects in the intercept and the slope. If the model was unstable we included 
random effects in the intercept only. Table 23 shows the relationship per month (slope) for the 
variables.  
 
Table 23  
Relationships between knowledge scores, perceived health beliefs, perceived benefits and 
barriers, and decisional conflict at two months, and adherence outcomes at two, four, and six 
months following the angiogram 
 
  
Knowledge 
of CAD and 
risk factors 
 
Perceived 
Susceptibilit
y of CAD or 
CAD 
progression 
   
Perceived 
Barriers to 
cardiac risk 
reduction 
behavior 
 
Perceived 
Severity of 
CAD or 
CAD 
progression 
Perceived 
Benefits of 
cardiac risk 
reduction 
behavior 
Decisional 
conflict 
  
Slope 
 
 
p -value 
  
p -value
 
Slope 
 
p -value
 
Slope 
 
p -value
 
Slope 
 
 
p -value 
 
Slope 
 
Slope p -value
             
Adherence to 
diet 
recommendation 
 
 
0.09 
 
 
.124 
 
 
-0.73 
 
 
.069 
 
 
0.11 
 
 
.716 
 
 
-0.19 
 
 
.735 
 
 
-0.96 
 
 
.041 
 
 
-0.04 
 
 
.003 
 
Adherence to 
activity 
recommendation 
 
 
0.05 
 
 
.518 
 
 
-0.99 
 
 
.073 
 
 
0.61 
 
 
.155 
 
 
0.388 
 
 
.608 
 
 
-1.08 
 
 
.099 
 
 
-0.06 
 
 
.002 
 
Adherence to 
taking their 
medication 
 
 
0.02 
 
 
.637 
 
 
0.08 
 
 
.777 
 
 
-0.23 
 
 
.309 
 
 
-0.45 
 
 
.260 
 
 
-0.58 
 
 
.117 
 
 
-0.02 
 
 
.026 
 
Adherence to 
stress reduction 
 
 
-0.01 
 
 
.845 
 
 
-0.30 
 
 
.441 
 
 
0.60 
 
 
.050 
 
 
0.23 
 
 
.668 
 
 
0.19 
 
 
.665 
 
 
0.01 
 
 
.523 
 
Adherence to  
no smoking 
 
 
0.04 
 
 
.531 
 
 
-1.63 
 
 
<.0001 
 
 
0.438 
 
 
.160 
 
 
-0.61 
 
 
.260 
 
 
0.59 
 
 
.195 
 
 
-0.02 
 
 
.179 
             
Note: Alpha =.05 
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Higher decisional conflict was significantly related to lower adherence to diet, activity, 
and taking medications recommendations. There was also a significant relationship between 
increased perceived susceptibility of CAD or CAD and lower adherence to no smoking.   
 
Patients’ acceptability of the DA with and without the DCP
We evaluated patients perceived usefulness of DA overall, and investigated if patients 
perceived the usefulness of the DA differently if they also received the DCP. 
      
The Chi-square tests was used to test differences in perceived DA usefulness between 
DA group and DA+DCP group. In both groups approximately 90% of the patients perceived 
the presentation of major risk and presentation of the options for lifestyle changes in the DA 
as good or excellent, and there were found no significant differences between DA group and 
DA+DCP group on these variables. However, patients in DA+DCP group perceived the 
information in the DA significantly more useful if they in addition had received the DCP for 
the following elements: calculating risks, thinking about possible changes, making the action 
plan and the information in the worksheet (Table 22). This suggests that when patients 
received the DCP in addition to the DA, they were more able to utilize the information in the 
DA. 
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Table 24 
The presentation of the options for lifestyle changes in the DA 
 
   
POOR 
 
 
FAIR 
 
GOOD 
 
EXCELLENT 
  
 n     Ȥ2 p-value 
Calculate your risk        
DA group  99 2.8 14.1 68.7 11.1   
DA+DCP group  
 
117 0.9 9.4 68.4 21.4 0.199 .031 
Thinking about 
possible changes 
       
DA group  97 1.9 9.3 79.4 7.2   
DA+DCP group  
 
117 0.0 6.8 70.1 23.1 0.250 .003 
Making your own 
action plan 
       
DA group  98 9.2 12.2 71.4 7.1   
DA+DCP group  
 
116 0.9 14.7 67.2 17.3 0.235 .006 
Monitoring your 
progress 
       
DA group  96 9.4 15.6 65.6 9.4   
DA+DCP group  
 
114 2.6 17.5 62.3 17.5 0.178 .076 
Information in 
worksheet 
       
DA group  64 1.6 17.2 75.0 6.2   
DA+DCP group  90 0.0 6.7 77.8 15.6 0.222 .047 
        
Note: Each observation is presented as Number and Percent  
      
Approximately 80% of the patients perceived the length of presentation and the amount 
of information in the DA as just right, and nearly 87 % perceived the risk information versus 
information about life changes as balanced. Again there were no significant differences 
between DA group and DA+DCP group. However, patients in DA+DCP group considered the 
influence of the DA on the decision of life changes as significantly easier than patients in DA 
group (Ȥ2 = 0.178, p = .015), significantly more useful (Ȥ2 = 0.216, p = .002), and they also 
considered the way the risk was presented in the DA as significantly easier than DA group  (Ȥ2 
= 0.177, p = .013). 
Patients’ acceptability of the DCP 
To understand how the patients in DA+DCP group assessed the DCP after receiving the 
DA, we asked them specifically about the usefulness of the additive counseling. 
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90-95 % of the patients in DA+DCP group perceived the form of communication in the 
DCP about the importance of the lifestyle change and options as good or excellent. 93% 
perceived the length of the individual decisional counseling, and the amount of information in 
the individual decisional counseling as just right. 95% of the patients perceived the risk 
information versus the information about life changes in the individual decisional counseling 
as balanced, while 96% perceived that the influence of the DCP on the decision of life 
changes made the decision easier. 93 % of the patients perceived the DCP as useful, and that 
the amount of information in the DCP was adequate. 96 % considered the way that the risk 
was communicated in the individual decisional counseling as easy. 
 
Diffusion of intervention 
The questionnaires at T2 and T4 asking where or from whom the patients had received 
information during the study period revealed that three patients in the Control group and one 
from the DA group had discussed CAD and lifestyle changes with other patients, but not with 
patients from our study.  We could therefore not confirm any diffusion of information from 
the interventions between the three groups.  
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Chapter 5  
Discussion, significance, and recommendations 
 
 
Overview  
 
The purpose of this three group randomized clinical trial was to evaluate the effects of a 
Decision Aid (DA) with and without the additional individual decision counseling program 
(DCP) on health outcomes and health-related quality of life (HRQoL) mediated by adherence 
to cardiac risk reduction behavior. We also investigated possible relationships between these 
variables as presented in Figure 2 page 19. 
 
One of the study’s  main hypothesis was uphold on the following outcomes: The 
DA+DCP group had a significant decrease in Body Mass Index, and significantly improved 
HRQoL on several dimensions compared to the Control group six months after the 
intervention. There was also a significant decrease in perceived barriers to cardiac risk 
reduction behavior in the DA+DCP group compared to the Control group at two months. 
There were no significant differences between The DA group and the Control group on any 
variables. The DA alone was not sufficient to achieve any effects. Our data indicate that 
combining a DA with additional decisional counseling may be more effective in achieving 
better outcomes than with the DA alone. We found no significant differences in adherence to 
cardiac risk reduction behavior between any of the groups.  
      
There were significant relationships between greater adherence to healthy life style 
recommendations, better HRQoL and better health outcomes. Intentions to follow lifestyle 
recommendations were significant predictors of adherence to cardiac risk reduction behavior. 
Increased perceived susceptibility of illness was significantly related to lower adherence to 
non- smoking behavior, while increased perceived barriers to cardiac risk reduction behavior 
were related to lower adherence to diet recommendations. Higher decisional conflict 
significantly predicted lower adherence to diet recommendations, activity recommendations, 
and taking medications. The patients considered both the Decision Aid and the additional 
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decisional counseling program as helpful. The patients in the DA+DCP group perceived the 
information in the DA significantly more useful than those only receiving the DA on the 
following elements: calculating risks, thinking about possible changes, making an action plan, 
and the information in the worksheet. This suggests that when patients received the DCP in 
addition to the DA, they were able to utilize the information in the DA more. 
 
 
Methodological considerations 
 
In this study we used the design of a randomized controlled trial (RCT) to test the effects 
of the interventions. Many challenges may occur when performing a RCT in clinical settings 
and in patients’ homes. The contribution to the quality of cumulative research is based on 
methodological assessment of the reliability and validity of the study.  In the following some 
important threats to reliability, validity and generalization in our work are discussed.  
 
Reliability
Reliability refers to the degree of consistent results of the scores on an instrument 
(Carmines & Zeller, 1979). If the scores are variable and fluctuating the measure is assessed 
as unreliable. An instrument is internally consistent to the extent that its items are highly 
inter-correlated. Random error affects reliability. When random error is low, reliability is 
high. We performed several strategies to reduce random error in our study. The questionnaires 
were pilot tested in 15 patients first, all data entry into SPSS were double checked, and 10% 
of the imputed data were randomly assigned to be checked a second time. Internal consistency 
in the measures in our study was comparable to previous validation studies, suggesting that 
the scores were performing as expected.  
 
The patients in our study answered many questionnaires several times, and the burden of 
answering so many questionnaires was the main reason for the decision not to perform a test-
retest procedure to assess for stability of responses. That is a limitation of our study. 
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Validity
The degree of validity is the extent to which the instrument used actually reflects the 
abstracts construct being examined. Validity addresses the appropriateness, meaningfulness, 
and usefulness of the specific inferences made from instrument scores (Carmines & Zeller, 
1979).  
 
Internal validity refers to whether the covariation of the presumed independent variable 
and dependent variable results from a causal relationship: did the experimental treatments 
make a difference in this specific experimental instance? Threats to internal validity are 
experimental procedures, treatments, or experiences of the participants that threaten the ability 
to draw correct inferences from the data in an experiment. Possible threats involved in our 
study will be presented. 
 
Mass media coverage and attention on lifestyle changes for cardiac patients occurring 
coincidently with the time interval between pretest and posttest measurement could have 
influenced the responses from the participants in our study. Therefore we read national 
newspapers and listened to national news from April 2008 to August 2009 to assess possible 
large attentions on cardiac patients and lifestyle changes that could interfere with our 
intervention. We found no large focus on cardiac patients in Norway during this time period.  
 
Repeated use of the same questionnaires might have resulted in a memory effect that 
could have influenced patients’ responses to questionnaires at measurement T2-T4. The 
baseline knowledge scores about cardiac risk factor reduction were conducted at the hospital 
without any sources of information available, while the T2 measurement was completed at 
home with possible knowledge sources available as internet, books, and family caregivers.  
  
The measurement of blood pressure may have created systematic errors of 
measurement. The measurement varied through different doctors and different circumstances. 
The first blood pressure was measured at the initial visit at the Cardiac Outpatient clinic. The 
patients BP were measured simultaneously as the nurse was preparing the patients for the 
ECG. The protocol of letting the patient sit down for two minutes before measuring the blood 
pressure was not always met.  
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The observed effects of the interventions could have been reduced because of possible 
contamination between patients because they shared room before and after angiogram, or at 
the setting in the Hospital Hotel area for those staying there. We attempted to prevent this bias 
by telling patients not to share with other patients what they had received of information 
through the study, and later asked them to describe what and from whom they had received 
information about lifestyle. No patients reported that they had discussed or received 
information from other patients enrolled in the study.  
 
The control participants might feel disadvantaged by the absence of the treatment in 
contrast to participants in the DA- and DA+DCP group and thus were motivated to compete 
for equity. To reduce the possibility of competition of this kind we told the participants in 
control group that they would receive the DA when T4 was completed, which they did.  
 
A strength in the study was that the interventions were conducted by the same person to 
promote consistency in delivering the counseling. We were monitoring the intervention 
delivery by training and the use of manuals. To monitor intervention adherence we used 
personal logs, and 10 % of the home visits were randomly picked to be observed by another 
nurse counselor to secure the fidelity of the DCP intervention.   
 
Threats to construct validity occur when investigators use inadequate definitions and 
measure of variables. Relevant outcomes variables are crucial for answering causal questions 
as in our study. This study used instruments derived from the Health Belief Model and 
thereby ensured that the definitions and instruments represent the variables in the model 
described in Figure 2. By measuring the intentions to adhere, rather than the actual adherence 
to cardiac risk reduction at baseline, we lost important information about the actual adherence 
to cardiac risk reduction prior to angiogram. Previous analysis has shown that the strongest 
predictor of adherence is past adherence (Sherbourne et al., 1992). The actual adherence at 
baseline, rather than their intentions the next months would have resulted in more valid 
measures to compare the differences in adherence at six months, when controlling for baseline 
scores. The bidirectional arrows and feedback loops in the Health Decision Model reflect the 
notion that adherence behavior can change health beliefs (Eraker et al., 1985). In this study 
we only addressed the directional arrows as shown in Figure 2. Thus, we were not able to 
discover reverse causality in that a good outcome may have promoted subsequent adherence 
in our study.  
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External validity asks the question of generalizability: to what populations, settings, 
treatment variables, and measurement variables can this effect be generalized? Both the 
representativeness of the participants and the experimental settings was considered in our 
study. External validity threats arise when experiments draw incorrect inferences from the 
sample data to other settings, and past or future situations. Factors affecting generalization 
(representativeness) are presented.  
 
Sample characteristics. The willingness to participate in a study of lifestyle may impact 
the results. Those already interested in changing health behavior may have preferred to be 
included in a study like ours. However, we found no significant differences in age and gender 
among patients completing the study with those who were not included or refused to 
participate or were lost to follow up.  
 
A particular threat in longitudinal studies occurs if participants are systematically 
dropping out of one treatment condition more than another. Unequal numbers of lost to follow 
up occurred in our study: 50% of the lost to follow up at six months came from the control 
group.  
 
Due to the lack of the possibility of stating “I have no pain in the chest” in the Treatment 
Satisfaction Scale (TSS) and Disease Perception Scale (DPS) it is reasonable to think that this 
may have been the reason for the large amount of missing data in the SAQ subscales. 
Participants with no chest pain were not able to find a statement suited for them. In the 
adherence scales, participants had to indicate their extent of carrying out the actions in four 
different environments:  “When at work...”; When I participate in sports or recreational 
activities..”; When I participate in social activities…”. It is reasonable to think that patients 
who were not working/not employed, not participating in sports or social activities skipped 
these items. 
 
The intervention took place in patients’ home, and the effects obtained are therefore not 
necessarily applicable to other settings that would be different from original setting. The 
environment of settings varies widely and most people would probably assume that their 
home is a nicer place to learn than in a hospital setting. The interaction between the setting 
(patients home) and the intervention is therefore, a threat to generalizability in our study. 
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Patients could choose the time for the DCP appointment, and were told that a potential partner 
could participate if the patients invited them into the counseling session.  
 
The question whether the effects obtained are applicable only to the specific time period 
within which the study is conducted is important. Unusual occurrences that coincide with 
study period can make the extrapolation of results to other periods of time questionable. Even 
that we controlled for media focus on cardiac patients during study period, other interactions 
could have occurred and make extrapolation of results to future time period difficult.  
 
As a result of sensitization to lifestyle changes due to information in the informed consent, 
participants in the control group could have initiate lifestyle changes soon after the research 
was begun. Thus the findings cannot be generalized to all patients admitted to coronary 
angiogram. However, if this was the case, group differences would be harder to detect. It is 
also important to be aware of the possible “Hawthorne effect” in our study. The “Hawthorne 
effect” is the reactive effects created by individuals’ knowledge that they are participating in 
an experiment.  
 
Lack of blinding may also have caused a “Hawthorne effect” among clinicians who knew 
about the study and may have wanted to do their best in providing patients with information 
about lifestyle changes. Some patients brought their DA with them to the angiogram, and 
nurses thereby could identify patients belonging to one of the intervention groups. This may 
have had an impact on their communication with the patients. We do not know whether the 
communication with patients changed at the ward during the study period.  
 
Our sample was quite heterogeneous with regard to previous cardiac events. Participants 
were selected on the basis of the admittance to coronary angiogram with no regard to previous 
illness history. The total sample encompassed healthy people with no significant stenosis in 
their coronary arteries to those receiving their second CABG surgery.  
 
There are some important differences between primary and secondary prevention of 
cardiac risk and the content in the DA and DCP covered these differences. The patient’s risk 
of CAD (HeartScore®) was presented to DA+DCP group. HeartScore® is a tool for 
predicting and managing the risk of heart attack and stroke in Europe, and used to support 
clinicians to better identify patients at high total risk of developing cardiovascular disease. 
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The threshold for high risk for fatal cardiovascular events is defined as "higher than 5%".  
HeartScore® is made for patients less than 65 years of age with no previous cardiac events, 
and should be used in primary prevention. We calculated HeartScore® for all patients, and 
told patients older than 65 that this was an estimate for younger persons, and told people with 
established CAD  that HeartScore® estimated their risk as if they had no previous cardiac 
events, and that they were automatically at a higher risk than the HeartScore® showed 
because the presence of their cardiac illness. We used the Swedish version of the 
HeartScore® to calculate the risk because it was based on newer data than the European 
version that are estimating too high risk in the Norwegian population.  
 
The DA used in this study was based on literature published up to 2002. To make it up 
to date we adjusted the literature in the Norwegian version with new references, in 
collaboration with the Canadian development team.  
   
It is well-known that the use of self-reported symptoms in research can be subject to 
bias caused either by differing perceptions of what constitutes a particular symptom or set of 
symptoms, failure to report symptoms, or various psychological characteristics of the patient. 
Despite the inherent bias, the self-reporting of symptoms continues to be used as a gold 
standard in research on cardiac risk reduction behavior. Possible memory bias must be 
acknowledged in our study. The period of recall was either the last four weeks or the last two 
months. The use of the last two months may have been a source of recall errors. 
     
     Our study did not intervene to increase adherence by using behavioral strategies such as 
reminder systems, cues, self-monitoring, feedback, and reinforcement. This may have led to 
the knowing-doing gap: because although someone might know what the best thing to do was, 
the person still may not know how to do it.  
 
On the other hand the study has a number of strengths. The generalizability of the findings 
was enhanced given that data were collected longitudinally from a broad sample of patients 
both in primary and secondary prevention needs. The length and the timing of the intervention 
were considered to be appropriate. Strict standardization was inappropriate in this intervention 
because the intervention was tailored to local circumstances (individual risk profile) as 
described in Chapter 3. The DCP was designed to let the content in topic area (the means of 
intervening) vary according to individual patient risk profile, while the function (theorized 
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mechanism) of the DCP remained unchanged over place and time. The local circumstances 
that have the permission to be changed or adapted in our study were: individual risk profile, 
individuals’ benefits of potential action taken, individuals’ barriers to potential action taken, 
and the individuals’ decision ruled out in an individual plan for cardiac risk reduction 
behavior. 
 
Due to the limitations mentioned above, caution should be used when drawing causal 
conclusions. Despite positive results for some of the main outcomes, the clinical impact of the 
DA and the DA+DCP was small. The changes in outcomes were modest for BMI and barriers 
to cardiac risk reduction behavior. The heterogeneity of participants in the study with some 
relatively low-risk patients, may have reassured them that their risk was low, and this may 
have reduced the overall perceived needs for changing lifestyle in the sample.  
 
 
Contribution to science 
 
Our study was guided by concepts and their relationships derived from the Health 
Behavior Model, one of many existing theories in health behavior change that stating the 
unhealthy behavior as a deficit or a problem to be solved (Becker, 1974; Ewart, 1989; 
Prochaska & DiClemente, 1983). Numerous models of health-related decisions and behavior 
have been developed that emphasize the processes of rational, cognitive appraisal of threat 
and response. In studies of health behavior change in CAD patients it has been found difficult 
to elucidate causal mechanisms that are empirically demonstrated. When carefully conducted, 
randomized trials, with treatment as usual care as the comparison condition, are undertaken to 
evaluate health behavior change interventions, they are typically found to produce modest 
effects on behavior change (Ebrahim et al., 2006; Noar et al., 2008).  
 
In contrast to previous studies guided by theories in health behavior change, our study 
added a new approach to promote healthy behavior by combining the use of a DA to help the 
patients understand treatment options, potential outcomes, and prepare them to shared 
decision-making with their care provider, and the use of counseling (DCP) to help them elicit 
their individual preferences and individually tailor their preferred behavior change, instead of 
 
 
107 
 
a one-size-fits all approach. We thereby recognize that individuals have different intervention 
needs and added several new approaches into the behavioral intervention.  
 
DAs are rooted in models of rational decision-making which view the actions as reasoned 
and intentional, requiring conscious control. DAs alone have shown limited effects in health 
behavior change (Koelewijn-van Loon et al.,2009, 2010; Krones et al., 2008, 2010; Lalonde, 
et al., 2004, 2006; Lenz et al., 2009; Pignone et al., 2004; Sheridan et al., 2006, 2010b; van 
Steenkiste et al., 2007, 2008).  
 
We added a more comprehensive approach to try to understand behavior change. By 
developing and adding a DCP derived from the Health Belief Model which encompasses 
adjusting the information in the DA to patients’ personal illness history, elicit their 
preferences for lifestyle changes and help them make their own action plan has, to our 
knowledge not been done before. The DCP proposed two systems of information processing: 
(1) the process of reflective, reasoned, thinking, and (2) the process of learned associations 
that are outside of conscious awareness, have a strong emotional component, and provides a 
possible urge to act. The empty spaces in the open-ended sentences can simultaneously evoke 
some kind of motivating excitement that contributes to more possible answers than without 
these open spaces. The purpose is to structure situations so that the patient can become aware 
of his preferences, emotions, and the relationship between benefits and barriers and the health 
problems that can occur.  
 
Other ingredients that may have contributed to the results in our study is the offering of 
choice in a situation where there are several management options, based on individual need 
and preference, a method that enhances active patient orientation (Coulter & Ellins, 2007; 
Ruland & Moore, 2001). It is also suggested that options offered as a menu of strategies, as 
we did in the DCP, are more successful because they encourage each patient’s task to be one 
of choosing rather than one of refuting. Providing choice allows different people to respond in 
different ways based on each person’s needs. Facilitating a collaborative relationship, as we 
did in the DCP, shared decision-making and communication of expectations in a supportive 
environment may help to motivate and contribute to the disease management process (Coulter 
et al., 2007). Studies have demonstrated that encouraging patients to participate in treatment 
decisions improves health status (Brody et al., 1989; Stewart, 1995) and treatment outcomes 
(Roter, 1977).  
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The Health Belief Model presents one view of health behavior change. Findings from our 
study support several of the concept relationships derived from the Health Belief Model. Our 
study may therefore contribute to the usefulness of the concept in Health Belief Model to 
explain important factors related to changing behavior in CAD patients when adding 
approaches from shared decision-making theory.  
 
 
Consistency with previous research 
 
Effects of the interventions 
Effects on primary health outcomes. Small but statistically significant group differences 
were found in Body Mass Index (BMI). The Control group showed an increased mean in 
BMI, while DA- and DA+DCP groups lost body weight; the DA+DCP group most. This is 
noteworthy, because a number of studies have not found significant effects of interventions on 
Body Mass Index (Cupples & McKnight, 1994; Jolly et al., 1999; Murphy et al., 2009). BMI 
is considered an important risk factor for CAD, therefore this is an important outcome. Also, 
it is known that obesity and increased body weight raise blood pressure levels, and that weight 
loss as well as increased physical activity is beneficial (Fagard et al., 2007; Sacks et al., 
2001).  As our study consists of multiple components it is difficult to determine the crucial 
component that achieved this effect. The active ingredients of the intervention can be seen as 
the combined effects of the DA with the DCP that both emphasized the importance to reach 
and/or to maintain a healthy body weight. We do not know if it is the DCP alone or the 
combination with the DA that achieved the effects. The mean BMI was still higher than 
normal BMI for all three groups six months following angiogram, but a weight loss makes 
physical activity easier to accomplish, and is a step in the right direction.   
 
No further group differences were found between groups in biological risk factors. This is 
consistent with other studies (Cupples et al., 1994; Howard-Pitney et al., 1997). Studies with 
disease-specific outcomes like blood pressure and cholesterol levels yielded lower effects 
than did those with non-disease specific outcome measures like pain and experience of 
symptoms. A number of factors affect outcomes, such as the strength and efficacy of 
recommendation, current understanding of the disease, adverse drug reactions, and 
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misdiagnosis. Reverse causality may also play an important role so that a good outcome may 
promote subsequent adherence. (DeMatteo et al., 2002). 
      
Effects on HRQoL. In our study there were significantly higher mean scores for patients 
in the DA+DCP group than in the Control group on several dimensions of the HRQoL. The 
DA+DCP group had statistically significantly less problems with work or other daily 
activities as a result of physical health and/or emotional problems, better personal health, and 
greater feelings of pep and energy all of the time.  Statistical significance does not itself 
provide concise information about a given intervention’s clinically meaningful effects 
(Kendall, 1999). However, a difference in score of five or more points, as we found on the 
SF-36 scales from 0 to 100, has been regarded as clinically significant (Pettersen, Reikvam, 
Rollag, & Stavem, 2008).   
      
We also found statistically significant differences in the DA+DCP group in less 
perceived burden of CAD on their quality of life compared to the Control group. Clinically 
important change in Disease Perception as measured by the Seattle Angina Questionnaire 
(SAQ) scores has previously been considered to be between 5 and 8 points (Dougherty et al., 
1998). Based on these premises the results of our study show that there was a clinically 
important change in all three groups regarding the perceived change in the disease perceptions 
in terms of limits on quality of life because of chest pain, chest tightness, or angina from 
baseline to six months following the angiogram. Again, only the differences between the 
DA+DCP group and the Control group were found statistically significant. 
    
Also, the findings in our study are supported by research showing that interventions that 
combine psychosocial and psycho-educational components, as we did in the DCP, with usual 
cardiological care can significantly improve quality of life (Aldana et al., 2006; Blumenthal et 
al., 2005; Dusseldorp et al., 1999; Linden et al., 1996; McAlister et al., 2001).  
 
Effects on adherence outcomes. We found no significant group differences in adherence 
to cardiac risk reduction behavior during the study period. Our findings are consistent with a 
recent study by Krones and colleagues (2008) who found that DAs enhance decisions without 
an impact on the actual adherence to the decision, and therefore only have a small impact on 
health outcomes. Sheridan and colleagues (2010b) tested the addition of a ranking and rating 
exercise to a cardiac DA in a hypothetical lab-based study and found no improvement in 
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patients’ intention to reduce their cardiac risk behavior. Since one of the central objectives of 
health behavior change interventions are to modify and shape healthy lifestyle behaviors, 
adherence measures are both primary behavioral outcome measures, and important 
determinants of biological responsiveness. The identification and tracking of behavioral 
adherence measures is therefore important when evaluating the efficacy of the intervention in 
our study.  
 
Although not statistically significant, an interesting finding in our study was that during 
the six months there were more smokers in  the DA+DCP group that attempted to quit 
(Control: 24.1%; Intervention I: 24.1%; Intervention II: 37.5%) and were adherent to quitting 
smoking at six months following the angiogram (Control: 17.2%; Intervention I: 20.7%; 
Intervention II: 31.0%). Data in our study indicate that the DCP together with the DA may 
initiate a cognitive and emotional process and thus help patients to see what is most important 
to them and what they prefer to do, which may have led to higher quitting rates. This is 
supported by Rosen (2000) who found that cognitive processes were used more in early stages 
of changing smoking habits, and Barth and colleagues (2008) who found that the psychosocial 
smoking cessation interventions compared to usual care were effective in achieving smoking 
cessation in CAD patients. Patients receiving specific psychosocial interventions had more 
than 60% higher odds of quitting. However, in the review of Barth and colleagues (2008) the 
effects must be interpreted with caution since there was a great heterogeneity in the patient 
sample. 
 
There may be several reasons why there were no direct effects of our study’s 
interventions on adherence to cardiac risk reduction behavior. One might be that our 
adherence measure lacked the sensitivity to measure the effect of the intervention on 
adherence, and the variance was low. The instrument was chosen because it is a questionnaire 
with evidence of validity and reliability in CAD patients.  
 
Other explanations might be that the action plan in our study included only the planning 
part, and did not allow for patients to monitor their progress which may have decreased the 
effect of the intervention over time. Bandura (1986) found that not only goal setting, but also 
monitoring has been shown to be important for the ability to control behavior. Lippke and 
colleagues (2009) reported recently that action plans mediated the actual behavior change if 
the level of self-efficacy was high. When patients lack self-efficacy the action plan was not 
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working. An initial visible success in the monitoring part of the action plan may increase self-
efficacy and motivation that may help patients maintain their behavior in health-related 
settings (Stretcher et al., 1995). It is extremely challenging for patients to develop and 
maintain consistent behavior and activities that entails major long-term changes in lifestyle. 
Our study lacked the possibility for patients to receive reminders or follow-up assessment and 
support that could have helped the patients in the long run. Only one consultation, as in our 
study, might not have enough impact on the adherence outcomes measured. A similar 
response was recently reported by Krones and colleagues (2010) who assessed CAD risk at 
six months’ follow-up primarily to exclude a deterioration of risk factors caused by the 
intervention, and concluded that the influence of only one consultation cannot be assumed to 
have a high impact on the maintenance of healthy behavior.  
      
In our study, the DA+DCP group was presented with their individual risks using the 
HeartScore®, and both Intervention groups were able to calculate their own risk by looking in 
the DA. The recent review of Sheridan and colleagues (2010a) demonstrated that providing 
risk information improves the accuracy of risk perception and the probability of the intention 
to start risk reduction behavior among adults at moderate to high risk. Further, they stated that 
risk information is a tool to be used together with repeated interventions like counseling or 
risk feedback to promote adherence and risk reduction. Therefore, providing global risk 
presentation only once, as in our study, may not be sufficient to promote risk reduction 
behavior.       
           
Another possible reason for the lack of a direct effect on a patient’s adherence may be 
the influence of other factors unrelated to the effect of the experimental intervention on 
adherence. Variables in the literature found to be associated with patient non-adherence are 
physical disabilities, a sense that “nothing helps” regarding their disease progression, or a 
perception that their heart disease is cured through PCI (Peterson et al., 2010). Sherbourne 
and colleagues (1992)  found that patients who reported that their physical and role 
functioning was poor, and reported feelings of frustration, despair, and other negative 
emotions about their health problems tended to be less likely to adhere to medical 
recommendations. This could explain the fact that these patients are sicker, and less able to 
manage the complexity of treatment regimens that has been recommended. These possible 
sources of variation were not encompassed by our intervention, nor were they measured or 
controlled for in our study.  
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Effects on Knowledge, Perceived Health Beliefs, and Perceived Benefits and Barriers of 
cardiac risk reduction behavior. The perceived barriers to cardiac risk reduction behavior 
were significantly lower in the DA+DCP group than in the Control group. This may be 
explained by explicitly addressing perceived benefits and barriers to cardiac risk reduction in 
the DCP. Addressing both is known as decisional balance, or pros minus cons. The idea is 
that individuals engage in relative weighing of the pros and cons, which are basic to models 
of rational decision-making, in which people intellectually think about the advantages and 
disadvantages, obstacles and facilitators, perceived benefits and barriers, pros and cons, of 
engaging in a particular action. In the DCP we enlarged the thinking focus on the perceived 
benefits and the barriers of cardiac risk reduction through the use of open-ended sentences 
that may have increased the person’s awareness of the personal importance of perceived 
benefits and barriers here and now. The DCP intervention was thereby tailored to each 
patient’s needs and preferences, and aimed to change the way people think about barriers to 
cardiac risk reduction behavior in an individualized way.   
      
When patients are faced with information about life threatening situations such as 
cardiac risk, they may react in several ways: They can become fearful, which can trigger 
denial or avoidance, or they can become alert to danger and motivated to do whatever is 
necessary to alleviate the threat. To present patients with their individual risk profile that 
showed an elevated risk of dying of cardiac disease in the next ten years may trigger their fear 
reactions. Such fear was not measured as increased perceived susceptibility or severity of 
CAD or CAD progression among patients in our study. In the DCP in our study, the risk 
presentation was coupled with efficacy messages. The information about effective ways to 
reduce the risk of dying from CAD or CAD progression in the DA and the DCP was probably 
contributing to reduce the fear related to the presentation of risk scores.  
 
In our study we did not find any group differences in knowledge scores. This conflicts 
with other studies showing that DAs have been effective in improving patients’ understanding 
of options, and for increasing knowledge about these options and potential outcomes, both 
positive and negative (O’Connor et al., 2009). An explanation for our findings may be that the 
knowledge of risk factors and CAD in our study was measured two months after the decision, 
while most of the evaluations of DAs on knowledge have been evaluating the knowledge 
scores at the time of the decision.  
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Relationships
Relationships between Intentions to adhere to cardiac risk reduction behavior, 
Perceived Health Beliefs, Perceived Benefits and Barriers of cardiac risk reduction, 
Decisional Conflict, and Adherence outcomes.  Results in this study show that intentions to 
adhere to cardiac risk reduction behavior were significantly related to several adherence 
outcomes over the study period. The intentions were measured before the randomization, and 
indicated how strongly the patients believed they would perform the behavior over the next 
two months. Higher intention to follow a healthy diet was significantly related to greater 
adherence to diet recommendations over the next six months. Higher intention to follow 
recommended activities was significantly related to greater adherence to diet 
recommendations and to activity recommendations over the next six months. The latter 
finding is supported by Rosen (2000) who found that physical activity and dietary change 
increased together, and suggested that the patterns of change differ across health areas. We 
know that some patterns exist, because some habits and behaviors co-occur, like weight, 
activity and diet, and also drinking and smoking. There has been proposed a need for a 
sequential behavior change process that first identifies risk-related behaviors and then lets the 
patient decide the importance and priorities of the risk-related behaviors to change, and finally 
to sequentially intervene on the prioritized behaviors (Strecher et al., 2002). Additional 
research supports that certain health risk behavior occurs in combination and tent to cluster 
within individuals (Strecher et al., 2002; Orleans, 2004). When multiple health behavior risk 
factors tend to occur in the majority of the population this creates the need for intervening 
broadly, comprehensively and efficiently on more than one risk behavior at a time (Calfas et 
al., 2002) as we did. Our study findings supports that it is feasible to let CAD patients decide 
to change two or more behaviors simultaneously. 
      
Results in our study show that higher perceived susceptibility of CAD and /or CAD 
progression was significantly related to lower adherence to non-smoking recommendations.  
This is supported by Schmitz and colleagues (1999) who compared two strategies related to 
smoking cessation in women with established CAD and in women at risk of, but not 
established, CAD. Women with established CAD perceived themselves as being more 
susceptible to future smoking-related health problems, they had lower ratings on the 
perceived severity of such problems, and reported fewer benefits of quitting smoking than 
women who were at risk of, but not established, CAD. Women with established CAD, who 
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already suffered from negative effects of smoking, felt highly threatened by their smoking 
habits, but did not believe that quitting smoking would be beneficial in reducing the threat.  
 
In our study, greater perceived severity of CAD was significantly related to greater 
adherence to stress reduction. This is supported by DiMatteo and colleagues (2007) who show 
that greater perceived disease severity is associated with better adherence. In other studies of 
more serious diseases that are amounted with poorer health and who rate their disease severe, 
patients are significantly less adherent than healthier patients with a less serious disease 
(DiMatteo et al., 2007). This may be due to the fact that cardiovascular disease risk is often 
underestimated and thought to be a natural part of aging (Emslie et al., 2001). Although CAD 
is not always seen as a chronic disease, 66% who had a heart attack do not make a complete 
recovery (Centers for Disease Control and Prevention, 2004).      
      
In this study, higher perceived barriers to cardiac risk reduction were significantly 
related to lower adherence to diet recommendations. When the perceived barriers are high, the 
perceived benefits must also be high to make a change. The perceived benefits must outweigh 
the costs and perceived barriers to adherence for change in health behavior to occur. (Linde et 
al., 2006). It is well known that CAD patients often have a sense that “nothing helps” 
regarding their disease progression, or a perception that their heart disease is cured through 
PCI (Peterson et al., 2010). Therefore, it is important to help patients to consider perceived 
benefits together with perceived barriers of cardiac risk reduction as we did in the DCP in our 
study, because this may be the mechanisms of helping patients to succeed in cardiac risk 
reduction behavior. Allowance must be made for a latency time until the benefits of 
controlling the risk factors are evident. The problems may be that the perceived benefits of a 
healthy lifestyle may take some time to obtain. It is important to structure situations where 
patients meet opportunities to appreciate both the perceived benefits and the barriers of 
cardiac risk reduction behavior as we did. Only when the importance of perceived benefits is 
appreciated on a personal level is a change in behavior possible.      
 
Results from our study show that higher decisional conflict was significantly related to 
lower adherence to diet-, activity-, and stress recommendations. Factors related to higher 
decisional conflict include feeling uninformed, unrealistic expectations, and unclear values 
(O’Connor et al., 2009). Data from our study indicate that it is important to consider factors 
that may reduce the decisional conflict because scores of 25 or lower are associated with 
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follow-through with decision, whereas scores that exceed 38 are associated with delay in 
decision-making (O’Connor et al., 1998b).   
      
Relationships between adherence outcomes, primary health outcomes, and HRQoL. In 
this study, greater adherence to diet recommendations were significantly related to lower BMI 
and might be the mechanisms by which lower BMI was achieved. A healthy diet is associated 
with being low in fat and cholesterol, low in salt, high in dietary fiber, high in omega-3 fatty 
acids, and low in alcohol. Compared to an unhealthy diet there are fewer calories, which will 
result in weight loss.  Adherence to diet recommendations was also significantly related to 
several better scores on HRQoL:  Physical functioning, Role functioning physically, bodily 
pain, general health, role functioning emotionally, and mental health.  
      
Findings from our study show that adherence to activity recommendations was 
significantly related to increased vitality. This is consistent with other research that have 
noted small improvements in quality of life among cardiac populations adhering to physical 
activity recommendations, or rehabilitation and education interventions (Belardinelli et al., 
2001; Clark et al., 2005; Thompson et al., 2003). 
       
Results from our study show that greater adherence to taking their medication was 
significantly related to lower physical functioning. This may be due to the fact that patients 
needing medications may be sicker and thereby less able to perform physical activity. Greater 
adherence to taking medications was also associated with lower HDL. CAD patients are often 
on cholesterol medication, and people who need to lower their LDL cholesterol often have 
low HDL cholesterol.  
      
The findings in our study underscore the idea that adherence might not be a unified 
construct: measurement of adherence and the context of research are important determinants 
of research results. This is supported by DiMatteo and colleagues (2002) who reported that 
when adhering, 26 % more patients experienced good outcomes compared to patients not 
adhering, and the adherence outcome relationships vary between the regimen, measurements 
and disease studied.  
     
Since cardiac risk reduction is in general the same as good health practice, it is not clear 
from our study that patients were practicing the behavior to promote wellness, to protect the 
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occurrence, and/or deterioration of CAD or both. Furthermore, adherence does not necessarily 
have specific effects. Studies of medication have found that adherence is related to better 
outcomes, not only when the drug is an active one, but also when it is a placebo (Epstein, 
1984; Horwitz et al., 1990). 
      
Relationships between primary health outcomes and HRQoL.  Results from our study 
show that there was a significant relationship between lower BMI and better physical 
functioning, less body pain, higher treatment satisfaction, and better disease perception. Also, 
there were significant relationships between the patients attending health services such as 
cardiac rehabilitation, smoking cessation programs, diet meetings, and weight reduction 
meetings, with perceived less bodily pain, better general health, and better vitality. A 
Cochrane review shows that patients with angina without having a MI and/or a CABG 
surgery appear less likely to receive appropriate secondary preventive care (Buckley et al., 
2010). Findings in our study indicate that it may be important to offer cardiac rehabilitation to 
angina patients following an angiogram even if they did not receive any treatment like PCI 
and/or CABG surgery.   
 
Additional findings 
Patients’ appraisal of the usefulness of the DA and the decisional counseling program 
(DCP). When asked specifically about the DA booklet the patients’ (DA and DA+DCP 
group) responses were predominantly very positive about the presentation of major risks, and 
the options for lifestyle changes. Overall, positive responses included the amount and length 
of the presentations, and most patients reported the DA as balanced between risk and options. 
There were some interesting significant differences between the two groups.  The DA+DCP 
group, who received both the DA and the DCP, rated the calculation of risk, the thinking of 
possible changes, the making of their own action plan, and the use of the information on the 
worksheet significantly higher than  the DA group. Besides, the DA+DCP group thought that 
the decision of cardiac risk reduction became significantly easier, that the way the risk was 
presented was easier, and thought the DA was more useful than the DA group did.  The 
reason may be that the combination of the DA with the additive DCP gave an extra “dose” to 
enforce and strengthen the effect on the usefulness of the DA.      
      
Research shows that tailored print communication increases recall and is perceived as a 
credible source of health information (Skinner et al., 1999). DCP uses tailored counseling and 
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involves messages that are individualized, and based on the personal assessments. Therefore, 
a combination of a DA and additional counseling like in our study, may be particular helpful 
for patients.   
 
Based on the appraisal from the patients in our study there is a need for developing and 
testing educational materials and counseling to support both the communication and the 
decision-making process. This is supported by van Steenkiste and colleagues (2004) who state 
that it is not easy to explain cardiovascular risk to patients with the help of just a risk table. 
Shared decision-making are a valuable approach in prevention, and DAs could support the 
caregiver and the patients (Edwards & Elwyn, 1999b), though the effect of such DAs remain 
to be investigated. A test using a patient workbook for self-assessment of coronary risk 
yielded promising results (Paterson et al., 2002), as in our study.  
 
The patients’ responses to the DCP (DA+DCP group) were also predominantly positive 
about the form of communication about the importance of cardiac risk reduction and options 
for cardiac risk reduction behavior in the counseling session. The length and amount of the 
counseling was mostly reported as just right. Most patients evaluated the proportion between 
risk and options as balanced, and that the risk was easily communicated. Only 3.5 % of the 
patients in DA+DCP group found the way the risk was communicated in the counseling to be 
difficult. Overall, positive responses were found, including the influence of the counseling on 
the decision of life changes, the usefulness of the counseling, and that the counseling included 
enough information to help them decide what to do next.  
 
DA is helping patients to understand what they prefer, and thereby be able to discuss 
their preferences with their doctor. The DA and the DCP were asking about patients’ values 
and asking them how they felt about what they have heard and read, and what they might be 
doing with the information. The great appreciation of the DA and the DCP in our study 
supports the importance of eliciting patients’ preferences for cardiac risk reduction behavior 
in the counseling. Just as the physical examination is important, patients’ preferences are too.  
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Contribution to clinical practice 
           
The interventions in this study were feasible, were done in real practice and in patients’ 
homes, and supported several mechanisms regarding initiating cardiac risk reduction behavior 
in patients with risk of CAD or CAD progression. Counseling is an important role in nursing, 
and the cooperation between the nurse counselors and the physician may relieve the physician 
in promoting healthy behavior interventions to CAD patients in cardiac outpatient clinics.  
      
This study provided a way to engage patients in the decision-making process about their 
options for lifestyle changes and possible cardiac risk reduction behavior. The DCP provided 
a structured counseling process that helped patients articulate their individual questions and 
concerns, as well as disclose and evaluated perceived benefits and barriers of cardiac risk 
reduction behavior. Patients are demanding more involvement in decisions about their care. 
To respond, health care providers need practical tools to help encourage patients’ participation 
and, at the same time, support high-quality decisions that are acted upon. Decision-making is 
more than the effect on the decision process, the results of the decision matters. 
      
Recent data from the Research Council of Norway shows that 98.5 % of the inhabitants 
have been assigned to a regular general practitioner. The average duration of the doctor-
patient relationship was 7.7 years in 2003. The sub-group of CAD patients shows that the 
mean duration of relationship between CAD patients and their doctor was 8.4 years. The 
longitudinal nature of this relationship provides multiple opportunities for clinicians and the 
nurses to provide health behavior advice and counseling over long periods of time to CAD 
patients in Norway. Patients with angina alone appear less likely to receive appropriate 
secondary preventive care (Buckley et al., 2010) than patients with MI and/or CABG surgery. 
Based on the association between cardiac rehabilitation and health outcomes found in our 
study may be important to offer cardiac rehabilitation to the angina patients following 
angiogram too, not only patients with MI and/or CABG surgery.  
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Recommendations for future research 
 
Interventions addressing multiple risk factors and including more comprehensive 
approaches to understand behavioral change is important. Incorporating processes that 
stimulate the emotions can give a sense of the wider theoretical context that may explain 
some effects of behavioral interventions. Existing behavioral theories and models using only 
rational processing can be reframed when adding new or even total different approaches to 
see if it can better explain the behavior change. It is important to challenge existing behavioral 
theories so we can expand behavioral theories. Including DAs and add decisional counseling 
can be tested in other settings, like a cardiac outpatient ward.   
 
Several suggestions for future research are recommended. The use of a comprehensive, 
valid, reliable measure of adherence to cardiac risk reduction behavior is important. Another 
suggestion is the inclusion of actual adherence at baseline, instead of intentions to adhere. 
Also, the large unexplained variance in adherence suggests that additional variables may 
better explain adherence to cardiac risk reduction. Findings in previous studies revealed that 
self-efficacy (Senécal et al., 2000) and reinforcement (Burke et al., 1995) are significant 
predictors of adherence among patients with chronic illness. Based on the results in our study 
we will suggest a greater dose of intervention to promote adherence including structured 
reminder systems, cues, self-monitoring, feedback, and reinforcement. 
 
Many factors like patients’ knowledge and beliefs about their illness, motivation and 
ability to engage in risk-reduction behavior, expectations regarding outcomes of lifestyle 
behavior, and consequences of poor adherence, interact in ways not yet fully understood. It is 
important to recognize that understanding the role of adherence in treatment outcomes 
requires further analysis of the conceptual and methodological factors that affect this 
relationship. DiMatteo and colleagues (2002) note that patient adherence is linked to greater 
positive outcomes than non-adherence, and therefore, that adherence may be a valuable goal 
of interventions at the individual level. Whether because of improved treatment effects, 
classical conditioning, positive expectations, or the inner pharmacy of neuroendocrine and 
immune responses mediated by the emotional experience that attends good care, data indicate 
that adherence promote patients’ health and recovery. Efforts to improve patients’ adherence, 
particularly in the context of active patient involvement and responsibility in collaboration 
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with their physicians, continue to represent a worthwhile enterprise. Therefore, we must 
explore how we can make clinical decisions about health behavior better. It is known that DA 
has limited effects on health outcomes (O’Connor et al., 2009). The best advantage of DAs is 
the chance to present the topic as best we can to the patients, and in doing so, we have the 
opportunity to standardize the information, eliminate or minimize biases, and present the 
information in a format that allows patients to assess their own values, and come to a 
personalized decision. If involvement is to be effective, adequate discussions of risks and 
perceived benefits associated with different choices is often required (Edwards et al., 2006). 
Therefore, an additive individual decisional counseling is still important. Discussion of 
personal risk factors are relevant to the decision, which means that the individuals’ own 
characteristics are taken into account in assessing their actual risk or elevated risk status 
relative to others (Edwards et al., 2006).   
      
Trying to achieve and maintain a healthy weight can be accomplished through particular 
changes in a variety of specific behavior. The specific actions taken may vary greatly from 
person to person and such an approach puts a focus on the issue of choice. For example, 
whereas an individual may choose to have a very strict diet and only limited physical activity, 
another individual may make fewer dietary changes, but focus more on adopting vigorous 
physical activities. Such an approach would focus on the outcome of healthy weight as a 
conceptual category to organize, and ultimately drive, a multitude of possible behavioral 
changes. As such, the intervention is organized around the healthy heart.  
      
Most people who attempt multiple behavioral changes in the context of cardiovascular 
risk reduction are not successful (EUROASPIRE II Study Group, 2001). We suggest that 
interventions should guide people in making choices based on an assessment of which 
behavioral changes are likely to be most easily and readily adopted, not necessarily the 
behavior that is likely to yield the most immediate health benefit. Selecting such a behavior 
may increase the likelihood that the individual will gain confidence and then attempt more 
difficult and potentially more beneficial behaviors.  
      
One central idea that has gained wide acceptance in recent years is the notion that 
behavior change is a process, not an event. It involves more than someone deciding one day to 
stop smoking, and the next day becoming a non-smoker for the rest of their life. Even if there 
is good initial compliance to a health related behavior using change advice or attempts relapse 
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is common. An important question is whether in fact there is a common set of principles of 
health behavior changes that make an impact on health behavior, and whether or not there are 
theoretical differences in additive versus non-additive behaviors, on-time behaviors versus 
those that are maintained, and adoption behaviors versus cessation behaviors. To maintain, for 
example, smoking cessation behavior requires developing self-management and coping 
strategies, and establishing new behavior patterns that emphasize perceived control, 
environmental management, and improved confidence in one’s ability to avoid temptation. 
Therefore, additional meta-analytic projects across behaviors are necessary to assess potential 
common and /or unique mechanisms of health behavior and health behavior change.  
 
This is the first study comparing the effect of a DA with and without additional individual 
preference-based decisional counseling on behavioral change and health outcomes and should 
therefore be repeated with a larger sample size before final conclusions about intervention 
effectiveness should be drawn.  
 
 
Summary 
 
In this study combining the DA with the DCP supported patients to individually tailor 
their cardiac risk reduction behavior to their health beliefs and preferences, resulting in better 
health outcomes and HRQoL on some dimensions. The DA alone did not improve health 
behaviors and outcomes. We do not know if these effects would have occurred by the DCP 
alone, without combining it with the DA. Finally, this study contributed to a better 
understanding of variables related to adherence to lifestyle recommendations and health 
outcomes.  
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Velkommen 
 
Dette beslutningsstøtteverktøyet passer for deg hvis: 
 
x Du er interessert i å lære om din egen risiko for hjertesykdom og hjerneslag. Med 
hjertesykdom menes her det som kalles iskemisk hjertesykdom, det vil si hjerteinfarkt 
og angina pectoris. 
 
x Du er bekymret for kolesterolet eller blodtrykket ditt 
 
x Du er klar til å overveie livsendringer for å redusere din risiko for hjertesykdom og 
hjerneslag 
 
 
Dette heftet og de personlige arbeidsarkene vil hjelpe til med å forberede deg til en samtale 
med legen din, en farmasøyt eller sykepleier om valgmuligheter du har for å redusere din 
risiko for hjertesykdom og hjerneslag. Disse valgmulighetene kan omfatte forandring av 
livsstilen din og det å ta medisiner. 
 
Dette beslutningsstøtteverktøyet ble utviklet av et team av leger, sykepleiere, farmasøyter og 
forskere og er basert på de beste tilgjengelige studier. Disse studiene er vist til i teksten i 
heftet med små tall og er ført opp under referanser bakerst i heftet. 
 
Faguttrykk er definert i ordboken som du finner bakerst i heftet. 
 
For å få mest ut av dette beslutningsstøtteverktøyet bør du: 
 
x Gjennomgå og svare på spørsmålene i heftet 
x Fylle ut ditt personlige arbeidsark 
x Ta med de utfylte arbeidsarkene når du møter legen din eller på apoteket for å 
diskutere måter å redusere din risiko for hjertesykdom og hjerneslag. 
 
 
For å redusere din risiko for hjertesykdom og hjerneslag må du tenke på 
 
 
langtidsforandringer.  Dette kan omfatte livsstilsendringer og det å ta medisiner. 
158 
 
Hjertesykdom og hjerneslag 
 
Hjertesykdom (hjerteinfarkt og angina pectoris) og hjerneslag skjer når blodårene dine blir 
trangere. Det er stort sett de samme risikofaktorene som øker faren for både hjertesykdom og 
hjerneslag.  
 
Når blodårene som forsyner selve hjertemuskelen med blod blir  
trange kan det medføre at hjertemuskelen får for lite surstoff i  
forhold til behovet, noe som kalles angina pectoris.  
Hvis blodårene som forsyner hjertemuskelen med blod går helt  
tett, stanser blodtilførselen til et område i hjertemuskelen, dette  
området vil etter hvert bli omdannet til et arr. Denne prosessen med  
skade på hjertemuskelen kalles hjerteinfarkt. Et hjerteinfarkt kommer  
plutselig. Både ved angina pectoris og hjerteinfarkt kan personen oppleve smerter i brystet: 
sammensnørende, klemmende, trykkende eller sviende. Smertene kan stråle ut til armene, 
kjeven eller ryggen. Noen kan få tung pust eller generell kraftløshet i stedet for, eller sammen 
med, brystsmerter. Det er ikke uvanlig at symptomene er mindre tydelige og annerledes hos 
kvinner enn hos menn. Kvinner kan for eksempel oppleve symptomer som tretthet, 
kortpustethet og kvalme. Pasienter med hjerteinfarkt må raskt på sykehus fordi effektiv, 
moderne behandling kan redusere risiko for å dø eller få varig skade på hjertet.  
 
Omlag (85%) av hjerneslag skyldes blodpropp i en av 
blodårene som frakter blod opp til hjernen. Bare 15% skyldes 
hjerneblødning hvor en av hjernens blodårer har sprukket. 
Utfallet er at den delen av hjernen som normalt får sin 
blodtilførsel gjennom blodåren som er rammet blir skadet. 
Hjerneslag forårsaker ofte tap av bevegelse eller tale. Tapet 
avhenger av hvilken del av hjernen som blir skadet. Et 
hjerneslag kan komme uten varsel, men ofte har det i forkant 
vært forbigående lammelser, synsforstyrrelse eller problemer 
med å snakke ( TIA-anfall eller ”drypp”).  
 
 
 
Hjerte- karsykdommer er den hyppigste dødsårsaken hos nordmenn. 
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Hjertesykdom og hjerneslag 
 
La oss se på hva som skjer med personer som har hjerteinfarkt eller hjerneslag:1-2 
 
 
Av 100 personer som får hjerteinfarkt…  
 
////////// /    Omlag 20 vil dø innen et halvt år (20 %) ////////// 
 .......... 
.......... .   Omlag 20 vil måtte begrense sine aktiviteter  ---------- 
       pga brystsmerter eller kortpustethet (20 %) ---------- 
---------- -   Omlag 60 vil bli i stand til å gå tilbake til sine   
normale aktiviteter etter noen få uker (60 %) 
---------- 
---------- 
---------- 
 
 
 
 Av 100 personer som får hjerneslag…  
 ////////// 
////////// /   Omlag 30 vil dø innen tre måneder (30 %) ////////// 
////////// /  Omlag 15 vil være på institusjon etter tre 
måneder fordi de trenger hjelp til å gå, spise 
eller komme seg på toalettet (15 %) 
/////..... 
.......... 
---------- 
---------- 
  .  Omlag 15 kan bo hjemme, men vil ha et  ---------- 
----------        varig fysisk handikap som for eksempel noe 
       problemer med å gå eller snakke (15 %)                                     
-    Omlag 40 vil bli i stand til å returnere  
       hjem og gjenvinne helsen fullstendig (40 %)                              
      
 
 
 
 
 
 
 
160 
 
Viktige risikofaktorer 
 
Personlige faktorer (for eksempel å være stresset) og livsstil (for eksempel røyking) øker din 
risiko for hjertesykdom og hjerneslag. De seks viktigste risikofaktorene er: 
x Unormale kolesterolverdier i blodet 
x Høyt blodtrykk 
x Mangel på regelmessig fysisk aktivitet eller mosjon 
x Røyking 
x Overvekt eller fedme 
x Stress 
Hvis du lider av diabetes eller hvis du har hatt hjerteinfarkt eller hjerneslag tidligere, er din 
risiko for utvikling eller forverring av hjerte-karsykdom høyere. La oss se nærmere på 
risikofaktorene og lære hva du kan gjøre for å redusere dem. 
 
UNORMALE KOLESTEROLVERDIER I BLODET3
 
 
 
           
Kolesterol er et fettliknende stoff. Det er 
nødvendig for å hjelpe kroppsfunksjonene. 
Imidlertid er for mye kolesterol skadelig fordi 
det kleber seg til veggene i blodårene og gjør 
dem trangere. Dette betyr at det blir vanskeligere 
for blodet å passere gjennom blodårene 
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Viktige risikofaktorer 
 
Det finnes to typer kolesterol i blodet. 
 
LDL-kolesterol (det ”dårlige” kolesterolet) 
x Det blir kalt det ”dårlig” kolesterolet fordi det er et kolesterol som avleires på 
veggene i blodårene dine. 
x Personer med høye verdier av LDL-kolesterol har en større risiko for å få 
hjertesykdom og hjerneslag. 
 
HDL-kolesterol (det ”gode” kolesterolet) 
x Det blir ofte kalt det ”gode” kolesterolet fordi det er et kolesterol som fraktes til 
leveren som kvitter seg med det. Dette hjelper til å åpne blodårene og gjøre dem vide. 
Så et høyere HDL-kolesterol er bra.  
x Personer som har lave verdier av HDL-kolesterol har større risiko for å få 
hjertesykdom og hjerneslag. 
 
Anbefalte kolesterolverdier 
x Anbefalte LDL-kolesterolverdier for en person: 
x Med diabetes, hjertesykdom eller hjerneslag, et nivå på 2,0 eller om mulig lavere 
x Uten andre risikofaktorer, et nivå på 2,5 eller lavere 
 
x Anbefalte HDL-kolesterolverdier er 1.2 eller høyere for kvinner, og 1.0 eller høyere 
for menn. 
 
x Anbefalte totalkolesterolverdier for en person: 
x Med diabetes, hjertesykdom eller hjerneslag, et nivå på 4,5 eller om mulig lavere 
x Uten andre risikofaktorer, et nivå på 5,0 eller lavere 
 
 
Personer som har for mye av det ”dårlige” kolesterolet (høyt LDL-
kolesterol) og for lite av det ”gode” kolesterolet (lavt HDL-kolesterol) har en 
større risiko for hjertesykdom og slag 
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Viktige risikofaktorer 
 
HØYT BLODTRYKK4-6 
 
Blodtrykket ditt måler hvor mye hjertet ditt må arbeide  
for å pumpe blodet gjennom kroppen din. Det er målt  
i millimeter (mm) kvikksølv (Hg) og benevnes med  
to tall, slik som for eksempel: ”135 over 85” 
 
 
 
Det høyeste tallet, 135, er det systoliske blodtrykket. Det er trykket i blodårene dine når 
hjertet ditt slår et slag.  
 
Det laveste tallet, 85, er det diastoliske blodtrykket. Det er trykket i blodårene dine når 
hjertet ditt hviler (mellom slagene). 
 
Tabellene nedenfor er eksempler på høyt, høyt-normalt og anbefalt blodtrykk.  
 
 Systolisk Diastolisk 
 
 
 
 
 
 
 
Blodtrykk endrer seg i løpet av dagen. For å finne ut om du har høyt blodtrykk må legen din 
sjekke blodtrykket ditt ved 3-5 legebesøk og ta flere målinger etter at du har vært i ro en 
stund. En kan også bruke tekniske hjelpemidler som du bærer med deg og som måler 
blodtrykket ditt periodevis i 24 timer. 
 
 
HØYT  HØYT 
140 eller høyere 90 eller høyere 
  
HØYT-NORMALT HØYT-NORMALT 
130-139 85-89 
  
ANBEFALT ANBEFALT 
129 eller lavere 84 eller lavere  
Du har høyt blodtrykk dersom et av tallene er høyere enn det anbefalte ved 
flere legebesøk 
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Viktige risikofaktorer 
 
MANGEL PÅ REGELMESSIG FYSISK AKTIVITET ELLER MOSJON 
Mangel på regelmessig mosjon eller fysisk aktivitet kan gi  
deg høyere risiko for å få høyt blodtrykk, usunne  
kolesterolverdier og høyt blodsukker.  
Høyt blodsukker kan forårsake diabetes. 
 
 
 
 
 
 
 
 
 
RØYKING 
Røyking øker din risiko for hjertesykdom og hjerneslag. 
Det øker også din risiko for å få lungekreft og andre 
kreftformer. Røyking forårsaker også kroniske 
lungelidelser som kronisk bronkitt. 
 
 
 
 
 
 
 
 
 
 
 
 
 
OVERVEKT  ELLER FEDME68,70 
Å være overvektig kan føre til høyt blodtrykk, høyt kolesterol, 
diabetes, hjertesykdom og hjerneslag. For å vurdere vekt brukes i 
dag oftest kroppsmasseindex (KMI) som er et uttrykk for vekt i 
forhold til høyde. En person som er 1,80 m høy har i følge 
Verdens helseorganisasjon (WHO) en normal vekt på 60-81 kg, 
forstadium til fedme når vekten er 81-97 kg, og fedme når vekten 
er over 97 kg. Tilsvarende har en person med høyde 1,65 m en 
normalvekt på 50-68 kg, forstadium til fedme når vekten er 68-82 
kg og fedme når vekten er over 82 kg. Forstadium til fedme øker 
risiko for hjertesykdom med 17%, fedme øker risiko for 
hjertesykdom med 45% 
 
 STRESS 
 Stress kan medvirke til at hjertesykdom bryter ut. 
Ikke minst innvirker stress på behandlingsforløpet.  
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Valgmuligheter for livsendringer 
 
Det er mange valg du kan gjøre for å redusere din risiko for hjertesykdom og hjerneslag. Du 
kan velge å endre livsstilen din og/eller å ta medisiner.  
 
 
 
 
 
 
 
 
 
 
 
 
Valgmuligheter for livsstil omfatter: 
x Ha et sunt og hjertevennlig kosthold 
x Gjøre mer regelmessig fysisk aktivitet eller 
mosjon  
x Ikke røyke eller slutte å røyke 
x Oppnå eller beholde en sunn vekt 
x Kontrollere stresset i livet ditt 
 
 
 
 
 
Hvis livsstilsendringer ikke resulterer i de ønskede eller forventede forandringer, kan du ta 
medisiner for å kunne kontrollere kolesterolnivået eller blodtrykket ditt bedre. 
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Valgmuligheter for livsstil 
 
Kostholdet ditt7-23 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bruk et minutt på å se på tabellene på de to neste sidene og kryss av (¥) alle valgmuligheter 
som du allerede har forsøkt… 
 
 
 
 
 
Et sunt og hjertevennlig kosthold inneholder: 
x Lite fett og kolesterol 
x Lite salt 
x Mye kostfiber fra mat som kli, grønnsaker og frukt 
x Mye omega-3 fettsyrer fra fet fisk eller kapsler 
med fiskeolje 
x Lite alkohol 
 
 
 
 
Et sunt og hjertevennlig kosthold reduserer: 
x LDL-kolesterolet ditt med 5% 
x Blodtrykket ditt med 5-9mmHg 
x Risikoen din for å få hjerteinfarkt 
x Risikoen din for å få hjerneslag 
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Valgmuligheter for livsstil 
 
Mål Valgmuligheter 
 
Redusere 
inntak av fett 
og kolesterol 
 
Ƒ Spis mindre porsjoner med kjøtt (omkring størrelsen av håndflaten 
din) og noen måltider uten kjøtt, bare grønnsaker. 
Ƒ Velg magert kjøtt (som fugl og fisk) og fjern synlig fett før 
tilberedning 
Ƒ Velg meieriprodukter med lavt fettinnhold som skummet eller ekstra 
lett melk, cottage cheese og lett-yoghurt 
Ƒ Lag mat med lite eller ikke noe fett, eller bruk små mengder 
vegetabilske oljer som olivenolje, rapsolje, maisolje, solsikkeolje og 
peanøttolje i matlagingen.  
Ƒ Unngå produkter som croissanter, muffins og berlinerboller. 
Ƒ Stek maten heller i ovn enn i panne 
 
Redusere 
bruk av salt 
 
Ƒ Begrens bruk av salt i matlagingen din 
Ƒ Begrens bruk av salt ved bordet 
Ƒ Unngå salte matvarer som f.eks. spekemat og potetgull 
Ƒ Bruk ferske eller frosne matvarer i stedet for hermetikk og ferdigmat 
fra ferskdisk 
Ƒ Unngå ferdigmat og sauser fra hylledisk på grunn av fett- og 
saltinnholdet 
Ƒ Les innholdsfortegnelsen på matvarene for å bli kjent med mengden 
fett og salt som er brukt. 
Ƒ Bruk smakstilsetninger som urter, krydder, sitronsaft og hvitløk i 
stedet for salt 
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Valgmuligheter for livsstil 
 
Mål Valgmuligheter 
 
Øke inntaket  
av fiber 
 
Ƒ Spis 5-10 porsjoner frukt og grønnsaker hver dag 
Ƒ Spis 5-10 porsjoner kornprodukter som havre, bygg, naturris, 
bokhvete og grov hvete hver dag 
Øke inntaket  
av omega-3  
fettsyrer 
Ƒ Spis 2-3 måltider med fet fisk som for eksempel laks, ørret, makrell 
eller tunfisk hver uke 
Ƒ Bland linfrø inn i kornblandinger, bakevarer og gryteretter 
Ƒ Spis salatblader, soyabønner og valnøtter. 
Redusere 
alkohol 
inntaket 
 
Hvis du drikker for mye alkohol kan det øke blodtrykket og risikoen for 
hjertesykdom og hjerneslag 
Ƒ Menn: Begrens alkoholmengden til ikke mer enn 2 små flasker øl, 2 
små glass vin eller 60 ml med sprit (gin, whisky, vodka) hver dag. 
Ƒ Kvinner: begrens alkoholmengden til ikke mer enn 1 liten flaske øl, 
1 lite glass vin eller 30 ml sprit hver dag. 
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Valgmuligheter for livsstil 
 
 
Ditt mosjons- eller fysiske aktivitetsnivå 15, 24, 29-39 
 
 
Du bør mosjonere regelmessig på et moderat intensitetsnivå  
Dette kan føre til at du: 
x Senker LDL-kolesterolverdien din med 4 % fra f. eks 5.6 til 5.3 
x Øker HDL-kolesterolverdien din med 5 % 
x Senker blodtrykket ditt med 5-7 mm Hg 
x Reduserer din risiko for hjertesykdom og hjerneslag 
 
 
 
 
 
 
 



 
 
 
 
 
 
Du kan øke din fysiske aktivitet på mange måter. Noen aktiviteter krever mer innsats enn 
andre og vil ha ulik effekt, slik det er vist i tabellen på neste side. 
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Valgmuligheter for livsstil 
 
Bruk tabellen som følger for å krysse av (¥) alle aktiviteter du liker å gjøre. 
 
INNSATS        AKTIVITET   EFFEKTER 
Lett innsats 
60 minutter  
hver dag 
 
 
 Lett gange 
 Volleyball 
 Lett hagearbeid 
 Bøy og tøy (stretching) 
 
Hjelper deg å: 
x Gå ned i vekt og holde 
den vekten 
 
Moderat innsats  
30-45 minutter  
de fleste 
dager i uken 
 Rask gange 
 Sykling 
 Rake løv 
 Svømme 
 Danse 
 Bassengtrening 
Hjelper deg å:  
x Gå ned i vekt og holde 
den vekten 
x Redusere blodtrykket 
x Senke LDL-kolesterol 
x Øke HDL-kolesterol 
 
Stor innsats 
20-30 
minutter 
3 ganger i uken 
 
 Aerobic 
 Jogge 
 Hockey 
 Basketball 
 Rask svømming 
 Rask dansing 
 
Hjelper deg å:  
x Gå ned i vekt og holde 
den vekten 
x Senke LDL-kolesterol 
x Øke HDL-kolesterol 
 
 
 
 
 
 
 
 
 
Hvis du mosjonerer på et nivå med en moderat innsats i 30-45 minutter de 
fleste dager i uken vil det hjelpe deg å redusere din risiko for hjertesykdom 
og hjerneslag 
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Valgmuligheter for livsstil 
 
 
Røyking 40-45 
 
 
Hvis du slutter å røyke reduserer du din 
risiko for hjertesykdom og hjerneslag. 
Men det er ikke lett.  
 
 
 
 
 
Bare 2-5 % av de som prøver å slutte å 
røyke på egenhånd er røykfrie 6 til 12 
måneder etterpå. Det er årsaken  
 
 
 
 
 
til at det finnes flere måter å hjelpe 
røykere til å slutte. 
 
 
 
  
 
 
 
 
 
I tabellen på neste side vil du finne forskjellige metoder som kan hjelpe deg å slutte å røyke. 
Tabellen viser antall personer av 100 som prøver å slutte å røyke ved hjelp av hver metode og 
som fremdeles er røykfrie etter 6 til 12 måneder. 
 
Hvis du har forsøkt å slutte å røyke, bruk tabellen til å krysse av (¥) metodene som du har 
prøvd som hjelp til å slutte. 
 
 
 
 
 
 
 
 
 
 
171 
 
Valgmuligheter for livsstil 
 
METODE 
 
RØYKFRIE ETTER 6-12 MÅNEDER  
Ƒ Slutte på egenhånd uten noe hjelp 2-5 av 100 
 
Ƒ Akupunktur 
Nåler satt gjennom huden 
 
Langtidseffekt er ikke sett. 
Ƒ Hypnose 
Lar pasienten konsentrere seg dypt, noe som 
kan føre til en forandring i pasientens syn på 
røyking. 
Langtidseffekt er ikke sett 
 
Ƒ Gruppeveiledning 
Tilbyr taktikk og tips og sørger for støtte fra 
gruppen. 
14 av 100 
 
Ƒ Individuell veiledning 
Møter med en kursleder i røykeavvenning 
14 av 100 
 
Ƒ Nikotinplaster 
Avgir nikotin gjennom huden. 
8 av 100 
 
Ƒ ҏNikotintyggegummi 
Avgir nikotin gjennom munnen 
8 av 100 
 
Ƒ Bupropion (Zyban) 
Tabletter mot depresjon som tas via munnen 
15 av 100 
 
Ƒ Nikotinplaster og bupropion 15 av 100 
 
Ƒ Varenicline (Champix) 23 av 100 
 
 
 
 
 
De fleste metodene er tilgjengelige uten resept. Spør etter tilleggsinformasjon 
på apoteket.  
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Valgmuligheter for livsstil 
 
Vekten din15, 25-28 
Fedme er forbundet med mange helseproblemer. 
Imidlertid kan et vekttap på så lite som 4.5 kg: 
x Senke LDL-kolesterolverdien din med 3 %. 
Dette vil si at din LDL-kolesterolverdi vil kunne gå  
fra 5.60 til 5.40 
x Øke HDL-kolesterolverdien din med 4 %. Dette vil si at 
din HDL-verdi vil kunne øke fra 1.00 til 1.04 
x Senke blodtrykket ditt med 7 til 12 mm Hg 
 
 
 
 
 
 
 
I tabellen på neste side vil du finne en liste over flere metoder å gå ned i vekt på.   
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Valgmuligheter for livsstil 
 
Hvis du har forsøkt å gå ned i vekt, kryss av (¥) for metodene du har prøvd. 
 
METODER 
 
LANGTIDS VEKTTAP ETTER 6-12 
MÅNEDER 
Ƒ Kosthold med mindre kalorier og 
regelmessig mosjon 
x 1200- 1800 Kcal daglig 
x Lett til moderat mosjon 30-60 minutter 
de fleste dager i uken                                  
Du vil kunne gå ned 6 til 7 kg 
 
Ƒ Veiledning sammen med 
kostholdsendring og regelmessig mosjon 
Kurs individuelt eller i grupper for å hjelpe 
til med omlegging av kosthold og 
regelmessig mosjon 
 
Kan hjelpe til med å holde vekten hvis du 
fortsetter veiledning og regelmessig mosjon  
Ƒ Medisiner  
Reduserer appetitt eller hindrer fett fra å bli 
fullstendig absorbert av kroppen. 
Ikke vist seg å virke over tid 
 
Ƒ Kirurgi 
(for de som har alvorlig fedme) 
Reduserer appetitten og forhindrer kroppen i 
å absorbere fett. 
 
Du vil kunne gå ned 28 til 46 kg i vekt 
 
 
 
 
 
 
 
 Å følge et kosthold med lavere kaloriinntak og regelmessig mosjon kan føre 
til et langtids vekttap på  6-7 kg 
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Valgmuligheter for livsstil 
 
Ditt stress46 
 
 
 
 
 
 
 
 
 
Stress oppstår når det ikke lenger er balanse 
mellom krav og påkjenninger vi utsettes for og 
vår mulighet for å mestre eller oppfylle disse. 
Når dette skjer over tid er sjansene for å reagere 
kroppslig og psykisk stor.  
 
Nedenfor kan du markere ditt samlede 
stressnivå: 
 
     Ƒ  Ƒ  Ƒ  Ƒ  Ƒ 
Ikke stresset i                                                                                   Ekstremt  
det hele tatt        stresset 
  
 
Hvis du allerede har høyt blodtrykk så kan stress øke blodtrykket ditt 
 
 
 
 
 
 
 
 
 
 
 
Vi kan ikke utrydde stress fra tilværelsen, men vi kan gjøre noe med måten vi forholder oss til 
stressfaktorer på. Ikke minst er det viktig å sørge for aktiviteter som høyner trivsel og 
livskvalitet. 
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Valgmuligheter for livsstil 
 
 
Hvis du har forsøkt å redusere stressnivået i livet ditt kryss av (¥) for metodene du har 
prøvd… 
 
 
Metoder 
 
Effekter på blodtrykket 
 
Ƒ Bruke en av disse metodene: 
Meditasjon, avspenning 
Ikke tydelig at dette hjelper til å redusere 
stress 
 
Ƒ Bruke mer enn en av disse metodene til 
å redusere stress: 
En kombinasjon av meditasjon og 
avspenning 
 
Kan senke blodtrykket med 7 til 10 mm Hg 
 
Ƒ Personlig veiledning for å diskutere og 
lære om: 
· Årsaker til og respons på stress 
· Ferdighetstrening i kommunikasjon 
· Ferdigheter i problemløsning 
· Mestring av negative følelser 
· Avspenning/regelmessig mosjon 
 
Kan senke blodtrykket med  
9 til 15 mm Hg 
 
 
 
 
 
 
 
 
Personlig veiledning om stress eller en kombinasjon av flere metoder som  
meditasjon og avspenning kan senke blodtrykket. 
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Valgmuligheter blant medisiner 
 
Medisiner er ikke ment å erstatte en sunn livsstil. Ingen medisiner kan kurere høyt kolesterol 
eller blodtrykk, men de kan bli brukt for å redusere din risiko for å utvikle hjertesykdom når 
livsstilsendringer ikke alene er nok for å senke verdiene dine til en sunt nivå.    
 
Medisiner for å senke kolesterol 47-57 
Kolesterolsenkende medisiner hjelper til å kontrollere blodkolesterolnivået. Hver enkelt av 
disse medisinene har ulik effekt på LDL- og HDL-kolesterol. Disse medisinene er bare 
virksomme hvis du tar dem regelmessig resten av livet ditt.  
 
 
 
  
 
Alle medisiner kan gi bivirkninger og noen virker bedre for noen personer enn for andre.  Av 
denne grunn kan du måtte prøve mer enn en type medisin for å finne den rette for deg. 
 
Det er grovt sett fire typer medisiner tilgjengelig: 
 Statiner 
 Fibrater  
 Resiner 
 Nikotinsyrer 
 
Tabellen på neste side gir en oversikt over forskning om effekter av disse familiene av 
medikamenter. Den første kolonnen inneholder virkestoff og navn på medisinen. Den andre 
kolonnen inneholder navnet på type medisin. Den tredje kolonnen inneholder informasjon om 
hvordan kroppen din kan reagere på medisinen.  Den fjerde kolonnen viser hvor mye 
medisinen er i stand til å senke LDL og øke HDL. 
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Valgmuligheter blant medisiner 
 
Virkestoff og navn 
på medisinen 
Type 
medisin 
 
Merknader og bivirkninger Effekter på kolesterol 
 
Atorvastatin 
(Lipitor) 
Fluvastatin 
(Lescol) 
Lovastatin 
(Lovastatin, Mevacor) 
Pravastatin 
(Pravachol) 
Rosuvastatin  
(Crestor) 
Simvastatin  
(Simvastin, Zokor) 
Statiner 
 
Bivirkninger er milde og 
påvirker bare noen pasienter. 
Ikke kjent hva 
langtidsvirkningen er, om det 
er noen. Mest vanlige 
bivirkninger er uvelhet i 
magen, oppblåsthet, 
muskelkramper. Kan påvirke 
leveren. 
Senker LDL verdien 
(20-50%) 
Øker HDL verdien 
(5-10 %) 
Ezetimib 
(Ezetrol) 
 Milde og forbigående. 
Magesmerter, hodepine 
Hemmer opptak av 
kolesterol fra tarm 
Bezafibrate 
(Bezalip) 
Fenofibrate 
(Lipanthyl) 
Gemfibrozil 
(Lopid) 
Fibrater 
 
Bivirkninger er ofte milde og 
ikke hyppige. De kan omfatte 
uvelhet i magen, eller 
muskelsmerte. Kan påvirke 
leveren. 
Senker LDL verdien 
(10-20%) 
Øker HDL verdien 
(0-30 %) 
 
Colesevelam 
(Cholestagel) 
Kolestyramin  
(Questran) 
Kolestipol 
(Lestid) 
Resiner 
 
Ubehagelig å ta, men sikker å 
ta over lang tid fordi kroppen 
ikke tar det opp. Kan forårsake 
oppblåsthet, tarmgasser, 
kvalme, føle seg forstoppet 
Senker LDL verdien 
(15-25%) 
Øker HDL verdien 
(0-5 %) 
 
Niacin 
(Niaspan) 
Nikotinsyre 
 
Personer stopper ofte å ta det på 
grunn av bivirkninger som: 
varmefølelse i ansikt og kropp 
hudkløe, utslett, kvalme. 
Senker LDL verdien 
(20 %) 
Øker HDL verdien 
(20-40%) 
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Valgmuligheter blant medisiner 
 
Medisiner for å senke blodtrykk58-66 
Du og legen din kan bestemme at du trenger å ta medisin for å senke blodtrykket ditt. Det 
finnes mange medisiner som kan behandle blodtrykk, men valget er oftest basert på to 
faktorer.  Den første faktoren er personens medisinske tilstand. Den andre faktoren er hvor 
mye personen er i stand til å leve med av bivirkninger av en spesifikk blodtrykksmedisin. 
 
 
 
 
 
 
 
 
 
 
Hvis du tar medisin for å senke blodtrykket kan det redusere systolisk blodtrykk med omkring 
7 til 15 mm Hg, og diastolisk blodtrykk med 5 til 10 mm Hg. Slik at hvis det systoliske 
blodtrykket ditt nå er 140, kan en av disse medisinene senke det ned til mellom 125-133. Hvis 
ditt diastoliske blodtrykk nå er omkring 90, kan det gå ned til 80-85. Noen personer kan hende 
trenger å ta mer enn en medisin.  
 
De mest hyppigst brukte medisiner er beskrevet i tabellen på neste side. Andre medisiner for 
høyt blodtrykk finnes også på markedet. 
 
 
 
 
 
 
 
 
I gjennomsnitt kan en enkelt blodtrykksmedisin senke systolisk blodtrykk med 
omkring 7 til 15 mm Hg og diastolisk blodtrykk med 5 til 10 mm Hg 67 
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Valgmuligheter blant medisiner 
 
Virkestoff og navn på 
medisin 
Type medisin Bivirkninger Effekter på 
blodtrykk 
Bumetanid  (Burinex), 
Hydroklortiazid (Esidrex), 
Amilorid (Moduretic mite, 
Normorix mite),  
Spironolakton (Aldactone, 
Spirix) 
Diuretika 
(vanndrivende)
 
Kan føle seg trøtt, ha 
hodepine, utslett, bli 
overfølsom for solen, 
være kvalm 
Senker systolisk 
7 til 15 mm Hg. 
Senker diastolisk 
5 til 10 mm Hg. 
Atenolol (Tenormin, Uniloc) 
Labetalol (Trandate) 
Metoprolol (Selo-Zok, Seloken) 
Propranolol (Inderal retard, 
Pranolol) 
Timolol (Blocadren) 
Beta-blokkere 
 
Kan føle seg trøtt, ha 
langsom puls, endring i 
søvnmønster, forverre 
pusteproblemer. 
 
Samme som 
ovenfor 
 
Enalapril (Renitec) 
Kaptopril (Captopril, 
Capoten) 
Lisinopril ( Vivatec, Zestril) 
Ramipril ( Triatec) 
Angiotensin 
-converting 
enzyme 
(ACE) 
hemmere 
Kan føle seg trøtt, ha 
tørrhoste, føle seg 
svimmel 
Samme som 
ovenfor 
 
Irbesartan  (Aprovel) 
Kandesartan (Atacand) 
Losartan (Cozaar) 
Telmisartan (Micardis) 
Valsartan (Diovan) 
Angiotensin- 
II-blokkere 
 
Kan føle seg trøtt, 
svimmel 
 
Samme som 
ovenfor 
 
Amlodipin (Norvasc) 
Felodipin (Plendil) 
Nifedipin (Adalat) 
Diltiazem (Cardizem retard, 
Cardizem uno)  
Verapamil (Isoptin, Veracard) 
Kalsium- 
blokkere 
 
Kan føle seg trøtt, ha 
hevelse i ankler, 
hodepine, lav puls, føle 
seg forstoppet 
(verapamil) 
Samme som 
ovenfor 
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Fire trinn for å redusere din risiko 
 
 
 
 
 
 
 
 
 
 
 
 
Nå er tiden kommet til å lære hvordan sette all informasjonen du har fått sammen til en 
løsning som er riktig for deg.  
 
Bla om for å lære om de fire trinnene for å redusere din risiko. 
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Fire trinn for å redusere din risiko 
 
 
Vi har tatt med noen personlig arbeidsark sammen med dette heftet som kan hjelpe deg å 
bestemme hva som er de beste måtene for å redusere din risiko for hjertesykdom og 
hjerneslag. Arbeidsarkene vil hjelpe deg til å: 
x Vurdere din egen risiko for å dø av hjertesykdom og hjerneslag 
x Tenke over livsendringer som kan redusere din risiko 
x Lage handlingsplanen din 
x Registrere framgangen din over tid med fastlegen din 
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Fire trinn for å redusere din risiko 
 
Arbeidsarket er delt inn i fire trinn: 
 
På Trinn 1 i arbeidsarket vil du se på dine egne risikofaktorer og finne ut hva disse betyr i lys 
av din nåværende risiko for å dø av hjerteinfarkt eller hjerneslag. Se på tabell side 40. 
 
På Trinn 2 i arbeidsarket vil du se på mulige fordeler ved forskjellig livsstil og 
valgmuligheter blant medisiner og forestille deg hvor viktige de er for deg. Du vil gjøre dette 
ved å rangere hvor viktig hver av fordelene er. Du vil gi 5 stjerner for forandringer som du 
synes er veldig viktige og færre stjerner for de du synes er mindre viktige. Du vil også se 
hvordan det å gjøre forandringer vil redusere din nåværende risiko for hjerteinfarkt eller 
hjerneslag.  
 
På Trinn 3 vil du lage din egen handlingsplan ved å sette opp de forandringer som du er 
interessert i å overveie å gjøre de neste 6 måneder. 
 
Tilslutt på Trinn 4 vil du kunne registrere framgangen din over tid med fastlegen din. 
 
 
For å hjelpe deg å lære hvordan du skal bruke arbeidsarket vil vi vise deg hvordan Marie og 
Per brukte det for å gjøre forandringer for å redusere deres risiko for å dø av hjerteinfarkt og 
hjerneslag. 
Du vil kanskje finne fram arbeidsarket ditt og følge med. 
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Maries situasjon 
 
Marie er en 55 år gammel kvinne som ikke har hatt  
hjerteinfarkt eller hjerneslag. Marie har forsøkt å senke 
kolesterolet sitt ved å følge et kosthold som inneholder  
lite fett og kolesterol, men etter tre måneder forblir hennes  
totalkolesterol fremdeles høy (8.0 mmol/l). 
 
Trinn 1: Maries personlige risiko for å dø av hjertesykdom og hjerneslag 
 JA NEI 
Unormale kolesterolverdier × Ƒ  
Høyt blodtrykk × Ƒ  
Røyking × Ƒ  
Fravær av regelmessig mosjon Ƒ  × 
Overvekt eller fedme Ƒ  × 
Diabetes Ƒ  × 
Hjerteinfarkt eller hjerneslag Ƒ  × 
 
Slik det er identifisert på Trinn 1 på arbeidsarket hennes har Marie 3 risikofaktorer som kan 
bli forbedret. Hun har usunne kolesterolverdier fordi hennes totalkolesterol er høy, hun har 
høyt blodtrykk (178/100) og hun røyker også. ---------- 
 ---------- 
---------- Marie har en beregnet risiko for å dø av hjerteinfarkt eller  ---------- 
---------- hjerneslag på 7 %. Dette vil si at hvis vi fulgte 100 kvinner 
---------- 
med samme risiko som Marie i de neste 10 år ville i  ---------- 
---------- gjennomsnitt 7 dø av hjerteinfarkt eller hjerneslag  ----------
----------
---/////// 
og 93 ville ikke. 
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Maries situasjon 
 
Trinn 2: Mulige fordeler ved livsendringer 
Marie kan redusere sin risiko for å dø av hjerteinfarkt eller hjerneslag ved å slutte å røyke, 
senke blodtrykket sitt og forbedre kolesterolverdien sin.  
 
  
Livsendringer Hvor viktig er fordelen (maksimum 
viktighet er 5 stjerner) 
* * * * * 
× Ingen forandring  
× Ļ Totalkolesterol med 
livsstilsendring 
* * * * * 
× Ļ Totalkolesterol med medisiner * * * 
× Ļ Blodtrykket med livsstilsendring * * * * 
× Ļ Blodtrykket med medisiner * * 
× Slutte å røyke * * * * * 
× Forandre alle risikofaktorene * * * * *  
 
 
Den andre kolonnen viser hvor viktig Marie synes mulige livsendringer for henne. For 
eksempel synes hun at å senke kolesterolet og blodtrykket ved å forandre livsstilen sin er mye 
viktigere enn senke det med medisiner. 
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Maries situasjon 
 
Dersom 100 personer som Marie forandret alle sine risikofaktorer ville i gjennomsnitt 1 av 
dem dø av hjerteinfarkt eller hjerneslag i løpet av de neste 10 årene Dette vil si at, som vist i 
illustrasjonen med 100 ansikter, i gjennomsnitt 1 ville dø av hjerteinfarkt eller hjerneslag og 
99 ville ikke. 
 
 
 
  ---------- 
 ---------- 
----------  ---------- 
 ---------- 
----------  
----------  ---------- 
 ---------- 
----------  ---------/
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Maries situasjon 
 
Trinn 3: Maries handlingsplan 
 
Marie diskuterte fordelene og ulempene ved  
de forskjellige behandlingsmulighetene med  
fastlegen sin. På trinn 3 i arbeidsarket sitt  
krysset Marie av valgmulighetene hun er interessert 
i å prøve de neste 6 måneder. Marie bestemmer  
seg for å prøve livsstilsendringer og medisiner for å  
forbedre kolesterolverdiene og blodtrykket sitt. Fordi hun  
allerede driver noe mosjon planlegger hun å øke sin  
fysiske aktivitet ved å melde seg på bassengtrening. Etter å ha snakket med en farmasøyt på 
apoteket bestemmer Marie seg for å prøve nikotinplaster for å hjelpe henne til å slutte å røyke.    
 
Trinn 4: Maries framgang 
Etter tre måneder kom Marie tilbake til legen for å diskutere framgangen sin. Hun hadde 
sluttet å røyke. Hennes kolesterol hadde gått ned til 6,3. Blodtrykket var 140 over 83. Hun 
hadde også gått nesten 1 kg ned i vekt.   
 
Maries risiko for å dø av hjerteinfarkt eller hjerneslag i løpet av de neste 10 årene var redusert 
til 1 av 100 fra 7 av 100.  
 
Marie er fornøyd med framgangen sin og velger å fortsette med handlingsplanen sin uten 
noen forandringer. 
Marie’s  
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Pers situasjon 
 
Per er en 65 år gammel mann som har hatt ett hjerteinfarkt.  
Per har også høyt blodtrykk 
 
Trinn 1: Pers personlige risiko for hjertesykdom og hjerneslag 
 JA NEI 
Unormale kolesterolverdier ͙ × 
Høyt blodtrykk × ͙ 
Røyking ͙ × 
Fravær av regelmessig mosjon Ƒ  × 
Overvekt eller fedme × ͙ 
Diabetes Ƒ  × 
Hjerteinfarkt eller hjerneslag × ͙ 
 
På Trinn 1 i arbeidsarket sitt kan Per se at han har 2 risikofaktorer som kan bli forbedret: Høyt 
blodtrykk (179 over 92) og overvekt. Per veier 100 kg. Ideelt sett burde han veie mellom 70-
80 kg. ---------- 
 ---------- 
---------- Per har en beregnet risiko for å dø av hjerteinfarkt eller  ----------
---------- hjerneslag på 16 %. Dette vil si at hvis vi fulgte 100 personer  
---------- 
som Per i de neste 10 år ville i gjennomsnitt 16 dø av  ---------- 
---------- hjerteinfarkt eller hjerneslag og 84 ville ikke. ----////// 
 ////////// 
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Pers  situasjon 
 
Trinn 2: Mulige fordeler ved livsendringer 
Per kunne redusere sin risiko for å dø av hjerteinfarkt eller hjerneslag ved å senke blodtrykket 
sitt med livsstilsendring og medisiner.  
 
  
Livsendringer Hvor viktig er fordelen (maksimum 
viktighet er 5 stjerner) 
* * * * * 
× Ingen forandring  
͙Ļ Totalkolesterol med livsstilsendring  
͙Ļ Totalkolesterol med medisiner  
× Ļ Blodtrykket med livsstilsendring * * * * * 
× Ļ Blodtrykket med medisiner * * * * * 
͙Slutte å røyke  
× Forandre alle risikofaktorene * * * * *  
 
 
Den andre kolonnen viser at Per synes livsstilsendringer er like viktig som å ta medisiner. 
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Pers  situasjon 
 
Dersom 100 personer som Per forandret alle sine risikofaktorer (senket blodtrykket med 
medisiner og livsstilsendringer) ville i gjennomsnitt 8 av dem dø av hjerteinfarkt eller 
hjerneslag og 92 ville ikke i løpet av de neste 10 årene  
. 
 
 
----------  
---------- 
 ---------- 
----------  
----------
----------  
 ---------- 
----------  ---------- 
 --////////
 
 
 
 
 
Trinn 3: Pers handlingsplan 
 
Per diskuterte fordelene og ulempene ved de forskjellige behandlingsmulighetene med  
Fastlegen sin. På trinn 3 i arbeidsarket sitt krysser Per av for valgmulighetene han er 
interessert i å prøve de neste 6 måneder. Han bestemmer seg for å begynne å ta medisiner for 
å senke blodtrykket sitt. Han tror også at en økning i mosjonsnivået hans kan forbedre 
blodtrykket og hjelpe han med å gå ned i vekt. Pers kardiolog henviser han til hjertetrening 
som er utviklet for pasienter som har hatt hjerteinfarkt. 
 
 
 
 
 
 
 
 
190 
 
Pers  situasjon 
 
Trinn 4: Pers framgang 
Etter tre måneder kommer Per tilbake til legen for å diskutere framgangen sin. Han har begynt 
å ta medisiner for å senke blodtrykket sitt. Han har vært oppmerksom på kostholdet sitt og har 
begynt på hjertetrening. Han har gått ned 4,5 kg og blodtrykket hans har gått ned til 158 over 
88.  
 
Pers risiko for å dø av hjerteinfarkt eller hjerneslag i løpet  
av de neste 10 årene er sunket til 11 av 100. 
 
Per ville gjerne redusere sin risiko enda mer.  
Han lager en handlingsplan for å lære mer om  
hvordan meditasjon og  avspenningsteknikker kunne  
redusere stresset i livet hans. 
 
 
 
 
 
 
Nå er det tid for at du skal gjøre ferdig ditt personlige arbeidsark. 
Lykke til med beslutningstakingen din! 
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Oppsummeringer i tabell 
 
 
Se på oppsummeringstabellen som følger som en rask referanseveiviser til informasjonen vi 
har presentert som valgmuligheter for livsstil 
 
I begge tabellene vil Ĺ pil mene økning og Ļpil mene senkning. 
 
 
FORANDRINGER AV LIVSSTIL 
BLODTRYKK   
LDL 
 
HDL SYSTOLISK DIASTOLISK 
 
Sunt og 
hjertevennlig 
kosthold 
 
Ļ 5 % 
  
Ļ 9 mm Hg 
 
Ļ 5 mm Hg 
 
Øke 
regelmessig 
mosjon 
 
Ļ 4 % 
 
Ĺ 5 % 
 
Ļ 5-7 mm Hg 
 
Ļ 5-7 mm Hg 
 
Slutte å røyke 
  
Ĺ 14 % 
  
Gå ned i vekt 
4,5 kg 
 
Ļ 3 % 
 
Ĺ 4 % 
 
Ļ 7-12 mm Hg 
 
Ļ 7-12 mm Hg 
 
Redusere stress 
    
 
Referanser 
 
7, 25, 28 
 
25, 28, 40-42 
 
8, 20, 26, 29 
 
8, 20, 26, 29 





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Oppsummeringer i tabell 

 
MEDISINER SOM SENKER KOLESTEROL 
BLODTRYKK    
LDL HDL SYSTOLISK DIASTOLISK 
 
Resiner 
 
Ļ 15-25 % 
 
Ĺ 0-5 % 
  
 
Nikotinsyre 
 
Ļ 20 % 
 
Ĺ20-40 % 
  
 
Fibrater 
 
Ļ 10-20 % 
 
Ĺ 0-30 % 
  
 
Statiner 
 
Ļ 20-50% 
 
Ĺ 5-10 % 
  
 
MEDISINER SOM SENKER BLODTRYKK   
 
Diuretika 
   
Ļ7-15 mm Hg 
 
Ļ5-10 mm Hg 
 
Beta-blokkere 
   
Ļ7-15 mm Hg 
 
 
Ļ5-10 mm Hg 
Angiotensin-
converting 
enzym (ACE) 
hemmere 
   
 
Ļ7-15 mm Hg 
 
 
Ļ5-10 mm Hg 
Angiotensin II-
blokkere 
   
Ļ7-15 mm Hg 
 
Ļ5-10 mm Hg 
 
Kalsium-
blokkere 
   
Ļ7-15 mm Hg 
 
 
Ļ5-10 mm Hg 
Referanser 47, 50-51, 53 45-47, 51, 53, 55 57-61, 63-65 57-61, 63-65 


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Tabell for risiko 
 
SCORE- Europeisk Risikotabell FOR 10 ÅRS DØD PÅ GRUNN AV HJERTE-KARSYKDOM69 
 
 
                               KVINNER                                     MENN 
         
  IKKE RØYKER  RØYKER  IKKE RØYKER  RØYKER 
                  ALDER           
180 7 8 9 10 12  13 15 17 19 22 14 16 19 22 26  26 30 35 41 47 
160 5 5 6 7 8  9 10 12 13 16 9 11 13 15 16  18 21 25 29 34 
140 3 3 4 5 6  6 7 8 9 11 6 8 9 11 13  13 15 17 20 24 
Sy
st
ol
is
k 120 2 2 3 3 4  4 5 5 6 7 
 
 
65 
år 4 5 6 7 9  9 10 12 14 17 
                          
180 4 4 5 6 7  8 9 10 11 13 9 11 13 15 18  18 21 24 28 33 
160 3 3 3 4 5  5 6 7 8 9 6 7 9 10 12  12 14 17 20 24 
140 2 2 2 3 3  3 4 5 5 6 4 5 6 7 9  8 10 12 14 17 
Sy
st
ol
is
k 120 1 1 2 2 2  2 3 3 4 4 
 
 
60 
år 3 3 4 5 6  6 7 8 10 12 
                          
180 2 2 3 3 4  4 5 5 6 7 6 7 8 10 12  12 13 16 19 22 
160 1 2 2 2 3  3 3 4 4 5 4 5 6 7 8  8 9 11 13 16 
140 1 1 1 1 2  2 2 2 3 3 3 3 4 5 6  5 6 8 9 11 
Sy
st
ol
is
k 120 1 1 1 1 1  1 1 2 2 2 
 
55 
år 
2 2 3 3 4  4 4 5 6 8 
                          
180 1 1 1 2 2  2 2 3 3 4 4 4 5 6 7  7 8 10 12 14 
160 1 1 1 1 1  1 2 2 2 3 2 3 3 4 5  5 6 7 8 10 
140 0 1 1 1 1  1 1 1 1 2 2 2 2 3 3  3 4 5 6 7 
Sy
st
ol
is
k 120 0 0 1 1 1  1 1 1 1 1 
 
 
50 
år 1 1 2 2 2  2 3 3 4 5 
                          
180 0 0 0 0 0  0 0 0 1 1 1 1 1 2 2  2 2 3 3 4 
160 0 0 0 0 0  0 0 0 0 0 1 1 1 1 1  1 2 2 2 3 
140 0 0 0 0 0  0 0 0 0 0 0 1 1 1 1  1 1 1 2 2 
Sy
st
ol
is
k 120 0 0 0 0 0  0 0 0 0 0 
 
 
40 
år 0 0 1 1 1  1 1 1 1 1 
  4 5 6 7 8  4 5 6 7 8  4 5 6 7 8  4 5 6 7 8 
  Kolesterol 
(mmol/L) 
    Kolesterol (mmol/L)     Kolesterol (mmol/L)     Kolesterol (mmol/L) 
                          
                                                                                                                                                      
 SCORE 
Risiko uttrykt i prosent for å dø av sykdom som 
hjerteinfarkt eller hjerneslag over en 10 års periode 
         15 % og høyere risiko for å dø av hjerteinfarkt eller 
hjerneslag de neste 10 år 
 10-14 % risiko for å dø av hjerteinfarkt eller hjerneslag 
de neste 10 år 
 5-9 % risiko for å dø av hjerteinfarkt eller hjerneslag de 
neste 10 år 
 3-4 % risiko for å dø av hjerteinfarkt eller hjerneslag de 
neste 10 år 
 2 % risiko for å dø av hjerteinfarkt eller hjerneslag de 
neste 10 år 
 1 % risiko for å dø av hjerteinfarkt eller hjerneslag de 
neste 10 år 
 Mindre enn 1 % risiko for å dø av hjerteinfarkt eller 
hjerneslag de neste 10 år 
For å finne absolutt 10 års risiko:  
Finn tabellen for kjønn, røykestatus og alder.  
I tabellen finner du ruten nærmest ditt 
systoliske blodtrykk og total kolesterol.  
Risiko er høyere enn indikert i tabellen for de 
med: 
Familiær hyperlipidemi, Diabetes, 
Familehistorie med tidlig hjertesykdom, Lav 
HDL, Høye triglycerider over 2 mmol/l, når 
vedkommende nærmer seg neste 
alderskategori og de som har utviklet 
hjertesykdom. Pasienter med hjerte-
karsykdom krever intensiv livsstilsendringer 
og hvis nødvendig medikamentell


 
 
194 
 
Ressurser 
 
Sosial – og helsedirektoratet 
www.shdir.no 
www.sef.no 
Tlf 24 16 30 00 
 
Røyketelefonen 800 400 85 
Gratis materiell kan bestilles på www.tobakk.no 
 
Bedre helse på 1-2-30 Sammen om fysisk aktivitet www.1-2-30.no 
 
 
Landsforeningen for kosthold og helse 
www.lkh.no 
Tlf 23 27 25 40 
 
Nasjonalforeningen for folkehelsen 
www.nasjonalforeningen.no 
tlf 23 12 00 00 
 
Nasjonalforeningens Hjertelinje 
23 12 00 50 
Svarer på spørsmål om hvordan man kan forebygge hjerte- og karsykdom ved hjelp av 
endring av levevaner 
 
Landsforeningen for Hjerte- og Lungesyke 
www.lhl.no 
tlf 22 79 93 00 
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Ressurser 
 
Grete Roede AS 
www.greteroede.no/ 
Tlf: 66 98 32 00 
 
Libra Helse og Kosthold 
www.libra-helse.no 
Tlf 800 48 148 
 
Dr Fedon Lindbergs 
www.drlindbergs.no 
 
Vgs vektklubb 
www.vektklubb.no 
 
Tips til deg som vil slutte å røyke: 
RING Røyketelefonen 800 400 85 
BESTILL gratis Guide til Røykfrihet 
SNAKK med fastlegen din 
GÅ på apoteket 
MELD deg på røykesluttkurs ved å kontakt fylkesmannen i ditt fylke 
http://fylkesmannen no 
Nett adresser som ellers kan hjelpe deg: 
Opptur. Et tilbud til deg som vil bli uavhengig av røyken 
www.slutta.no 
 
www.roykstopp.no 
 
www.happyending.no 
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Ordbok for faguttrykk 
 
Akupunktur: Tynne nåler som blir stukket gjennom huden inn i energipunkter som finnes i 
spesifikke områder av kroppen for å balansere energinivå. Nålene kan også bli varsomt vridd 
eller varmet. 
Angina: Brystsmerter forårsaket av mangel på surstoff (oksygen) til hjertet. 
Angiotensins-converting enzyme (ACE) hemmere: Medisiner som reduserer blodtrykket 
ved å redusere sammensnøringen av blodårer og tillater blodet å strømme lettere i årene. 
Angiotensin II - blokkere: Reduserer sammensnøringen av blodkar, noe som gjør det lettere 
for blodet å strømme gjennom dem, reduserer blodtrykk og øker utskillelsen av vann og 
salter i nyrene. 
Avspenning: En metode for bevisst å frigjøre spenninger i musklene for å hjelpe en person til 
å bli roligere. 
Beta-blokkere: Medisiner som senker blodtrykk ved å sette ned pulsen og redusere kraften i 
sammentrekningene i hjertemuskelen. 
Biofeedback: En teknikk hvor personer lærer å kontrollere kroppsfunksjoner, slik som 
blodtrykk, noe som normalt ikke er under en persons kontroll. 
Blodtrykk: Et mål for hvor kraftig hjertet ditt må arbeide for å pumpe blodet rundt i kroppen 
din. Det er målt i millimeter (mm) kvikksølv (Hg) og blir framstilt med to tall, slik som "135 
over 85". Det høyeste tallet er det systoliske blodtrykket ditt, og det laveste tallet er det 
diastoliske blodtrykket ditt. 
Diastolisk blodtrykk: Det laveste tallet i avlesning av blodtrykket ditt. Dette er trykket i 
blodårene når hjertet ditt er i hvile (mellom hjerteslagene) 
Diuretika: En gruppe medisiner som kan hjelpe til å fjerne ekstra vann fra kroppen ved å  
stimulere nyrene til å bli kvitt mer urin. 
Fibrater: Medisiner brukt som et supplement til livsstilsendringer for å redusere 
triglycerider og øke HDL-kolesterol. 
HDL-kolesterol: High-density lipoprotein, eller HDL-kolesterol er kjent som det ”gode” 
kolesterolet fordi det fremmer fjerning av kolesterol fra blodet noe som forårsaker at årene 
blir videre. Personer med lave verdier av HDL eller det ”gode” kolesterolet har høyere risiko 
for hjertesykdom og hjerneslag. 
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Hjerneslag: Skade i en del av hjernen forårsaket av en avbrytelse av blodforsyningen eller en 
lekkasje av blod gjennom åreveggene. Sansefornemmelse, bevegelse eller funksjon som blir 
styrt av det skadede området i hjernen er svekket. Hjerneslag kan være dødelig.  
Hjerteinfarkt: Alvorlig og kraftige brystsmerter forårsaket av plutselig innsettende celledød i 
deler av hjertemuskelen. 
Hjertesykdom: En forsnevring av arteriene i hjertet som kan resultere i angina og 
hjerteinfarkt. 
Kalsium-blokkere: Medisiner som virker på hjertemuskelen. De reduserer hjertets arbeid 
med å pumpe blod, senker trykket av blodstrømmen gjennom kroppen og forbedrer 
blodsirkulasjonen gjennom hjertemuskelen. 
Kolesterol i blodet: En absolutt nødvendig bestanddel i kroppen. Det blir fraktet rundt i 
kroppen av lipoproteiner. Det er tre typer kolesterol i blodet: LDL-kolesterol, HDL-
kolesterol og triglycerider 
Kroppsmasseindeks (KMI).. For å vurdere vekt brukes i dag oftest kroppsmasseindex 
(KMI) som er et uttrykk for vekt i forhold til høyde. KMI= vekt (kg) / høyde x høyde (m2). 
Verdens helseorganisasjon (WHO) har gjort følgende vurdering av sammenheng mellom KMI 
og helse for voksne uansett alder: 
 
Klassifisering 
 
KMI, kg/m2 Sykdomsrisiko 
Undervekt 
 
Under 18,50 Lav risiko for diabetes, økt risiko for andre 
helseproblemer 
Normalvekt 
 
18,50-24,99 Lav risiko 
Overvekt 
 
Over 24,99  
x forstadium til fedme 
 
25,00-29,99 Økt risiko for diabetes 
x moderat fedme 
 
30,00-34,99 Økt risiko for diabetes. Økt dødelighet 
x alvorlig fedme 
 
35,00-39,99 Høy risiko for flere helseproblemer. Økt 
dødelighet 
x svært alvorlig fedme Over 39,99 Ytterligere økt helserisiko 
 
LDL-kolesterol: Low-density lipoprotein, eller LDL-kolesterol er kjent som det ”dårlige” 
kolesterolet fordi det fremmer avleiring av kolesterol i åreveggene og forårsaker at de blir 
trange. Personer med høye verdier av LDL eller det ”dårlige” kolesterolet har høyere risiko 
for å utvikle hjertesykdom og hjerneslag. 
Lipoproteiner: Partiklene som transporterer kolesterol og fett rundt i kroppen. 
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Meditasjon: En teknikk hvor personer konsentrerer seg om et objekt, et ord eller en ide i den 
hensikt å endre sinnstilstanden sin. 
Niacin: En medisin brukt som supplement til livsstilsendringer for å øke HDL-kolesterol 
eller senke triglycerider. Kan bli brukt alene eller i kombinasjon med andre medisiner. 
Personlig veiledning: For eksempel, det å møte en profesjonell veileder regelmessig for å 
hjelpe deg å snakke om årsaker til ditt stress, forbedre ferdighetene dine i kommunikasjon for 
å styre stress, lære hvordan en kan løse problemer og styre de negative følelsene dine ved 
bruk av avspenning og øvelser. 
Resiner: Medisiner brukt som supplement til livsstilsendringer for å senke LDL-kolesterol. 
Mest brukt sammen med andre kolesterolsenkende medisiner. 
Statiner: Medisiner brukt sammen med livsstilsendringer for å senke LDL-kolesterol. Kan 
bli brukt alene eller sammen med andre kolesterolsenkende medisiner. 
Systolisk blodtrykk: Det høyeste tallet i avlesningen av blodtrykket ditt. Det er trykket i 
blodårene dine når hjertet ditt slår. 
Transitorisk Ischemisk Attakk: En kort avbrytelse av blodforsyningen til deler av hjernen 
som resulterer i en midlertidig svekkelse av syn, tale, sansefornemmelse eller bevegelse. 
Triglycerider: Kjemisk form av fett som finnes i blodet. Representerer en veldig viktig 
beholdning av fettsyrer. 
Veiledning: Råd og psykologisk støtte gitt av helsepersonell som har som mål å hjelpe deg i å 
klare et spesifikt problem. 
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Gjøre valg: Livsendringer for å redusere din 
risiko for hjertesykdom og hjerneslag 
     
     
 
 
 
 
 
Ditt personlig arbeidsark 
 
 
 
 
 
 
 
Oversatt fra engelsk til norsk av Liv Wensaas. Tilbakeoversatt fra norsk til engelsk av Gail 
Adams Kvam 
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Trinn 1: Din personlige risiko for hjertesykdom og 
hjerneslag 
 
 
Du har følgende risikofaktorer:  
 
Ja 
 
 
Nei 
 
Unormale kolesterolverdier 
 
͔ 
 
͔ 
 
Høyt blodtrykk 
 
͔ 
 
͔ 
 
Røyking 
 
͔ 
 
͔ 
 
Fravær av regelmessig mosjon 
 
͔ 
 
͔ 
 
Overvekt eller fedme 
 
͔ 
 
͔ 
 
Diabetes 
 
͔ 
 
͔ 
 
Hjerteinfarkt eller hjerneslag 
 
͔ 
 
͔ 
 
 
 
 
 
 
 
Hvis vi følger 100 personer som deg i de ..........
..........
..........
..........
..........
..........
..........
.......... 
neste 10 årene (se tabell s. 40) ville i gjennomsnitt 
 _____________dø av hjerteinfarkt eller hjerneslag,  
______________ ville ikke. 
 
 .......... 
 .......... 
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Trinn 2: Mulige fordeler ved livsendringer 
 
 
 
 
Livsendringer Hvor viktig er fordelen for deg? 
(maksimum viktighet er 5 stjerner) 
* * * * * 
͙  Ingen forandring  
͙  Ļ Totalkolesterol med livsstilsendring  
͙  Ļ Totalkolesterol med medisiner  
͙  Ļ Blodtrykket med livsstilsendring  
͙  Ļ Blodtrykket med medisiner  
͙  Slutte å røyke  
͙  Forandre alle risikofaktorer  
 
 .......... 
 .......... 
.......... Hvis 100 personer som deg forandret alle .......... 
.......... sine risikofaktorer (se tabell s. 40) i de neste10 årene ville i  
.......... 
gjennomsnitt  _____________dø av hjerteinfarkt eller hjerneslag, .......... 
.......... ______________ ville ikke. .......... 
 ..........
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Trinn 3: Handlingsplanen din 
 
Kryss av for valgmuligheter du er interessert i å overveie de neste 6 måneder. Vær konkret 
vedrørende forandringer 
 
 
VALGMULIGHETER FOR LIVSSTIL 
 
 Gjør 
dette 
allerede 
Vil 
prøve å 
gjøre 
dette 
Tenker 
på å gjøre 
dette 
Plan for konkret forandring 
 
Sunt og 
hjertevennlig 
kosthold 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
Gå ned i vekt 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
Mosjonere mer 
regelmessig 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
Slutte å røyke 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
Redusere stress 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
Begrense 
alkoholinntaket 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
VALGMULIGHETER BLANT MEDISINER (hvis det er anbefalt av lege) 
 
 
Kolesterol 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
Blodtrykk 
 
Ƒ 
 
Ƒ 
 
Ƒ 
 
 
Andre 
 
Ƒ 
 
Ƒ 
 
Ƒ 
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Trinn 4: Framgangen din 
 
Du kan fullføre denne delen sammen med fastlegen din for å følge framgangen din de neste 6 
måneder 
 Mål I dag: 
Dato: 
2 mnd 
Dato: 
4 mnd 
Dato: 
6 mnd: 
Dato: 
 
LIVSSTILSENDRING 
 
Valgmulig- 
heter 
 
Kryss av for valgmuligheter du følger 
 
Sunt og hjertevennlig 
kosthold 
 
Ƒ 
    
 
Gå ned i vekt 
 
Ƒ 
    
Mosjonere mer 
regelmessig 
 
Ƒ 
    
 
Slutte å røyke 
 
Ƒ 
    
 
Redusere stress 
 
Ƒ 
    
 
Begrense 
alkoholinntaket 
 
 
Ƒ 
    
 
MEDISINER 
 
  
Skriv ned navn på medisinen(e) 
 
For kolesterol 
 
Ƒ 
    
 
For blodtrykk 
 
Ƒ 
    
 
Andre 
 
Ƒ 
    
 
RESULTATENE DINE 
 
Anbefalte  
verdier 
 
Før opp verdiene dine 
 
HDL-kolesterolverdi 
     
 
LDL-kolesterolverdi 
     
 
Total kolesterolverdi 
     
 
Blodtrykk 
 
/ 
 
/ 
 
/ 
 
/ 
 
/ 
Risiko for å dø av hjerte-
karsykdom: 
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Spørsmålene dine 
 
 
 
Skriv ned ethvert spørsmål du kan ha til apoteket eller til fastlegen din: 
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Appendix B 
 
Decisional Counseling Program (DCP) 
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SAMTALE GUIDE OG STIKKORDLISTE FOR INNLEDNING (DCP) 
 
INNLEDNING 
 
 
Innhold:  
Beskrive mål/hensikt med veiledningen 
Oppmerksomhet på at det er ikke er riktige eller gale svar 
 
Mål/Resultat 
Tema og prosess for veiledningen er identifisert 
 
 
Samtale guide og stikkord: 
Det er ikke sikkert at du går rundt og tenker på at du har noen risikofaktorer du kan 
gjøre noe med....eller at du har ønske om endring av livsstil......derfor er hensikten 
med dette besøket å hjelpe deg til å oppdage: 
 - Hvilke risikofaktorer du eventuelt står over for  
 - Hvilke livsstilsendringer som er mulig for deg å gjennomføre 
 - Hvilke endringer du synes er viktig å gjøre  
 - Fordeler ved og eventuelle ulemper som kan hindre deg i å gjennomføre 
livsstilsendringer 
 - En plan for livsstilsendringer som du lager selv 
 
Det er ikke noen gale eller riktige svar 
 
 
 
 
 
 
 
 
 SAMTALE GUIDE OG STIKKORDSLISTE FOR TEMA 1 (DCP) 
KUNNSKAP, ERFARING OG FORSTÅELSE AV HJERTESYKDKOM 
 
Innhold: 
Kort repetisjon om nødvendig 
Hjelp til forståelse.  
Tilpasse informasjonen til personens situasjon og framtid. 
 
Mål/resultat: 
Har samtalt om: 
Diagnose 
Prognose 
Anbefalinger om livsstilsendringer 
 
Samtale guide og stikkord:  
Har du lest heftet: “Gjøre valg: Livsendringer for å redusere din risiko for 
hjertesykdom og hjerneslag”? 
Hvor mange ganger? 
Har du noen spørsmål angående det du har lest? 
Kan eventuelt konkret spørre om tema som: 
- Årsaker til hjertesykdom og hjerneslag? 
- Hva kan skje med de som får hjerteinfarkt og slag 
- Viktige risikofaktorer 
- Valgmuligheter for livsendringer 
- Mulige fordeler eller ulemper ved livsstilsendringer 
Eventuelt en kort repetisjon ved behov 
 
 
 
 
 
 
 
 SAMTALE GUIDE OG STIKKORDSLISTE FOR TEMA 2 (DCP) 
 
GENERELLE OVERBEVISNINGER OM HELSE 
SPESIELLE OVERBEVISNINGER OM HELSE 
 
Innhold: 
Individuell risikoprofil 
 
Hjelp til å forstå mulige risiko 
 
Mål/Resultat: 
Har samtalt om: 
Mottagelighet for og alvorlighet ved mulig utvikling eller forverring av deres 
hjertesykdom 
 
 
Samtale guide og stikkord: 
Presentasjon av individuell risikoprofil utarbeidet ved bruk av HeartScore, svensk 
versjon http://www.escardio.org/knowledge/decision_tools/heartscore/     på 
grunnlag av data innhentet ved T1. 
 
Når du ser denne risikoprofilen din, hvilke tanker gjør du deg om utvikling/mulig 
forverring av hjertesykdom? 
 
Hva betyr dette, slik du ser det? 
 
Hva er viktig for deg? 
 
 
 
 
 
 
 
 SAMTALE GUIDE OG STIKKORDSLISTE TEMA 3 (DCP) 
FORDELER OG EVENTUELLE ULEMPER VED 
LIVSSTILSENDRINGER 
Innhold:  
Rangering viktighet av ulike livsstilsendringer 
Vurdere individuelle fordeler 
Vurdere individuelle ulemper 
 
Mål/resultat: 
Har tro på at:  
(1) Handling er fordelsaktig (redusere mottagelighet og alvorlighet) 
(2) Det ikke finnes noen overveldende ulemper 
 
Samtaleguide og stikkord: 
For å gå litt nærmere inn på hva dette kan bety for deg, og hva du synes blir viktig 
tenker jeg at du kan jobbe litt med hvor viktig enkelte endringer faktisk er for deg 
nå.  
 
Hva mener du er de viktigste beslutninger om livsstilsendringer for deg? Kan du 
angi viktigheten av at du gjør livsstilsendringer ved å krysse av på skalaen fra 0 
ikke viktig i det hele tatt til 10 svært viktig for meg. 
 
Du skal få noen oppgaver vedrørende forskjellige livsstilsendringer 
 
Vær vennlig å fullfør de påbegynte setningene, skriv ned det som først dukker opp, 
husk det er ikke noe riktig eller galt svar. 
 
Hva er det du ønsker å unngå skal skje 
Hva er de viktigste fordelene og eventuelle ulempene ved livsstilsendringer for deg 
Hva ville være lett for deg å gjøre? 
Fordeler versus ulemper ved livsstilsendringer slik du ser det 
Veie din viktighet av fordeler og ulemper ved livsstilsendringer opp mot hverandre  
 
Hvordan er tyngden lagt på balanse-vektene dine?  
 
Er fordelene viktigere enn ulempene? Eller er ulempene viktigere enn fordelene?  
 
Hva sier dette deg? 
 
Hjelpeark: 
”Viktighet av livsstilsendringer” 
”Livsstilsendringer A-E” 
 
 
 
 
 
 VIKTIGHET AV LIVSSTILSENDRINGER  
Akkurat nå, hva mener du er de viktigste beslutninger om livsstilsendringer 
for deg? 
Vær vennlig å angi viktigheten av at du gjør livsstilsendringer ved å krysse av på 
skalaen  
fra 0 (Ikke viktig i det hele tatt) til 10 (Svært viktig for meg). 
(A) 
Slutte å røyke
 
(B) 
Ha et sunt og 
hjertevennlig 
kosthold 
(C) 
Oppnå eller 
beholde en 
sunn 
kroppsvekt 
(D) 
Mosjonere 
regelmessig 
 
(E) 
Redusere 
stress 
 
Svært viktig 
for meg 
Svært viktig for 
meg
Svært viktig for 
meg
Svært viktig for 
meg
Svært viktig 
for meg 
10  10  10  10  10 
9 9 9 9 9
8 8 8 8 8
7 7 7 7 7
6 6 6 6 6
5 5 5 5 5
4 4 4 4 4
3 3 3 3 3
2 2 2 2 2
1 1 1 1 1
0 0 0 0 0
Ikke viktig i 
det hele tatt 
Ikke viktig i det 
hele tatt 
Ikke viktig i det 
hele tatt 
Ikke viktig i det 
hele tatt 
Ikke viktig i 
det hele tatt 
 
 
 
  
A. Å slutte å røyke 
Vær vennlig fullfør de påbegynte setningene med det første som du tenker på 
1.  Fokus på ”Å slutte å røyke” og hvorfor dette er viktig for deg:  
Å slutte å røyke er viktig for meg 
fordi_____________________________________________________________ 
og fordi____________________________________________________________ 
og fordi____________________________________________________________ 
I tillegg er det viktig for meg å slutte å røyke fordi___________________________ 
 
Det viktigste jeg ønsker å unngå ved å slutte å røyke 
er_______________________________________________________________ 
og _______________________________________________________________ 
og _______________________________________________________________ 
I tillegg ønsker jeg ved å slutte å røyke å unngå____________________________ 
__________________________________________________________________ 
 
De viktigste fordelene jeg får ved å slutte å røyke er ________________________ 
__________________________________________________________________ 
og________________________________________________________________ 
I tillegg, en annen fordel er____________________________________________ 
__________________________________________________________________ 
 
 
 
 
 
 2. Fokus på ulemper ved å slutte å røyke 
Hvis det skulle være noen ulemper ved å slutte å røyke måtte det være 
at_______________________________________________________________ 
og at _____________________________________________________________ 
og kanskje _________________________________________________________ 
 
3. Når jeg tenker på å slutte å røyke ville det være lett for meg å slutte å røyke 
dersom jeg_________________________________________________________ 
Og sannsynligvis lett hvis jeg __________________________________________ 
__________________________________________________________________ 
 
4. Fordeler versus ulemper ved å slutte å røyke.  
Vær vennlig kryss av for viktighet 
Hvor viktig er fordelene 
ved å slutte å røyke? 
 
Hvor viktig er 
ulempene ved å slutte 
å røyke? 
 
Svært viktige for meg Svært viktige for meg 
10 10
9 9
8 8
7 7
6 6
5 5
4 4
3 3
2 2
1 1
0 0
        Ikke viktige i det 
hele tatt
    Ikke viktige i det  
hele tatt 
Viktighet 
fordeler: 
Viktighet 
ulemper: 
________ ________ 
Før viktigheten 
på 
balansevekten 
 
 
 B. Å ha et sunt og hjertevennlig kosthold 
Vær vennlig fullfør de påbegynte setningene med det første som du tenker på  
1.  Fokus på ”å ha et sunt og hjertevennlig kosthold” og hvorfor dette er 
viktig for deg:  
Å ha et sunt og hjertevennlig kosthold er viktig for meg fordi__________________ 
og fordi____________________________________________________________ 
og fordi____________________________________________________________ 
I tillegg er det viktig for meg å ha et sunt og hjertevennlig kosthold fordi_________ 
 
Det viktigste jeg ønsker å unngå ved å ha et sunt og hjertevennlig kosthold er___ 
_________________________________________________________________ 
og________________________________________________________________ 
og________________________________________________________________ 
I tillegg ønsker jeg ved å ha et sunt og hjertevennlig kosthold å unngå__________ 
__________________________________________________________________ 
 
De viktigste fordelene jeg får ved å ha et sunt og hjertevennlig kosthold er ______ 
__________________________________________________________________ 
og________________________________________________________________ 
I tillegg, en annen fordel er____________________________________________ 
__________________________________________________________________ 
 
 
 
 
 
 
 2. Fokus på ulemper med å ha et sunt og hjertevennlig kosthold 
Hvis det skulle være noen ulemper med et sunt og hjertevennlig kosthold måtte 
det være at_________________________________________________________ 
og at _____________________________________________________________ 
og kanskje_________________________________________________________ 
 
3. Når jeg tenker på å ha et sunt og hjertevennlig kosthold ville det være lett 
for meg å ha et sunt og hjertevennlig kosthold dersom jeg____________________ 
og sannsynligvis lett hvis jeg___________________________________________ 
__________________________________________________________________ 
 
4. Fordeler versus ulemper ved å ha et sunt og hjertevennlig kosthold  
Vær vennlig kryss av for viktighet 
Hvor viktig er fordelene 
ved å ha et sunt og 
hjertevennlig kosthold?  
Hvor viktig er 
ulempene ved å ha et 
sunt og hjertevennlig 
kosthold? 
Svært viktige for meg Svært viktige for meg 
10 10
9 9
8 8
7 7
6 6
5 5
4 4
3 3
2 2
1 1
0 0
Ikke viktige i det 
 hele tatt 
Ikke viktige i det
hele tatt 
Viktighet 
fordeler: 
Viktighet 
ulemper: 
________ ________ 
Før viktigheten 
på 
balansevekten 
 
 
 C. Å oppnå eller beholde en sunn kroppsvekt 
Vær vennlig fullfør de påbegynte setningene med det første som du tenker på 
1.  Fokus på ”Å oppnå eller beholde en sunn kroppsvekt” og hvorfor dette er 
viktig for deg:  
Å oppnå eller beholde en sunn kroppsvekt er viktig for meg fordi______________ 
og fordi____________________________________________________________ 
og fordi____________________________________________________________ 
I tillegg er det viktig for meg å oppnå eller beholde en sunn kroppsvekt 
fordi______________________________________________________________ 
 
Den viktigste jeg ønsker å unngå ved å oppnå eller beholde en sunn kroppsvekt 
er________________________________________________________________ 
og________________________________________________________________ 
I tillegg ønsker jeg ved å oppnå eller beholde en sunn kroppsvekt å 
unngå_____________________________________________________________ 
 
De viktigste fordelene jeg får ved å oppnå eller beholde en sunn kroppsvekt er __ 
__________________________________________________________________ 
og________________________________________________________________ 
I tillegg, en annen fordel er____________________________________________ 
 
 
 
 
 
 
 
 
 2. Fokus på ulemper ved å oppnå eller beholde en sunn kroppsvekt 
Hvis det skulle være noen ulemper ved å oppnå eller beholde en sunn kroppsvekt 
måtte det være at____________________________________________________ 
og at _____________________________________________________________ 
og kanskje_________________________________________________________ 
 
3. Når jeg tenker på å oppnå eller beholde en sunn kroppsvekt ville det være 
lett for meg å oppnå eller beholde en sunn kroppsvekt dersom jeg_____________ 
__________________________________________________________________ 
Og sannsynligvis lett hvis jeg___________________________________________ 
 
4. Fordeler versus ulemper ved å oppnå eller beholde en sunn kroppsvekt 
Vær vennlig kryss av for viktighet 
Hvor viktig er 
fordelene ved å oppnå 
eller beholde en sunn 
kroppsvekt 
Hvor viktig er 
ulempene ved å oppnå 
eller beholde en sunn 
kroppsvekt 
Svært viktige for meg Svært viktige for meg 
10 10
9 9
8 8
7 7
6 6
5 5
4 4
3 3
2 2
1 1
0 0
Ikke viktige i det
hele tatt 
Ikke viktige i det 
hele tatt 
Viktighet 
fordeler: 
Viktighet 
ulemper: 
________ ________ 
Før viktigheten på 
balansevekten 
 
 
 
 D. Å mosjonere regelmessig 
Vær vennlig fullfør de påbegynte setningene med det første som du tenker på  
1.  Fokus på ”Å mosjonere regelmessig” og hvorfor dette er viktig for deg:  
Å mosjonere regelmessig er viktig for meg fordi____________________________ 
og fordi____________________________________________________________ 
og fordi____________________________________________________________ 
I tillegg er det viktig for meg å mosjonere regelmessig fordi___________________ 
 
Det viktigste jeg ønsker å unngå ved å mosjonere regelmessig er_____________ 
og________________________________________________________________ 
I tillegg ønsker jeg ved å mosjonere regelmessig å unngå____________________ 
__________________________________________________________________ 
 
De viktigste fordelene jeg får ved å mosjonere regelmessig er ________________ 
__________________________________________________________________ 
og________________________________________________________________ 
I tillegg, en annen fordel er____________________________________________ 
__________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 2. Fokus på ulemper ved å mosjonere regelmessig 
Hvis det skulle være noen ulemper ved å mosjonere regelmessig måtte det være 
at_______________________________________________________________ 
og at______________________________________________________________ 
og kanskje_________________________________________________________ 
 
3. Når jeg tenker på å mosjonere regelmessig ville det være lett for meg å 
mosjonere regelmessig dersom jeg______________________________________ 
__________________________________________________________________ 
Og sannsynligvis lett hvis jeg___________________________________________ 
__________________________________________________________________ 
4. Fordeler versus ulemper ved å mosjonere regelmessig 
Vær vennlig kryss av for viktighet 
Hvor viktig er 
fordelene  
ved å mosjonere 
regelmessig 
Hvor viktig er 
ulempene ved å 
mosjonere 
regelmessig 
Svært viktige for meg Svært viktige for meg 
10 10
9 9
8 8
7 7
6 6
5 5
4 4
3 3
2 2
1 1
0 0
Ikke viktige i det
hele tatt 
Ikke viktige i det
hele tatt 
Viktighet 
fordeler: 
Viktighet 
ulemper: 
________ ________ 
Før viktigheten 
på 
balansevekten 
 
 
 E. Å redusere stress 
Vær vennlig fullfør de påbegynte setningene med det første som du tenker på   
1.  Fokus på ”Å redusere stress” og hvorfor dette er viktig for deg:  
Å redusere stress er viktig for meg fordi__________________________________ 
og fordi____________________________________________________________ 
og fordi____________________________________________________________ 
I tillegg er det viktig for meg å redusere stress fordi_________________________ 
 
Det viktigste jeg ønsker å unngå ved å redusere stress er___________________ 
og________________________________________________________________ 
I tillegg ønsker jeg ved å redusere stress å unngå__________________________ 
__________________________________________________________________ 
 
De viktigste fordelene jeg får ved å redusere stress er ______________________ 
__________________________________________________________________ 
og________________________________________________________________ 
I tillegg, en annen fordel er____________________________________________ 
__________________________________________________________________ 
 
 
 
 
 
 
 
 
 
 2. Fokus på ulemper ved å redusere stress 
Hvis det skulle være noen ulemper ved å redusere stress måtte det være at______ 
__________________________________________________________________ 
og at______________________________________________________________ 
og kanskje_________________________________________________________ 
 
3. Når jeg tenker på å redusere stress ville det være lett for meg å redusere 
stress dersom jeg____________________________________________________ 
Og sannsynligvis lett hvis jeg___________________________________________ 
__________________________________________________________________ 
 
4. Fordeler versus ulemper ved å redusere stress 
Vær vennlig kryss av for viktighet 
 
Hvor viktig er 
fordelene ved å 
redusere stress? 
Hvor viktig er 
ulempene ved å 
redusere stress? 
Svært viktige for meg Svært viktige for meg 
10 10
9 9
8 8
7 7
6 6
5 5
4 4
3 3
2 2
1 1
0 0
Ikke viktige i det
hele tatt 
Ikke viktige i det
hele tatt 
Viktighet 
fordeler: 
Viktighet 
ulemper: 
________ ________ 
Før viktigheten 
på 
balansevekten 
 
 
 
  
 
SAMTALE GUIDE OG STIKKORDSLISTE TEMA 4 (DCP) 
 
BESLUTNING 
 
Innhold: 
 
Hva er best for deg? 
Utarbeide en skriftlig plan 
Hvem må gjøre hva og når? 
Hva trengs for å oppnå målet? 
 
Mål/Resultat: 
Har valgt livsstilsendringer 
Har tidfestet endringer 
Har vurdert egeninnsats 
Har vurdert behov for sosial støtte 
Har laget plan for livsstilsendringer 
 
 
Samtale guide og stikkord: 
Ut fra dette du har jobbet med og oppdaget nå, hva vil du bestemme deg for å 
gjøre de neste 6 måneder? Kan du krysse av på dette skjemaet for de 
livsstilsendringer du vil utføre de neste 6 måneder? 
 
På de neste sidene kan du sette opp konkrete måter å gjøre forskjellig ting på, 
samtidig som du skriver ned: 
Når vil du begynne med dette 
Hva må du gjøre for å få dette til 
Hva trenger du for å få dette til 
Hva må andre gjøre for at du skal få dette til 
 
Fylle ut ”Min plan for livsstilsendring” 
 
 
 
  
Min plan for livsstilsendring 
 
 
 
Kryss av for de livsstilsendringer du vil utføre de neste 6 månedene 
 
 Gjør dette 
allerede 
Vil helt sikkert 
begynne å gjøre 
dette  
Vil tenke over å 
gjøre dette  
Vil ikke gjøre 
dette  
Slutte å røyke 
 ͙ ͙ ͙ ͙ 
Ha et sunt og 
hjertevennlig 
kosthold 
 
͙ ͙ ͙ ͙ 
Oppnå eller 
beholde en sunn 
kroppsvekt 
͙ ͙ ͙ ͙ 
Mosjonere 
regelmessig ͙ ͙ ͙ ͙ 
Redusere stress 
 ͙ ͙ ͙ ͙ 
Ta mine 
foreskrevne 
medisiner 
͙ ͙ ͙ ͙ 
Annet (Beskriv) ͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Slutte å røyke 
 
 Gjør dette 
allerede 
Vil helt sikkert 
begynne å gjøre 
dette  
Vil tenke over å 
gjøre dette  
Vil ikke gjøre 
dette  
Slutte på 
egenhånd uten 
hjelp 
 
͙ ͙ ͙ ͙ 
Akupunktur 
 ͙ ͙ ͙ ͙ 
Hypnose 
 ͙ ͙ ͙ ͙ 
Røykeslutt kurs 
i gruppe ͙ ͙ ͙ ͙ 
Røykeslutt 
kurs/veiledning 
individuelt 
͙ ͙ ͙ ͙ 
Nikotin plaster ͙ ͙ ͙ ͙ 
Nikotin 
tyggegummi ͙ ͙ ͙ ͙ 
Annet (beskriv) 
 
 
͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
 
Jeg begynner med dette (dato)______________   
 
For å få til dette må jeg_______________________________________________________ 
 
For å få til dette trenger 
jeg____________________________________________________ 
 
For å få til dette må andre_____________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Ha et sunt og hjertevennlig kosthold 
 
 Gjør dette 
allerede 
Vil helt sikkert 
begynne å gjøre 
dette  
Vil tenke over å 
gjøre dette  
Vil ikke gjøre 
dette  
Redusere inntak 
av fett og 
kolesterol 
͙ ͙ ͙ ͙ 
Redusere inntak 
av salt ͙ ͙ ͙ ͙ 
Øke inntak av 
fiber ͙ ͙ ͙ ͙ 
Øke inntak av 
omega-3 
fettsyrer 
͙ ͙ ͙ ͙ 
Redusere 
alkoholinntaket ͙ ͙ ͙ ͙ 
Øke mengden 
frukt og grønt ͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
 
Jeg begynner med dette (dato)______________   
 
For å få til dette må jeg_______________________________________________________ 
 
For å få til dette trenger 
jeg____________________________________________________ 
 
For å få til dette må andre_____________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Oppnå eller beholde en sunn kroppsvekt 
 
 Gjør dette 
allerede 
Vil helt sikkert 
begynne å 
gjøre dette  
Vil tenke over 
å gjøre dette  
Vil ikke gjøre 
dette  
Klare dette på 
egenhånd ved å 
spise sunt og øke 
fysisk aktivitet 
͙ ͙ ͙ ͙ 
Vektreduksjonskurs 
som: Grete Roede, 
Fedon Lindberg, 
Libra, Vekt-voktere 
osv 
͙ ͙ ͙ ͙ 
Treningskurs med 
kostholdsveiledning ͙ ͙ ͙ ͙ 
Medikamenter ͙ ͙ ͙ ͙ 
Kirurgi ͙ ͙ ͙ ͙ 
Annet (Beskriv) ͙ ͙ ͙ ͙ 
Annet (Beskriv) ͙ ͙ ͙ ͙ 
 
Jeg begynner med dette (dato)______________   
 
For å få til dette må jeg_______________________________________________________ 
 
For å få til dette trenger 
jeg____________________________________________________ 
 
For å få til dette må andre_____________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Mosjonere regelmessig 
 
 Gjør dette 
allerede 
Vil helt sikkert 
begynne å gjøre 
dette  
Vil tenke over 
å gjøre dette  
Vil ikke gjøre 
dette  
Starte på kurs I 
hjerterehabilitering ͙ ͙ ͙ ͙ 
Lett aktivitet 60 
minutter hver dag ͙ ͙ ͙ ͙ 
Moderat aktivitet 
50-60 minutter 3-4 
ganger I uken 
͙ ͙ ͙ ͙ 
Intens aktivitet 20-
30 minutter 3 
ganger I uken 
͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
 
Jeg begynner med dette (dato)______________   
 
For å få til dette må jeg_______________________________________________________ 
 
For å få til dette trenger 
jeg____________________________________________________ 
 
For å få til dette må andre_____________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Redusere stress 
 
 Gjør dette 
allerede 
Vil helt sikkert 
begynne å gjøre 
dette  
Vil tenke over å 
gjøre dette  
Vil ikke gjøre 
dette  
En av disse 
metodene: 
meditasjon, 
avspenning 
͙ ͙ ͙ ͙ 
Kombinere 
disse metodene: 
meditasjon og 
avspenning 
 
͙ ͙ ͙ ͙ 
Personlig 
veiledning for å 
diskutere og 
lære om stress 
͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
 
Jeg begynner med dette (dato)______________   
 
For å få til dette må jeg_______________________________________________________ 
 
For å få til dette trenger 
jeg____________________________________________________ 
 
For å få til dette må andre_____________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Ta mine foreskrevne medisiner 
 
 Gjør dette 
allerede 
Vil helt sikkert 
begynne å gjøre 
dette  
Vil tenke over å 
gjøre dette  
Vil ikke gjøre 
dette  
Snakke med 
legen min om 
mine medisiner  
 
͙ ͙ ͙ ͙ 
Ta mine 
foreskrevne 
medisiner 
͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
Annet (beskriv) ͙ ͙ ͙ ͙ 
 
Jeg begynner med dette (dato)______________   
 
For å få til dette må jeg_______________________________________________________ 
 
For å få til dette trenger 
jeg____________________________________________________ 
 
For å få til dette må andre_____________________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
1 MINUTTS EVALUERING AV HJEMMEBESØKET 
 
1. Vær vennlig å vurdere nytten av hjemmebesøket du har hatt med studiens 
sykepleier ved å sette en ring rundt det alternativet som passer best for deg: 
 
 
 
1--------------------2------------------------3------------------------4----------------------5 
Ikke             Ganske                   Svært            
særlig                                            nyttig                                                 nyttig 
nyttig 
 
 
 
 
2. Hva er den viktigste oppdagelsen du tar med deg videre framover fra 
hjemmebesøket? 
 
 
 
 
 
 
 
 
 
3. Hvilke(t) spørsmål står fremdeles ubesvart? 
 
 
 
 
 
 
 
 
 
 
4. Hvordan kan hjemmebesøket bli bedre? 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Appendix C 
 
Fidelity strategies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Effects of a Decision Aid with and without additional decisional 
counseling for patients being examined for coronary artery 
disease on cardiac risk reduction behavior and health 
outcomes 
 
Intervention Fidelity Strategies 
 
A. Study design 
 
Goal Description Strategies
Same intervention 
“dose” within 
intervention group 
Description of 
intervention “dose” 
described in research 
proposal and REK 
protocol 
 
The “dose” is measured 
by a strict comply with 
the overview of the 
intervention and the 
keywords in the 
interview guide:  
-Introduction 
-Topic 1:  
Knowledge, Experience 
of CAD 
-Topic 2: 
General and Specific 
Health Beliefs 
-Topic 3 
Benefits and Barriers 
-Topic 4 
Decision 
Scripted counseling with 
manual 
Intervention monitor  
- interventionist 
interview guide 
and keywords 
Record variations 
- interventionist 
notations using 
field notes 
- site monitoring 
with feedback 
from observation 
Reinforcement of dose 
requirements 
Same intervention 
“dose” across 
intervention group 
Research design Intervention design 
- dose is 
consistent 
- information is 
consistence 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
B. Provider Training                       Standardized manual 
 
Goal Description Strategies
Intervention training is 
uniform 
Training constructed in 
a similar way for all 
Interventionist trained 
together or trained using 
a similar method 
Training manuals are 
standardized 
Re-training around any 
problems observed 
Supervision teaching 
initial intervention 
Skills acquisition Criteria: teaching the 
module according to the 
script and training is 
consistent 
Skills checklist with 
teaching 
De-briefing and problem 
solving 
Site audit 
Minimize drift Measure skills over time 
to ensure that skills do 
not deteriorate 
Subject T2 evaluations 
“Usefulness of DCP” 
Interventionist boosters 
Site audit 
Booster audit 
Accommodate 
differences 
In skill level or 
experience 
Professional leader 
supervision 
Monitor differentiation in 
dropout rates 
Analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
C. Delivery of Intervention 
 
Goal Description Strategies
Control for differences in 
interventionist over time 
Monitor subject 
assessment of the 
interventionist across 
intervention group 
Minute evaluations with 
feedback to the 
interventionist after 
counseling session 
Subject evaluation with 
perceptions of the 
interventionist and the 
counseling session  
Minimize differences 
within the intervention 
Delivery of the same 
intervention 
Scripted intervention 
protocol 
Assess drift 
- intervention 
observation/audit 
Adherence to 
intervention 
Intervention delivered as 
written/intended 
Random monitoring for 
protocol adherence 
- Intervention 
observation/audit 
- analysis 
Minimize contamination Reduce contamination 
between intervention 
groups 
Reduce contamination 
across treatment groups 
Provider training as 
outlines 
Supervision 
Ensure comfort in 
reporting deviations 
from the recommended 
intervention 
Field notes 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 D. Receipt of Intervention 
 
Goal Description Strategies
Subject comprehension Understanding of 
intervention material 
taught in the 
intervention 
Interventionist 
- review 
worksheets 
- summarized what 
has been taught 
- provides 
feedback 
- reinforces 
concepts 
Subject 
- Can discuss use 
of concepts 
- Can complete 
worksheets 
- Provide feedback 
- Development of 
Action Plan 
Use outcome measures 
- minute 
evaluations 
T2 evaluations 
Ability to use cognitive 
skills 
 
Subjects can use what 
is taught in the 
intervention 
Same as above 
Able to perform 
behavioral skills 
Subjects can use what 
is taught in the 
intervention 
Same as above 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 E. Enactment of Intervention Skills  
What are the active ingredients: Adherence? 
Goal Description Strategies
The subject 
demonstrate use of 
cognitive skills 
Has the subject used 
the cognitive skills that 
were taught in the 
intervention in life 
settings 
Intervention specific T2 
2 self-report 
questionnaire: 
“Usefulness of DCP” 
Use of printed materials 
to foster adherence: DA 
and worksheet 
Action plan 
Retest calls about 
adherence 
The subject 
demonstrates use of 
behavioral skills 
Has the subject used 
the behavioral skills that 
were taught in the 
intervention in life 
settings 
Intervention specific 
time 2, 3, 4, self-report 
questionnaires about  
adherence 
Use of printed materials 
to foster adherence: DA 
and worksheet 
Action plan 
Retest calls about 
adherence  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Date:______________ Interventionist:___________ Observer:______________ 
 
Effects of a Decision Aid with and without additional decisional counselling for 
patients being examined for coronary artery disease on cardiac risk reduction 
behavior and health outcomes 
 
Intervention Fidelity Observation 
 
CRITERIA ASSESSED 
 
YES NO COMMENTS 
 
Introduction 
Content: 
o Identification of topics 
o Identification of the process 
   
Activities: 
o Conversation about: 
o Goal for counselling 
o Desired participation 
o No right or wrong answers 
   
Topic 1 
Knowledge and Experience of CAD 
Content 
o Diagnosis 
o Prognosis 
o Health Recommendations 
   
Activities: 
o Interview 
o Questioning 
o Conversation 
   
Topic 2 
General Health Beliefs, Specific Health Beliefs 
Content 
The susceptibility and the severity of 
potential progression of their CAD 
   
Activities 
o Presentation of individual risk profile 
o Help to comprehend the possible risks 
   
Topic 3 
Benefits and barriers of lifestyle changes 
Content 
o Believe that actions is beneficial 
o Believe there is no overwhelming 
barriers 
   
Activities 
o Worksheet  
o Rating of importance of potential 
actions 
o Balance scale 
   
 
 
  
 
CRITERIA ASSESSED 
 
YES NO COMMENTS 
o Assessment of benefits 
o Assessment of barriers 
 
Topic 4 
Decision 
Content 
o Treatment selection 
o Action items 
o Barriers and resources 
o Social support 
o Plan for cardiac Risk Factor 
Modification Behavior 
   
Activities: 
o Rule out the decision in a form: 
o Which is best 
o Who needs to do what and 
when 
o What do you need to achieve 
this outcome 
   
 
Minute Evaluation 
   
 
Overall field assessment 
o Counselling within recommended 
timeframe 
o Time started:____________ 
o Time ended: ____________ 
o Using scripted interview guide 
o Appropriate emphasis on session topics 
o No omission of information 
o No contaminating information  
   
 
 
Observation feedback with interventionist: Ƒ Yes        Ƒ  No 
Comments: 
 
Review of Minute Evaluation with interventionist:  Ƒ Yes        Ƒ  No 
Comments: 
 
 
 
 
Follow up: 
